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Summary 
D6 is an atypical chemokine receptor related to CCR1-5 that binds to many 
inflammatory CC chemokines. Experiments using transfected cell lines have 
shown that upon binding to a chemokine ligand D6 does not trigger cellular 
signalling pathways, but rather acts to scavenge the bound ligand. It achieves 
this by constitutively travelling to and from the cell surface via early and 
recycling endosomes, internalising chemokines bound when it is at the cell 
surface. Over time, D6 removes a large amount of ligands from the extracellular 
compartment. In vivo, this scavenging activity is thought to regulate the level of 
CC chemokines, and thus controls inflammation locally and systemically. Lack of 
D6 has been shown to result in elevated amounts of bioavailable chemokines, 
and is associated with over exuberant inflammatory responses.  
In human, D6 mRNA and protein is highly expressed in trophoblast-derived 
gestational tissues. The expression of D6 mRNA in the placenta is by far the 
highest, compared to other solid tissues being studied. The importance of D6 in 
protecting the offspring has been demonstrated in animals. In pigs, a defect in 
D6 expression was discovered in placental attachment sites in endometrium from 
arresting fetuses. In mice, lack of D6 results in an increase in fetal loss after 
challenge with lipopolysaccharide (LPS) or antiphospolipid autoantibodies (aPL), 
and an increase in the number of abnormal pups when mouse embryos are 
transferred into fully allogeneic pseudo-pregnant female recipients. 
In view of these results suggesting a critical role for D6 in placental mediated 
complications, the expression and molecular function of D6 in primary human 
trophoblast cells were studied, as to date in vitro human studies have utilised 
the choriocarcinoma cell line BeWo or immortalised cell lines engineered to 
over-express exogenous D6. Secondly the impact of D6 deficiency on placental 
structure, chemokine expression and leukocyte abundance in mice was 
examined.  
Chapter 3 presents the results of experiments on primary human trophoblasts. 
Protocols for routine primary trophoblast isolation, purification and culture from 
fresh term placentas were optimised in our laboratory. D6 mRNA was detected in 
these primary cells. Using Western blotting, immunofluorescence and flow 
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cytometry, D6 was shown to be present predominantly in the intracellular 
vesicles of the cells. Competition chemokine uptake assays, analysed by flow 
cytometry, showed that CCL2 was internalised by trophoblasts using D6. 
Competitive chemokine scavenging assays, analysed by quantitative Western 
blot, confirmed that D6 was functioning as a chemokine scavenger on primary 
human trophoblasts and that it progressively removed substantial quantities of 
chemokine from medium bathing the cells. This is the first set of experiments 
that confirms D6 is present, and functioning as a chemokine scavenger in 
primary human cells.  
Chapter 4 contains the results from the mouse experiments. Even in an 
unchallenged environment it was shown that, on the DBA-1 genetic background, 
D6 deficiency in the mother and pups leads to higher rates of stillbirth and 
neonatal deaths, resulting in a reduction in the number of pups weaned per 
litter than their WT counterparts. By gestational age E14, pup weight was 
significantly smaller in the D6 KO mice. Using stereological techniques, the 
placenta of the D6 KO mice at this gestation was found to have a smaller 
labyrinthine zone. The volume of the labyrinthine zone was positively correlated 
with pup/placenta ratio. These phenotypes could be due to a maternal or fetal 
effect of D6 deficiency. To ascertain the answer to this question, the 
experiment at E14 was extended by breeding DBA-1 females heterozygous for 
the deleted D6 allele (D6 HET) with D6 deficient (D6 KO) males.  In this model 
the phenotypes of D6 KO pups and placentas could be compared with their D6 
HET siblings that developed in a mother expressing some D6 (i.e. D6 HET). 
Although there were no differences in pup weight, placental weight and 
pup/placenta ratio between these two groups, stereology revealed a decrease in 
labyrinthine zone volume fraction in the D6 KO placentas in comparison to their 
D6 HET siblings. The observed fetal compromise and placental defect at E14 was 
not apparent at the later gestational age of E18. Luminex multiplex protein 
assay showed an elevated level of circulating chemokine CCL2 in the serum of D6 
KO pregnant mice in comparison to their WT counterpart, so loss of chemokine 
regulation could be responsible for the defects observed in D6 deficient 
placentas. In summary, D6 deficiency results in an increase in perinatal death, a 
fundamental defect in placental formation (reduced labyrinthine zone) and 
dysregulation of circulating chemokine levels.  
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Chapter 5 discusses the mechanisms of D6 in regulating placental formation and 
reproductive outcome and the novel insights that this work provided into 
placental D6 function. It also describes the design of future experiments to 
reveal the precise role of D6 in chemokine regulation and cell signalling in 
reproductive immunology, and discusses how D6 might contribute to pregnancy 
outcome in humans.  
 
 
 
! !
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Abbreviations 
 
2D    two-dimensional 
3D    three-dimensional 
7-AAD    7-aminoactinomycin D 
ACKR    atypical chemokine receptor 
APC    antigen presenting cell 
aPL    antiphospholipid autoantibodies 
ApoE    apolipoprotein E 
APS   antiphospholipid syndrome 
bioCCL2    biotinylated CCL2  
C3    complement component 3 
CCL    CC-chemokine ligand 
CCL2AF647    AlexaFluor647 CCL2 
CCR    CC-chemokine receptor 
CCX-CKR    chemocentryx chemokine receptor 
CD    cluster of differentiation 
cDNA    complementary deoxyribonucleic acid 
COPD    chronic obstructive pulmonary disease 
CP    chorionic plate 
Crry    complement receptor-1 related gene/protein Y 
CTL    cytotoxic T lymphocyte 
CTLA    cytotoxic T-lymphocyte-associated protein 
CX3CL    CX3C-chemokine ligand 
CX3CR    CX3C-chemokine receptor 
CXCL    CXC-chemokine ligand 
CXCR    CXC-chemokine receptor 
DAF    decay-accelerating factor 
DAPI    4'-6-diamidino-2-phenylindole 
DARC    Duffy antigen receptor for chemokines 
DB    decidua basalis 
DC-SIGN    dendritic cell-specific intercellular adhesion molecule-3 grabbing                           
    nonintegrin  
DM    diabetes mellitus 
DMEM    Dulbecco's Modified Eagle Medium 
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DNAse    deoxyribonuclease 
EAE    experimental autoimmune encephalomyelitis 
ECM    extracellular matrix 
EDTA    ethylenediaminetetraacetic acid 
EVT    extravillous cytotrophoblast 
Exx    embryonic day xx 
FACS    fluorescence-activated cell sorting 
FITC    fluorescein isothiocyanate 
Foxp3    forkhead box p3 
GAPDH    glyceraldehyde 3-phosphate dehydrogenase 
GDP    guanosine diphosphate 
GPCR    G-protein-coupled receptor 
GTP    guanosine-5'-triphosphate 
HEK293    human embryonic kidney 293 
HEK-D6    HEK293 transfected with D6 expression constructs 
HET    heterozygous 
HIV    human immunodeficiency virus 
HLA    human leukocyte antigen 
HRP    horseradish peroxidase 
IBD    inflammatory bowel disease 
iEVT    interstitial extravillous cytotrophoblast 
IFN-γ    interferon-γ 
Ig    immunoglobulin 
IL    interleukin  
IUGR    intrauterine growth restriction 
JZ    junctional zone 
KC    keratinocyte chemoattractant 
KIR    killer inhibitory receptor 
KSHV    Kaposi's sarcoma herpesvirus 
KO    knockout 
LDS    lithium dodecyl sulfate 
LEC    lymphatic endothelial cells 
LIF    leukocyte inhibitory factor 
LIR    leukocyte immunoglobulin-like receptor 
LPS    lipopolysaccharide 
 18 
LZ    labyrinthine zone 
MCP    membrane cofactor protein 
MFI    mean fluorescence index 
MHC    major histocompatibility complex 
MIF    migration inhibitory factor 
MIP    macrophage inflammatory protein 
MOG    myelin oligodendroglial glycoprotein 
mRNA    messenger ribonucleic acid 
MS    multiple sclerosis 
NaCl    sodium chloride 
NH4Cl    ammonium chloride 
NK    natural killer 
NKG2    natural-killer group 2 receptor 
NSCLC    human non-small cell lung cancer 
OVA    chicken egg ovalbumin 
PBS    Dulbecco's phosphate buffered saline 
PBST    PBS-0.05% Tween 20 
PCR    polymerase chain reaction 
PD-1    programme death-1 receptor 
PDL    programme death ligand 
PGS    PBS, 0.2% gelatine, 0.05% saponin 
PIPES    4-piperazinediethanesulfonic acid 
PMN    polymorphonuclear 
pNK    peripheral blood natural killer cells 
qPCR    quantitative polymerase chain reaction 
RA    rheumatoid arthritis  
RANTES    regulated on activation, normal T cell expressed and secreted 
RCF    relative centrifugal force 
RPE    R-Phycoerythrin 
rRNA    ribosomal ribonucleic acid 
SDS    sodium dodecyl sulfate 
SDS-PAGE    sodium dodecyl sulfate polyacrylamide gel electrophoresis 
siRNA    small interfering ribonucleic acid 
SNPs    single nucleotide polymorphisms 
ST    syncytiotrophoblast 
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TAE    Tris-acetate-EDTA 
TCA    trichloroacetic acid 
TCR    T-cell receptor 
TGF    transforming growth factor 
Th    T helper 
TNF    tumor necrosis factor 
TOP-1    topoisomerase 1 
Treg    regulatory T cells 
Tris-HCL    Tris(hydroxymethyl)aminomethane hydrochloride 
uNK    uterine natural killer 
VEGF    vascular endothelial growth factor 
vEVT    endovascular extravillous cytotrophoblast 
VT    villous cytotrophoblast 
WT    wild type 
XCL    XC-chemokine ligand 
XCR    XC-chemokine receptor 
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1 Introduction  
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1.1 Adequate placentation is crucial for a successful 
pregnancy 
Major adverse perinatal outcomes are increasingly recognised as having their 
origins in early pregnancy and abnormal placentation.  Stillbirth is a devastating 
outcome of pregnancy for women and their families, with one in 170 babies 
affected (Office for National Statistics); (Bukowski et al., 2011). Pre-eclampsia, 
part of the spectrum of the gestational hypertensive disorders is also a major 
contributor to perinatal morbidity and mortality and affects 3% of pregnancies 
(Jacobs et al., 2003, Lee et al., 2004, Roberts et al., 2005, Geelhoed et al., 
2010). Intrauterine growth restriction (IUGR), affects 10% of pregnancies and is 
associated with prematurity, cerebral palsy and neonatal death (Stoknes et al., 
2012). All of these conditions have been associated with abnormal placental 
histology at delivery. More striking are the observations that these adverse 
events in late pregnancy have their origins in early pregnancy as demonstrated 
by first trimester assessment of placental biomarkers and fetal growth (Khong et 
al., 1986, Smith et al., 2004, Bukowski et al., 2011). Despite recognition of the 
major contribution of placentation to adverse perinatal outcomes the underlying 
pathophysiology remains poorly understood.  
1.2 The placenta 
The placenta is the first organ to form during pregnancy (Rossant and Cross, 
2001), and is vital to support the survival and growth of the fetus in utero. 
Without the placenta, the procreation of the mammalian species is not possible.  
The placenta forms an interface between the mother and fetus, performing its 
main function of facilitating the exchange of gases, nutrients and metabolic 
wastes. The placenta is also a barrier, protecting the fetus from the harmful 
attack of pathogens and the maternal immune system (Rossant and Cross, 2001). 
It produces hormones and growth factors which are needed for the advancement 
and flourishing of the pregnancy; they uphold the balanced physiological 
condition in the uterus for the continuation of the pregnancy. The hormones and 
growth factors produced also affect the physiological changes of the maternal 
body, to adapt to and support the pregnancy.  
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Some authors simplify human and rodent placentas into 3 major anatomical 
structures; each structure has their specific roles in providing support for the 
placenta to function as a whole unit (Watson and Cross, 2005). The outer 
maternal layer, which consists of the maternal decidual cells and vasculature, 
provides the blood supply to the placenta. The middle junctional layer contains 
giant cells and spongiotrophoblasts that anchor the placenta to the uterus, these 
cells may also play a role in the process of decidual remodelling (Adamson et al., 
2002, Georgiades et al., 2002). The inner layer is the region where the maternal-
fetal vasculature intertwines and closely approximates each other for the 
exchange of gases and nutrients.  
The most important cells in the placenta are the fetal-derived trophoblasts. 
They are the main cells that line the maternal-fetal interface, the main 
structure for the placenta to serve its function (Rossant and Cross, 2001). 
Trophoblasts also have a major role to play in orchestrating the process of 
successful placental morphogenesis.  
1.2.1 The human placenta 
The mature human placenta is a discoid organ; its size and weight vary between 
individuals (Fig 1.1a). The mean radius of round placentas was estimated to be 
9.1cm at term, with the mean thickness at the centre of 2.5cm (Salafia et al., 
2010, Benirschke et al., 2012). The majority of placentas are round or oval in 
shape, however, in 10% of cases, the placentas have different shapes 
(Benirschke et al., 2012). They can have a smaller accessory (succenturiate) lobe 
(placenta succenturiata), be bilobal in shape (placenta bilobata) or, when the 
separation of the lobe is more pronounced, it can appear almost entirely 
detached from the main part of the placenta (placenta duplex). With these 
abnormal non-oval shaped placentas there is a significant association with lower 
placental efficiency linking with either maternal utero-placental or feto-
placental vascular pathology (Salafia et al., 2010).  
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b) 
 
Figure 1.1 Schematic illustrations of the anatomy and chorionic villus of the full term human 
placenta. a) Fetal blood flows from the umbilical artery into the capillaries in the chorionic villi, 
which are bathed in the maternal blood in the intervillous space. b) The human placenta is 
monochorial, the syncytiotrophoblast is in direct contact with maternal blood. Gases and nutrients 
pass through one layer of syncytiotrophoblast, and the endothelium to reach the fetal circulation. 
Adapted from (Rossant and Cross, 2001). 
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a) 
 
 
b) 
 
Figure 1.2 Schematic illustrations of the anatomy and labyrinth of mouse placenta. a) 
Maternal vessels and fetal umbilical vessels subdivide into capillaries in the labyrinth for fetal-
maternal exchange. b) The mouse placenta is trichorial as there are 3 layers of trophoblasts 
(bilayer of syncytiotrophoblasts and a monolayer of mononuclear trophoblasts) in the fetal-maternal 
membrane, distinguishable in electron micrograph (Georgiades et al., 2002). Gases and nutrients 
have to pass through these three layers of trophoblasts, and another layer of endothelial cells 
before reaching the fetal circulation. Adapted from (Rossant and Cross, 2001). 
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The side of the placenta facing the amniotic cavity is the fetal surface, also 
called the chorionic or amniotic surface. This surface appears glossy, due to the 
avascular, intact epithelium of the amnion that covers the chorionic plate 
(Benirschke et al., 2012). From the fetal surface of the placenta, the umbilical 
cord connects to the fetus. It carries the communicative vessels between the 
fetus and the placenta, which comprises one umbilical vein and two arteries that 
spiral within the cord. Surrounding those vessels is the jelly like connective 
tissue called the Wharton’s jelly. Wharton’s jelly gives the cord its sponge like 
characteristic. The site of insertion of the cord to the placenta is usually off 
centre (Pathak et al., 2010). Eccentric umbilical cord insertion has been 
associated with a decrease in placental efficiency, but has not been found to be 
linking with adverse obstetric outcome (Yampolsky et al., 2009, Pathak et al., 
2010). In slightly less than 1% of pregnancies, the cord inserts outwith the 
placenta into the membrane (velamentous cord insertion), with the blood 
vessels being exposed when they travel along the thin membrane (vasa praevia) 
before insertion into the chorionic plate (Sepulveda, 2006). This exposes the 
fetus to the danger of profuse blood loss if the vessels are punctured when the 
membrane ruptures either spontaneously or iatrogenically.  
The basal (maternal) surface of the placenta is traversed by sets of grooves, 
which divide this part of the placenta into different lobes, or cotyledons. Each 
of these cotyledons contains one or several chorionic villous trees, the principal 
functioning units of the placenta (Benirschke et al., 2012). The sub-branches of 
the blood vessels from the umbilical cord form the chorionic villous trees. The 
most common classification of the subdivision of the chorionic villi is the one 
described by Kaufmann et al. in 1979 (Kaufmann et al., 1979). The stem villi are 
the main framework providing support for the villous tree, they are formed at 
the start of the ninth week of pregnancy. These stem villi branch out, forming 
extensions called immature intermediate villi by the 16th week of pregnancy. 
Near the end of the second trimester, the stem villi also form mature 
intermediate villi, which are side branches more slender than the ones 
previously formed. By week 32, the mature intermediate villi begin to give rise 
to the terminal villi, which are grape-like capillaries forming the main fetal-
maternal interface (Schoenwolf et al., 2009). The chorionic villi channel the 
fetal blood to the fetal-maternal interface; fetal blood flows from the umbilical 
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arteries to the villi, and then returns via the umbilical vein. The chorionic villi 
are bathed in the maternal blood, which flows directly into the intervillous 
space. The fetal-maternal interface of a mature human placenta is 
haemochorial, with the mono-layered barrier of the syncytiotrophoblast, and the 
fetal endothelium separating the fetal and maternal blood (Fig 1.1b). Between 
the syncytiotrophoblast, and the fetal endothelium, there is a non-continuous 
layer of mononuclear villous cytotrophoblast, also known as the Langhans cells. 
From the first trimester until around 20 weeks, the fetal-maternal membrane 
comprises four layers: syncytiotrophoblast, cytotrophoblast, villous connective 
tissue and endothelium of fetal capillaries (Moore et al., 2013). At this stage the 
cytotrophoblast forms a continuous layer. After the 20th week of gestation, the 
continuity of the cytotrophoblast layer in most of the villi is broken due to 
cellular changes. In some of the distal villi the fetal-maternal interface becomes 
thinner, forming a vasculosyncytial placental membrane where the 
syncytiotrophoblast directly contacts the endothelium of the fetal capillaries 
(Georgiades et al., 2002). This thin surface provides close proximity for the fetal 
and maternal blood, and thereby enhances the efficiency of fetal-maternal 
exchange. 
At term, maternal blood flow to the placenta is estimated to be up to 
700ml/minute (Wang and Zhao, 2010), with a surface area for fetal maternal 
exchange of more than 10m2 (Ellery et al., 2009). This dynamism of placental 
function provides the support required for fetal survival until term pregnancy. It 
has been reported that maternal blood flow into the placenta is not established 
until at least after the first 12 weeks of pregnancy (Hustin and Schaaps, 1987), 
thereby protecting the early fetus from the oxidative stress and mechanical 
pressure from the maternal blood flow. During this period the delicate fetus is 
undergoing the important process of organogenesis (Georgiades et al., 2002).  
1.2.2 The murine placenta 
Murine placentas are widely used in research studies for greater understanding 
of the developmental, cellular and molecular structures and functions of the 
organ. Development of murine placentas is sensitive to genetic disruption 
(Rossant and Cross, 2001), and thus it is a good model for studies to gain new 
insights into the cellular and molecular biology of the placenta. Several 
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indispensible genes for mouse placental development, for example Mash2 and 
Gcm1, are also expressed in humans (Alders et al., 1997, Janatpour et al., 1999, 
Nait-Oumesmar et al., 2000), however the understanding of their functional role 
in human placental development is very limited (Rossant and Cross, 2001).  
The detailed anatomies of the murine and human placentae are not exactly the 
same (Fig 1.1 and 1.2), but grossly there are certain similarities in the structure 
of the functional units, and also the cellular mechanisms underlying their 
development (Table 1.1) (Rossant and Cross, 2001).  
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Anatomical site Structure/ cell Function(s) 
Murine Human 
Outer maternal layer Trophoblast giant cell Invasive extravillous 
cytotrophoblast 
Invasion and modelling of decidua 
Middle junctional 
layer 
Giant cell (differentiated 
from spongiotrophoblast) 
Cytotrophoblastic shell Anchoring villus (human) and labyrinth 
(murine) 
Inner layer 
 
Labyrinth Chorionic villus Fetal-maternal interface  
Single cotyledon Multiple cotyledon Containing labyrinth (murine) and chorionic 
villus (human) 
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Table 1.1 Structural and functional units of murine and human placentas. Summarised from (Georgiades et al., 2002, Rossant and Cross, 2001). 
 
 
 
Maternal-fetal 
interface (Fig 1.1b 
and 1.2b) 
Trichorial haemochorial Exchange of gases, nutrients and wastes. 
Physical barrier to hydrophilic substances. 
Invaginations on the surface facing maternal 
blood for both species, to increase absorption 
of substances. 
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Mouse placenta, like human, is discoid. Both the maternal and fetal arteries 
subdivide into smaller branches, and eventually into smaller capillaries at the 
fetal-maternal interface. The capillaries are interconnected and form a maze-
like architecture at the labyrinthine zone (LZ) in the inner layer of the placenta; 
the mouse placenta is described as a labyrinthine placenta (Georgiades et al., 
2002). LZ is the most important zone in the placenta. This is the area where the 
placenta performs its vital role of supporting the fetus in utero; the fetal 
capillaries are situated in close proximity with maternal blood, forming the 
fetal-maternal interface for crucial exchanges described above. Unlike the 
haemochorial human placenta, fetal-maternal membrane in the trichorial mouse 
placenta comprises three layers of trophoblasts, and also the fetal endothelium 
(Fig 1.2b). 
In mouse, it has been discovered that LZ continues to grow up to E18.5, even 
though the maximum volume of the placenta is reached at E16.5 (Coan et al., 
2004). This leads to an increase in the representative proportion of LZ in the 
placenta, essential in supporting the bigger pup at this gestation.  It has also 
been proven that smaller volume of LZ is related to fetal growth restriction, 
even after taking into account the size of the whole placenta in relation to the 
fetal weight (Coan et al., 2008, Coan et al., 2010). Within this functional zone, 
stereological analyses showed malformation of microstructures could also cause 
growth restriction in the fetuses. Stereology is a well established method for 
generating absolute three-dimensional (3D) quantities from two-dimensional (2D) 
paraffin and resin histological sections (Coan et al., 2004). This method of 
analysis showed that compromised fetuses had smaller surface area of fetal and 
maternal trophoblast membrane, shorter total capillary length, and also larger 
mean fetal-maternal membrane thickness; these lead to poorer theoretical 
diffusion capacity in the fetal-maternal interface (Coan et al., 2008).  
Recent studies of placental development in rats show that the pattern of 
placental invasion of this species may be more representative of human 
placentation (Caluwaerts et al., 2005, Carter et al., 2006). Trophoblast invasion 
in rats involves a deeper part of the placental bed, leading to the development 
of an area called the mesometrial triangle. The mesometrial triangle is an 
extension of the decidua, consists of a mass of decidualised cells and uterine NK 
cells, and also numerous loops of spiral arteries (Caluwaerts et al., 2005, Carter 
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et al., 2006). In contrary, the invasion of trophoblasts in mice is merely 
restricted to the decidua. The mesometrial triangle in rat pregnancy is thought 
to be somewhat comparable to the invasion of the inner myometrium in human; 
structural arterial changes in this area has been studied to understand the 
process of uterine spiral arteries remodelling in rat pregnancy (Caluwaerts et 
al., 2005, Vercruysse et al., 2006, Geusens et al., 2010). It has been suggested 
that trophoblast invasion may play a more important role in rat pregnancy in 
comparison the mouse (Carter et al., 2006). It will be interesting to follow the 
development of further comparative studies. Perhaps in the future the rat will 
be more frequently used for placental research when more experimental genetic 
model systems are available for this species.  
1.3 The critical role of successful placentation in 
pregnancy 
For successful placentation, the decidua has to tolerate the invasion of the 
embryo, and also protect this semi-allogeneic tissue from maternal 
immunological rejection. The decidua is subjected to modification of the tissues 
and blood vessels for adequate formation of vasculature to the placenta for an 
increased and undisturbed blood supply (Georgiades et al., 2002).  
As early as day six in human pregnancy, the blastocyst comes into the close 
proximity of the uterine epithelium, a process referred to as apposition (Hannan 
and Salamonsen, 2007). This is followed by the process of adhesion (Hannan and 
Salamonsen, 2007), and then invasion of the endometrium by 
syncytiotrophoblast at day seven to nine (implantation). Prior to implantation, 
the blastocyst consists of only 50-60 trophoblasts, thus vast proliferation of 
trophoblast happens after endometrial invasion (Cross, 2000). After 
implantation, cytotrophoblasts from the trophectoderm proliferate and 
emanate, breaking through the primitive syncytium to reach the basal plate 
(Knofler and Pollheimer, 2013). On the distal sites, proliferative cell columns of 
these cytotrophoblasts give rise to invasive extravillous trophoblasts. During 
placentation, the formation of vascular network involves branching 
morphogenesis of the epithelial surface along with underlying stroma. This is an 
embryonic developmental mechanism to construct large areas of maternal-fetal 
interface for exchanges of nutrients and gases (Cross et al., 2003). 
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In the subsequent weeks, the extravillous trophoblasts erode the maternal 
connective tissues and spiral arteries via two routes. The first route of invasion 
is directly into the decidual stroma, the extravillous trophoblasts that invade via 
this route are termed interstitial extravillous trophoblasts. The second group of 
extravillous trophoblasts, termed endovascular extravillous trophoblasts, 
migrate to the lumen of the spiral arteries following the erosion of the maternal 
endometrial tissues. These two groups of extravillous trophoblasts play a major 
role in the remodelling of the spiral arteries within the decidua and the inner 
third of the myometrium (Pijnenborg et al., 1980). They contribute to the 
destruction of the endothelium, vascular smooth muscle and elastic lamina, and 
the replacement of these structures by fibrinoid (Lyall et al., 2013). A recent 
study systematically quantified changes in spiral artery features in human; it 
revealed a major defect in myometrial spiral artery remodelling in pregnancies 
associated with pre-eclampsia and fetal growth restriction (Lyall et al., 2013). 
Immunostaining detected differences in the quantity and functional status of 
extravillous trohoblasts in the myometrial vessels between these pregnancies 
and the normal pregnancy. Less fibrinoid deposition was detected in abnormal 
pregnancies, associated with inadequate spiral artery remodelling. The study 
also demonstrated the capability of extravillous trophoblasts to migrate deeply 
into the myometrium during placentation. Endovascular extravillous trophoblasts 
are also believed to serve the purpose of controlling the timing and amount of 
maternal blood flow into the placenta (Hamilton and Boyd, 1966, Pijnenborg et 
al., 2006, Knofler and Pollheimer, 2013). This regulatory process of placentation 
eventually allow the flow of maternal plasma and blood into the intervillous 
space of the placenta in the late first trimester, forming the maternal-fetal 
interface for the placenta to carry out its primary function (Huppertz, 2007, 
Burton et al., 2010).  
Human is not the only species with haemochorial placenta. The placenta from 
higher and lower simian primates are also haemochorial (Rosenberg and 
Trevathan, 2007, Cole, 2009). In comparison with trichorial placenta as 
described earlier, there are fewer layers separating the maternal-fetal blood in 
the haemochorial interface, allowing more efficient exchanges to happen. In 
human, the degree of trophoblast invasion is unusually deep in comparison to 
other mammalian species, and up to the first third of uterine myometrium and 
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spiral arteries are invaded by trophoblasts during the process of implantation 
(Hannan and Salamonsen, 2007). Even in higher simian primates like baboon and 
orang-utan, only one tenth of the myometrium is invaded (Cole, 2009). The 
depth of placental invasion in human gives rise to adequate remodelling of spiral 
arteries in both the decidua and myometrium, transforming them into distended, 
thin-walled flaccid vessels (Lyall et al., 2013). These remodelled vessels form a 
vast network for maternal blood flow into the placenta at low pressure, creating 
a large surface area for feto-maternal exchange without subjecting the placenta 
to the stress of high pressure flow. This mechanism provides sufficient blood 
supply to the feto-maternal membrane, bringing essential nutrients and oxygen 
needed for the development of the brain of the human fetus. Via evolution, 
human has a uniquely large brain to body mass ratio in comparison to other 
mammals, and even our closely related primates; relative to other mammals it is 
thought that the development of the human brain requires ultra high energy and 
nutritional provision from the maternal blood supply (Gibbons, 1998, Rosenberg 
and Trevathan, 2007, Cole, 2009, Carter and Pijnenborg, 2011). This high 
demand of placentation predisposes human to pathological processes, for 
example pre-eclampsia/eclampsia, which is believed by some to be unique to 
pregnancy of human species (Rosenberg and Trevathan, 2007, Cole, 2009). 
Humans also have a higher pregnancy failure rate (41% vs. ≤10%) in comparison 
to other mammalian species (Wilmut et al., 1986). Interestingly, pre-eclampia 
has been reported in gorillas and chimpanzees (Thornton and Onwude, 1992, 
Carter and Pijnenborg, 2011). Similar to human pregnancy, during placentation 
in these great apes deep invasion of the interstitial and spiral arteries extends 
into the inner myometrium (Carter and Pijnenborg, 2011).  
A significant number of miscarriages and diseases in pregnancy are caused by 
failed implantation and inadequate placentation. While it is difficult to 
accurately determine the causes of miscarriages, it has been reported that 
failure of implantation accounts for up to 75% of miscarriages, which occurs in 
up to 50% of pregnancies before 20 weeks of gestation (Norwitz et al., 2001, 
Macklon et al., 2002, Christiansen et al., 2006). Failed implantation also 
potentially contributes to recurrent implantation failure in assisted conception. 
Besides determining the continuation of pregnancy at the early stages, 
inadequate placentation has also been associated with complications in later 
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gestational ages. Shallow invasion and inadequate placental villous formation 
are linked with severe pre-eclampsia, intrauterine growth restriction (IUGR), 
late sporadic miscarriage and preterm labour (Kim et al., 2003, Ball et al., 2006, 
Brosens et al., 2011, Kovo et al., 2013, Lyall et al., 2013). At the other extreme, 
excessive invasion of the trophoblasts can result in abnormally adherent 
placenta to the myometrium (placenta accreta) or even the uterine serosa and 
adjacent organs (placenta percreta), collectively classified as placenta creta in 
pregnancy (Norwitz et al., 2001). This poses a risk of major haemorrhage during 
the time of delivery. Recent studies have shown the importance of the decidua 
in regulating extravillous trophoblast invasion and spiral artery modelling; the 
absence of decidua is associated with placenta creta (Tantbirojn et al., 2008, 
Hannon et al., 2012).  
1.4 Communication between maternal and fetal cells 
during placentation 
During implantation, the female reproductive tract is not immunologically inert. 
Specialised immune cells are recruited to precise locations to aid the 
appropriate invasion of the developing placenta into the endometrium, 
remodelling of the endometrial vessels, and also providing immunological 
sanctuary for the conceptus. During the female menstrual cycle, the number of 
immune cells (decidual leukocytes) increases substantially from proliferative 
towards mid-secretory phase to prepare for implantation of the embryo (Bulmer 
et al., 2010). In early pregnancy the majority of cells (up to 70%) in the decidua 
are leukocytes (Red-Horse et al., 2004). These immune cells consist of 
neutrophils, uterine natural killer (uNK) cells, macrophages, T cells and 
dendritic cells.  
Optimal crosstalk between the maternal and fetal cells determines the success 
of implantation, and the outcome of pregnancy. The endometrium is only 
receptive to implantation during a very short period in the menstrual cycle 
during the mid-secretory phase, known as the ‘window of receptivity’ 
(Dimitriadis et al., 2010). Following the priming with oestrogen, and under the 
influence of progesterone, the endometrium undergoes decidualisation. Besides 
the infiltration of large number of leukocytes, the process is also characterised 
by the differentiation of stromal cells in the endometrium, the modification of 
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the extracellular matrix (ECM), and the increase in vascular permeability 
(Garlanda et al., 2008). In the mid-secretory phase, regulatory molecules such as 
LIF, CX3CL1 and CCL14 are released into the uterine lumen (Dimitriadis et al., 
2010), affecting the behaviour of the cells in the blastocyst coming into contact 
with the decidua. Fetal cells in the blastocyst are first presented to the uterine 
epithelial cells during apposition. At this very first stage of implantation, 
dialogues are established between these two groups of cells, utilising soluble 
mediators being released and regulated precisely locally. This crosstalk not only 
influences the receptivity of the endometrium to the implantation of the 
blastocyst, but also triggers the expression of a unique repertoire of surface 
adhesive molecules on both fetal and maternal cells, for example L-selectin on 
the trophoblasts, and integrins on the endometrium (Genbacev et al., 2003, 
Hannan and Salamonsen, 2007, Mangale and Reddy, 2007). Within the placenta 
throughout pregnancy, there are also other stages where fetal cells are in close 
contact and directly communicating with maternal cells: the migration of the 
invasive interstitial extravillous trophoblast into, but not through, the inner third 
of the myometrium; the remodelling of the wall of the uterine spiral arteries by 
the endovascular trophoblast; and the role served by villous syncytiotrophoblast 
as an endothelial-like lining soaking in maternal blood in the placental 
intervillous space (Huppertz, 2007). These cellular and molecular interactions 
ensure placentation is successful to serve its function in supporting and 
protecting the fetus throughout pregnancy, and at the same time not over 
adherent so that it can be separated after delivery to avoid haemorrhage.  
1.5 Receptivity of decidua to the invasion of semi-
allogeneic embryo 
In prehistoric life, placental pioneers (the group of mammals whose young 
develop inside their bodies) appeared 135-65 million years ago in the Late 
Cretaceous period (Lambert et al., 2001). Prior to this era, even mammals are 
thought to have produced eggs where the shells separated the offspring from 
their mother’s body. One reason for this is that placentation requires complex 
immunological regulation, and it took millions of years for this adaptation to 
emerge. Interestingly there are exceptions to this biological evolution. 
Monotremes such as duck-billed platypus and spiny anteaters are modern egg-
laying mammals. Marsupials are pouched mammals which delivers their offspring 
   36
at a very early fetal stage, where the young lived in the pouch, completing the 
maturation by attaching to the teats which lactate milk with specific 
components, controlling the development of the babies (Trott et al., 2003). 
Although the pregnancy of marsupials occurs over a relatively short period of 
time, in some species of marsupials there is evidence showing the presence of 
maternal recognition of pregnancy, leading to changes necessary in the uterine 
environment to accommodate the growing fetus (Renfree, 1972, Renfree, 2000).  
Understanding the immunological regulation of embryonic implantation into the 
decidua remains a huge challenge. The embryo carries histocompatibility 
antigens from the father (Bulmer et al., 2010), and yet the mother’s decidua can 
tolerate the invasion of this foreign body and coexist with it until the delivery of 
the fetus. One experiment in the 1970s revealed female mice could carry the 
fetuses fathered by allogeneic or semi-allogeneic males, but readily rejected 
organs transplanted from the same males (Borland, 1975). This phenomenon 
shows the uniqueness of the immunomodulation of the female reproductive tract 
during the time of implantation and pregnancy. Different experiments have been 
performed to study the tolerogenic properties of the maternal immune system 
towards the placenta, leading to various models being constructed. The 
following sections provide a summary of some of the models described. The role 
of chemokines in pregnancy will be discussed later in section 1.7. 
1.5.1 Regulation of antigen presentation in the placenta 
During pregnancy in both humans and mice, there seems to be mechanisms in 
place to regulate the presentation of fetal antigens to the maternal immune 
system to avoid the phenomenon of graft rejection. 
It is well known that T cells only recognize an antigen when it is associated with 
a major histocompatibility complex (MHC) molecule, in humans it is also called 
human leukocyte antigen (HLA). The MHC is a region of multiple loci that 
function as antigen-presenting structures; they play major roles in determining 
whether transplanted tissue will be accepted as self (histocompatible) or 
rejected as foreign (histoincompatible). T cells interact with the MHC either 
through the direct or indirect pathway. Most cells express MHC class I. In the 
direct pathway CD8+ T cells directly engage MHC I complexes on the surface of 
   37
the transplanted cells. Host CD8+ T cells that recognise peptides in the context 
of MHC I kill the transplanted cells by this direct pathway. In the indirect 
pathway, peptides have to be presented, or cross-presented, by host antigen 
presenting cells (APCs) in a host MHC-restricted fashion. MHC II are only 
expressed by APCs; CD4+ T cells are activated by engaging with these MHC 
complexes. APCs also prime CD8+ T cells by cross-presenting antigens on MHC I.  
In mouse pregnancy, the fetal allograft is presented exclusively through the 
indirect pathway; T cell engagement requires the uptake and processing of 
fetal/placental antigen by maternal APCs (Erlebacher et al., 2007). Mouse 
pregnancy has the ability to avoid direct antigen presentation for T cell 
recognition.  This relatively minor allorecognition pathway removes a major 
threat to fetal survival, since it avoids the large number of T cells that typically 
drive acute transplant rejection in mouse, through their ability to directly 
interact with foreign MHC I molecules. In these experiments it was also observed 
that T cells that indirectly recognise the fetus were poorly primed and 
underwent clonal deletion.  
Collins et al described that the mouse fetus and placenta are encased by the 
decidua, a stromal cell-derived structure (Collins et al., 2009). The authors 
discovered that dendritic cells stationed at the fetal-maternal interface were 
unable to travel to the lymphatic vessels of the uterus and thus reach the 
draining lymph nodes. Dendritic cells function as critical antigen-presenting cells 
for naive T-cell activation. After capturing antigen in the tissues, dendritic cells 
usually migrate to various lymphoid organs where they present the antigen to 
lymphocytes. Entrapment of dendritic cells at the fetal maternal interface is 
therefore an important mechanism by which the alloantigen (fetus and placenta) 
can escape the T cell response.  
In human, HLA class II molecules are immunogenic cell surface markers 
associated with allogeneic transplant graft rejection (Ober, 1998); thus 
prevention of direct antigen presentation may not effectively avoid fetal 
rejection. Fetal derived trophoblast cells have unique patterns of HLA expression 
in comparison to other nucleated cells. These trophoblasts, which are in contact 
with the maternal immune system, do not express HLA-A and HLA-B (HLA class I 
gene), or HLA-DR, HLA-DQ and HLA-DP (HLA class II genes) (Hunt et al., 1987, 
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Mattsson, 1998, Ober, 1998, Rizzo et al., 2011). Instead these cells express HLA-
G, a non-classical class I molecule, and also low levels of HLA-C, HLA-E and HLA-
F (Ishitani et al., 2003).  
Although there is a lack of major histocompatibility complex (MHC) molecules 
expression in the trophoblasts, maternal antibodies against paternally derived 
HLA expressed by the fetus are detectable in pregnancies. The maternal immune 
system is probably sensitised by fetal nucleated cells that have escaped into the 
maternal circulation. Paradoxically, incompatibility of HLA expression between 
the parents is thought to be beneficial for pregnancies. In prospective and 
retrospective studies, HLA-A and HLA-B matched couples were observed to have 
higher miscarriage rates (Schacter et al., 1979, Ober, 1998). In pregnant 
subjects with rheumatoid arthritis (RA), women with pregnancy-induced 
amelioration of their RA had more maternal-fetal disparities in the alleles at 
HLA-DRB1, HLA-DQB1 and HLA-DQA1 loci, compared with pregnancies affected 
by active RA (Nelson et al., 1993). These observations suggest increased 
variability of HLA expressions in the offspring may have an important role in 
immunomodulation during pregnancy. The exact mechanism of this process is yet 
to be explored.  
HLA-G is strongly expressed during pregnancy. It was initially detected only in 
fetal cells at the maternal-fetal interface, but expression was later found in 
thymus, cornea, erythroid and blood cells, and also in non-physiological 
environment in transplantation, cancer, infections and autoimmunity (Rizzo et 
al., 2011). HLA-G is a HLA gene that has an intron-exon structure identical to 
other class I genes, with a premature stop in exon 6 resulting in a much shorter 
cytoplasmic tail with six amino acids (RKKSSD) (Park et al., 2001). The truncated 
tail lost its potential endocytosis signals found in the cytoplasmic tail with a 
tyrosine or dileucine-based motif in all other MHC class I molecules. This results 
in a slower turnover and prolonged expression of HLA-G at the cell surface, and 
a diminished retrieval of this molecule upon assembly with high affinity 
peptides; HLA-G is not an efficient molecule to present exogenous peptides 
(Park et al., 2001). Due to this characteristic, it is thought this molecule’s main 
function is in immunomodulation. HLA-G is presented in many different 
transmembrane and soluble isoforms due to alternative splicing; in the soluble 
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forms, transmembrane and cytoplasmic domains are absent in the molecules 
(Ober, 1998).  
HLA-G has been found to suppress the proliferation and cytotoxic ability of T 
cells and natural killer (NK) cells. Through its ability (HLA-G5 isoform) to induce 
the differentiation of T cells into regulatory T cells (Treg), it may also be 
responsible for better graft acceptance (Le Rond et al., 2006). In another 
experiment, HLA-G1 transfected antigen-presenting cells (APCs) were capable of 
inhibiting the proliferation and induce anergy of CD4+ T cells and providing non-
antigen specific, inhibitory or proapoptotic signals (LeMaoult et al., 2004). 
Soluble HLA-G can induce apoptosis in CD8+ T cells, possibly via the Fas ligand 
(FasL) pathway (Contini et al., 2003). In human placenta, HLA-E is found to be 
co-expressed in all cells that express HLA-G. It is thought that HLA-G and HLA-E 
act synergistically, binding to CD94/NKG2 receptor on NK cells, leading to their 
inhibition (Ishitani et al., 2003). In the context of in vitro fertilisation in assisted 
reproductive treatment, HLA-G expression was associated with better quality 
embryos with higher cleavage rates; pregnancy rates were better when their 
sibling embryos from the same treatment cycle were replaced (Jurisicova et al., 
1996a, Jurisicova et al., 1996b).  
1.5.2 The role of regulatory T cells (Treg) in pregnancy 
Balance between the subtypes of CD4+ helper T cells is one of the classic models 
described in immunohomeostasis in pregnancy. CD4+ T cells can be classified 
into Th1 cells, which are involved in cellular immunity; Th2 cells, which are 
involved in humoral immunity; Th3 cells, which produce immunosuppressive 
cytokine transforming growth factor (TGF)-β; Treg 1 cells, which produce 
immunosuppressive cytokine interleukin (IL)-10; and also CD4+CD25+ regulatory T 
cells (CD4+CD25+ Treg) (Saito et al., 2007). Other Th subsets have also been 
described more recently (e.g. Th17 cells). Traditionally the model of Th1/Th2 
shift has been used in pregnancy, where successful pregnancy was believed to be 
a Th2 phenomenon; this model is now thought to be an oversimplification 
(Chaouat, 2007). The role of immunoactivation is played by Th1 and Th2 cells, 
while Th3 and Treg 1 cells are responsible for immunoregulation (Saito et al., 
2007).  
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Recent studies discovered that CD4+CD25+ Treg is essential in maintaining 
tolerance of semi-allogeneic fetus in mouse. These cells are increased 
significantly during pregnancy. This phenomenon occurs in the conception of 
both syngeneic and semi-allogeneic fetuses, thus is independent of the exposure 
of paternal alloantigen (Aluvihare et al., 2004). Mice depleted of CD4+CD25+ Treg 
carrying semi-allogeneic fetuses are shown to have no successful pregnancy, 
while 50% of those carrying syngeneic fetuses had normal pregnancies (Aluvihare 
et al., 2004). In vitro, CD4+CD25+ Treg transfer has been shown to inhibit the 
proliferation and secretion of interferon-γ by lymphocytes from the spleen and 
decidua; in vivo it prevents fetal rejection in mice prone to abortion, produced 
by mating CBA/J females with DBA/2J males resulting in the initial abortion rate 
of 18% (Zenclussen et al., 2005). These results confirmed that CD4+CD25+ Treg 
have an important role in protecting fetuses in mice.  
In human, systemic CD4+CD25+ Treg level is increased in pregnancy. It starts to 
elevate from the early gestational period, peaks during the second trimester, 
and declines after delivery (Somerset et al., 2004). A few theories of the 
regulation of CD4+CD25+ Treg in pregnancy have been presented. CD4+CD25+ Treg 
expresses chemokine receptor CCR4 (Curiel et al., 2004). CCR4 has two ligands, 
CCL17 and CCL22, which are known to be secreted by the maternal and fetal 
tissues in pregnancy. These chemokines may be responsible to attract Treg cells 
to the decidua, similar to the mechanism of Treg being attracted to tumours 
secreting CCL22 (Curiel et al., 2004). In a different study, the authors discovered 
oestrogen treatment increased the expression of Foxp3 in vivo and in vitro 
(Polanczyk et al., 2004). Foxp3 is a transcription factor that controls the 
phenotype and function of Treg, it is also a reliable marker for CD4+CD25+ Treg 
cells (Fontenot et al., 2003).  
Collectively the above findings suggest pregnancy upregulates and attracts 
CD4+CD25+ Treg cells locally to modulate the maternal immune system. Recent 
observations suggest in human CD4+CD25+ Treg can be subgrouped into 
CD4+CD25high and CD4+CD25low; CD4+CD25high Treg has a strong immunoregulatory 
role, and should be studied specifically to ascertain the role of CD4+CD25+ Treg 
in pregnancy (Saito et al., 2005, Saito et al., 2007).  
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1.5.3 Uterine natural killer (uNK) cells 
As part of the innate immune response, natural killer (NK) cells are bone 
marrow-derived lymphocytes that are able to secrete cytokines and kill target 
cells without prior sensitisation. This characteristic gives NK cells important 
roles in tumour immunity, host defence against intracellular pathogens, 
rejection of bone marrow transplants, and the development of acquired 
immunity through the production of specific cytokines (Riley and Yokoyama, 
2008). During the first trimester of human pregnancy, more than 75% of the 
immune cells in the decidua are uterine natural killer (uNK) cells, a subset of NK 
cells with the cell surface phenotype of CD56bright/CD16- (Bulmer et al., 1991, 
Moffett-King, 2002). In the periphery this subset only makes up 10% of the total 
number of peripheral blood NK (pNK) cells (Cooper et al., 2001). CD56bright/CD16- 
NK cells produce abundant cytokines following activation by 
monocytes/macrophages, but have low cytotoxicity. When macrophages 
encounter pathogens as part of the innate immune response, they produce 
monocyte-derived cytokines (monokines) such as IL-12 and IL-15. When activated 
by these monokines, CD56bright/CD16- NK cells produce much more interferon γ 
(IFN-γ) compared with CD56dim NK cell subset. The IFN-γ released by 
CD56bright/CD16- NK cells is requisite for the elimination of the pathogens, it also 
elicits a positive feedback response resulting in further release of monokines 
from the monocytes (Cooper et al., 2001).  
Comparison of uNK and CD56bright/CD16- pNK cells showed differences in the 
expression of 278 genes, the majority of which encode surface proteins 
(Koopman et al., 2003). uNK cells in first trimester gravid uterus have also been 
found to be distinctive from the uNK cells in non-pregnant cycling endometrium 
(Kopcow et al., 2010). uNK cells in pregnancy (decidual NK) preferentially 
express cholesterol 25-hydroxylase, which may affect the synthesis of 
cholesterol and steroid hormones in the decidua (Kopcow et al., 2010). Other 
decidual NK cells specific molecules may have immunomodulatory functions 
during pregnancy, for example CCL4, interleukin 16 and CD9 (Koopman et al., 
2003, Kopcow et al., 2010). These findings suggest uNK are specialised cells, 
playing an important role during pregnancy. 
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The receptors on uNK cells can be classed as activating (for example NKp46, 
NKp44, NKp30, NKG2d, and 2B4) or inhibitory (for example LIR-1, KIR2DL4, and 
CD94/NKG2A) (Bulmer et al., 2010). During pregnancy, the expression of KIR2D 
on uNK cells is upregulated (Verma et al., 1997, Sharkey et al., 2008, Male et 
al., 2011). The KIR2D receptor recognises maternal and fetal HLA-C, which is 
expressed on extravillous trophoblasts and uterine stromal cells when the 
endometrium transforms into decidua in pregnancy (King et al., 2000, Chazara et 
al., 2011, Male et al., 2011).  This pregnancy related transformation biases uNK 
cells towards HLA-C interaction, which appears to regulate trophoblast invasion 
and vascular remodelling (Hanna et al., 2006, Lash et al., 2006, Male et al., 
2011). The pattern of expression of KIR and HLA-C are highly polymorphic. While 
KIR2DL4, KIR3DL2 and KIR3DL3 are present in all individuals, the expression of 
other KIRs is variable (Nowak et al., 2011). Two different haplotypes are 
commonly described: “A” haplotypes consist of seven mostly inhibitory KIR 
genes, while “B” haplotypes have additional activating KIR genes in addition to 
the inhibitory ones; HLA-C is classified to C1 and C2 allotypes based on a 
dimorphism at position 80, each of these allotypes binds to different sets of KIRs 
with different affinities (Male et al., 2011). It is thought that the combination of 
different maternal and fetal KIR and HLA-C variants can affect the depth of 
placentation and the outcome of pregnancy (Hiby et al., 2004, Hiby et al., 2008, 
Hiby et al., 2010, Male et al., 2011). Women with KIR AA genotype have an 
increased risk of adverse pregnancy outcome, particularly if this is combined 
with certain maternal and fetal HLA-C genotypes (Hiby et al., 2010, Nowak et 
al., 2011). 
As mentioned above, it is believed CD94/NKG2A reacts with HLA-G and HLA-E 
leading to the inhibition of uNK cells. Binding of HLA-G to KIR2DL4 on uNK cells 
led to the production of cytokine IFN-γ, which may have roles of controlling the 
invasion of trophoblasts, or modulating inflammation at the fetal-maternal 
interface (Rajagopalan et al., 2001, Hunt et al., 2005, Hu et al., 2006).  
uNK cells also secrete many other different cytokines, some of which were found 
to stimulate (CXCL8 and CXCL10) or inhibit (TNF-α, TGF-β1 and IFN-γ) 
trophoblast invasion (Bulmer et al., 2010). It was demonstrated that differences 
in gestational age affect the pattern of cytokines release from uNK cells (Lash et 
al., 2006, Bulmer et al., 2010). In theory, perhaps the cytokines produced by 
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uNK cells also differ depending on their location. This in turn can control the 
process of trophoblasts invasion up to the precise depth required. In human, 
research of uNK cells in pathological pregnancy has produced inconsistent results 
(Zenclussen et al., 2001, Bulmer et al., 2010). However, there is some evidence 
that an increased abundance of uNK cells in mid-secretory phase endometrium is 
linked to recurrent miscarriage, and is predictive of future miscarriage in 
subsequent pregnancy; severe IUGR and pre-eclampsia have also been associated 
with an alteration in the number of uNK cells in the decidua (Quenby et al., 
1999, Eide et al., 2006, Bulmer et al., 2010).   
1.5.4 Decidual macrophages 
Macrophages are the second most abundant leukocytes in the decidua next to 
uNK cells. They represent 20% of white blood cells in the maternal-fetal 
interface during pregnancy (Lessin et al., 1988). In general, functionally 
polarised macrophages can be broadly grouped as classically activated, M1, or 
alternatively activated, M2 (Mantovani et al., 2004, Rozner et al., 2011). M1 has 
cytotoxic property, and usually responds to inflammatory stimuli; M2 is more 
involved in immunoregulatory processes, and also tissue remodelling and 
regeneration. Studies suggested macrophages in the decidua are distinctive 
subsets of cells, not fitting in the conventional pro-inflammatory (M1) or anti-
inflammatory (M2) macrophages (Houser et al., 2011). Phenotypically, most of 
the decidual macrophages express CD14, with about 70% expresses C-type lectin 
CD209 (DC-SIGN) (Kammerer et al., 2003). CD14 is frequently used as a marker 
for the identification of decidual macrophages (Bulmer et al., 2010). The role of 
macrophages during placentation is not fully understood. Decidual macrophages 
constitutively produce abundant IL-10 and CCL18, suggesting their characteristic 
is closer to M2 (Lidstrom et al., 2003, Gustafsson et al., 2008, Erlebacher, 2013). 
Contradictorily, in vitro they have been shown to induce pro-inflammatory 
cytokines such as IL-6 and TNF-α with LPS stimulation (Li et al., 2009, 
Erlebacher, 2013). One study comparing the cells of Rhesus Monkey showed that 
decidual macrophages release higher level of CCL3 and CCL4, and same level of 
CCL2 and CXCL8 comparing to peripheral blood monocyte-derived macrophages 
(Rozner et al., 2011). Helige et al. revealed decidual macrophages have the 
ability to restrained uNK cells from killing extravillous cytotrophoblasts, 
controlled by a TGF-β dependent mechanism (Helige et al., 2013). There has 
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been some interest in studying the functional roles of the two separate groups of 
decidual macrophages: CD209+CD11CLO macrophages and CD209-CD11CHI 
macrophages (Houser et al., 2011, Erlebacher, 2013). As mentioned above, 
majority (~70%) of the macrophages consists of the earlier group. CD209-CD11CHI 
macrophages are able to process protein antigen, and are believed to be the 
major antigen-presenting cells (APCs) in the decidua (Houser et al., 2011, 
Houser, 2012). They are not known to migrate to the draining lymph nodes of 
the decidua, thus provide the advantage of avoiding immune recognition by T 
cells. The lack of DCs in the decidua suggests that CD209-CD11CHI decidual 
macrophages may be the most important APCs during placentation.   
1.5.5 B7 family T-cell co-stimulatory molecules 
There has been some research interest into the role B7 family of co-stimulatory 
molecules in regulating immune responses in pregnancy. Based on the two-signal 
model of T-cell activation, APCs interact with T cells by presenting the antigen 
associated with MHC, for ligation to the T-cell receptor (TCR) (first signal). A 
second co-stimulatory signalling between these two cells is provided by the co-
stimulatory B7 receptors. This set of receptors regulates the immune response 
by their stimulatory or inhibitory effects upon binding to their ligands. B7-1 
(CD80) and B7-2 (CD86) were expressed by cultured human decidual stromal 
cells, and the cells were able to stimulate allogenic T cells in vitro (Olivares et 
al., 1997). In vivo studies revealed that blockade of these receptors at the time 
of implantation inhibits maternal rejection of the allogenic fetuses in abortion 
prone mouse matings (Jin et al., 2005). At the fetal-maternal interface, 
inhibitory co-stimulatory receptors were also detected. Cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), a negative regulator of T cell activation was 
detected on human placental fibroblasts throughout gestation (Kaufman et al., 
1999). Paradoxically women with spontaneous miscarriage had a higher 
expression of this molecule. Recurrent miscarriage was associated with a higher 
ratio of expression of CTLA-4 to CD28, another co-stimulatory receptor, 
suggesting a more complex mechanism of action (Wang et al., 2006b). The 
programme death-1 (PD-1) receptor, as its name suggest, has the character of 
initiating inhibitory pathway (Khoury and Sayegh, 2004). Its ligands, PDL1 and 
PDL2, were detected in human trophoblasts and mouse placenta (Petroff et al., 
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2003, Guleria et al., 2005). Blockade of PDL1 signalling was shown to result in 
rejection of allogeneic, but not syngeneic, concepti (Guleria et al., 2005).  
1.5.6 Other modulating pathways 
Complement regulatory proteins such as decay-accelerating factor (DAF, CD55), 
membrane cofactor protein (MCP, CD46) and CD59 were detected in human 
placenta from 6 weeks gestation until term (Holmes et al., 1992). The 
importance of these proteins was shown in the phenotype of mouse pregnancies 
in a study (Xu et al., 2000). Mouse Crry is a complement regulatory protein that 
controls C3 activation, like human DAF and MCP (Xu et al., 2000). Survival of 
Crry-/- mouse embryos was compromised, caused by C3 complement deposition 
resulting in placenta inflammation. The lethality of Crry-/- embryos was rescued 
by breeding to C3-/- phenotype, confirming the pathway of this protein in the 
regulation of fetal-maternal tolerance.  
Other immunomodulatory models being studied in pregnancies include 
macrophage migration inhibitory factor (MIF), a cytokine being expressed at the 
fetal-maternal interface (Arcuri et al., 2001). MIF regulates innate and adaptive 
immunity by affecting the trafficking and behaviour of macrophages and 
lymphocytes (Vigano et al., 2007). During pregnancy, MIF is thought to play a 
role in modulating trophoblastic invasion of the decidua by regulating cytolytic 
activity of NK cells; and secondly by controlling macrophages trafficking in the 
placental bed (Vigano et al., 2007). Elevated level of MIF has been observed in 
patients with pre-eclampsia, supporting the role of aberrant inflammatory 
process involved in this pathological process (Todros et al., 2005). Recurrent 
miscarriage was associated with suppressed level of MIF (Yamada et al., 2003).  
Collectively, these various studies have shown that during implantation, the 
interaction of the decidua with the semi-allogeneic embryo involves complex 
immunological pathways. A healthy immuno-regulatory environment is crucial to 
ensure a successful pregnancy. The evidence strongly suggests the presence of 
specialised leukocytes in the decidua is necessary during implantation. The 
trafficking of leukocytes to the organs in the body is highly dependent on 
chemoattractants. The family of chemokines is one of the most important groups 
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of chemoattractants; this group of proteins, and their receptors are explored in 
more details in the next section.   
1.6 Chemokines and their receptors 
1.6.1 Introduction to chemokines 
Chemokines, a large family of chemotactic cytokines, are small secreted 
proteins (Calderon et al., 2005). They are essential for the chemoattraction and 
activation of leukocytes and other type of cells, with a role to selectively moving 
subsets of these cells into, and between, microanatomical domains within 
tissues (Mackay, 2001). A cysteine motif in the N-terminal region of the mature 
chemokine molecule is highly conserved and adopts distinct arrangements that 
are used to classify chemokines into four subgroups:  C chemokines, CC 
chemokines, CXC chemokines, and CX3C chemokines (Bacon et al., 2002, 
Calderon et al., 2005). In C chemokines there is only one cysteine residue in the 
N-terminal region; in CC chemokines two cysteine residues are directly 
juxtaposed; in CXC chemokines the two cysteine residues are separated by a 
non-conserved amino acid; and in CX3C chemokines three amino acids separate 
the cysteine residues (Fig 1.3) (Zlotnik and Yoshie, 2000, Bacon et al., 2002). 
The cysteine residues are involved in forming disulphide bonds in the mature 
protein that maintain the structure of the protein.  Chemokines act by binding 
to their G protein-coupled receptors on the surface of the target cells. The N-
terminal tail of the chemokine is important in receptor activation, whilst the 
body of the chemokine mediates initial tethering of the chemokine to the 
receptor.  Other determinants, particularly at the C-terminus, are involved in 
mediating interactions with extracellular matrix components, including 
glycosaminoglycans, and this is important for the function of chemokines in vivo. 
A two-step model has been described for the activation of chemokine receptors: 
after the initial binding of the body of the chemokine to the receptor (first 
step), the chemokine undergoes conformational change due to the flexible N-
terminal tail (second step) (Fernandez and Lolis, 2002). The receptor is 
activated by the N-terminus of the chemokine following the conformational 
change, leading to the exchange of bound GDP to GTP in the α subunit of the G 
proteins. Subsequently, the G proteins dissociate from the receptor and trigger a 
cascade of signalling events within the cytoplasm of the cell (Fig 1.4). In relation 
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to leukocyte trafficking, each chemokine attracts a distinctive set of white blood 
cells (Le et al., 2004). Generally CC chemokines attract mononuclear cells, 
eosinophils and basophils; C chemokines attract T cells; CX3CL1 is chemotactic 
to T cells, natural killer cells and monocytes. The CXC group of chemokines are 
further subclassified into ELR+ and ELR-, depending on the presence of a triplet 
amino aced motif (Glu-Leu-Arg) that precedes the first cysteine residue in the 
primary amino acid sequence of the chemokines. ELR+ CXC chemokines have 
angiogenic property and attract neutrophil, while the ELR- group is angiostatic 
and attracts lymphocytes (Le et al., 2004). CXCL12 is an exception, it is an 
angiogenic ELR- CXC chemokine (Salcedo et al., 1999, Le et al., 2004).  
 
a)                                                                                   b) 
      
 
 
 
c)                                                                                    d) 
 
 
 
   
         β sheet                  α helix                 mucin domain                     disulphide bond 
Figure 1.3 Schematic illustrations of the major secondary structural motifs of the four 
chemokine subfamilies.  a) CX3C chemokine, CX3CL1 can occur as a transmembrane protein as 
shown, or after cleavage forming a soluble form; b) CXC chemokine; CXCL16, similar to CX3CL1 
as described above, is also produced as a transmembrane form that can be cleaved to be released 
as a soluble form; c) CC chemokine; d) C chemokine, depicted with dotted line as structure not fully 
known. Adapted from (Frederick and Clayman, 2001). 
   48
 
 
 
 
 
 
Figure 1.4 Structure and function of G protein coupled chemokine receptor. Interaction of 
chemokine ligand results in the exchange of GTP for GDP in the α subunit of the G protein. This 
dissociates the heterotrimeric G protein complex from the receptor into an α monomer and a β/γ 
dimer, triggering a cascade of signalling events. Information from (Fernandez and Lolis, 2002). 
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The production, localisation and destruction of chemokines are finely regulated 
by spatial and temporal controls (Comerford et al., 2007, Rodriguez-Sanabria et 
al., 2010). Chemokines are characterised as being either inflammatory or 
homeostatic. Inflammatory chemokines e.g. CCL3 are released in response to 
inflammatory stimulus, and they usually have rapid local effects and are short 
lived (Hannan and Salamonsen, 2007). Pathological conditions such as 
rheumatoid arthritis and airway inflammation have been associated with 
dysfunctional expression of inflammatory chemokines (Fox and Pease, 2005). 
Homeostatic chemokines are expressed constitutively for physiological 
maintenance of cells and tissues. For example CCL19 and CCL21 coordinate 
thymocyte trafficking within the thymus, and also control entry of T cells into, 
and movement within lymph nodes (Charo and Ransohoff, 2006, Teng et al., 
2011). The distinction of chemokines for their inflammatory or homeostatic roles 
is not absolute, as some chemokines can have both characters (Fox and Pease, 
2005), depending on the space and time of their release. The effects of 
chemokines locally and systematically are targeted and precise, but the 
mechanisms of their action can be very complex. In the process of cell 
signalling, chemokines have promiscuous interactions with the target cells; a 
responsive cell will usually have multiple receptors for different chemokines, 
and no chemokine is solely active on one leukocyte population (Borroni et al., 
2008). When required chemokines exert their influence multi-dimensionally, by 
binding to different receptors they selectively recruit specific populations of cell 
types. As a consequence, chemokines are known to play major roles in the 
biological functions of lymphoid trafficking, lymphoid organ development, 
wound healing, Th1/Th2 development, angiogenesis/angiostasis, metastasis, cell 
recruitment, and inflammation (Table 1.2) (Rossi and Zlotnik, 2003). 
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Receptor Chemokine ligands Examples of physiological functions and 
pathological connections 
CCR  
CCR1 CCL3  CCL5  CCL7  CCL14 RA; MS 
CCR2 CCL2  CCL7  CCL8  CCL13  
CCL16 
atherosclerosis; RA; MS; resistance to 
intracellular pathogens; type 2 DM 
CCR3  CCL5  CCL7  CCL8  CCL11  
CCL13 CCL26 CCL28 
allergic asthma & rhinitis 
CCR4 CCL17  CCL22 parasitic infection; graft rejection; T-
cell homing to skin 
CCR5 CCL2  CCL3  CCL4  CCL5  
CCL7  CCL8  CCL11  CCL13 
CCL14  CCL16 
transplant rejection 
CCR6 CCL20 mucosal humoral immunity; allergic 
asthma; intestinal T-cell homing 
CCR7 CCL19  CCL21 transport of T cells & dendritic cells to 
lymph node; antigen presentation; 
cellular immunity; T cells development 
in thymus 
CCR8 CCL1 dendritic-cell migration to lymph node; 
type 2 cellular immunity; granuloma 
formation 
CCR9 CCL25 homing of T cells & IgA+ plasma cells to 
the intestine; IBD; T cells development 
in thymus 
CCR10 CCL27  CCL28 T-cell homing to intestine & skin 
CXCR  
CXCR1 CXCL6  CXCL8 inflammatory lung disease; COPD 
CXCR2 CXCL1  CXCL2  CXCL3  
CXCL5  CXCL6  CXCL8   
inflammatory lung disease; COPD; 
angiogenic for tumour growth; 
improvement of neutrophil homing 
CXCR3-A CXCL9  CXCL10  CXCL11 inflammatory skin disease; MS; 
transplant rejection; T cell homing to 
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virally infected tissue 
CXCR3-B CXCL4  CXCL9  CXCL10  
CXCL11 
angiostatic for tumour growth 
CXCR4 CXCL12 HIV-1 coreceptor (T-cell-tropic); 
tumour metastases; haematopoiesis; 
blood vessels, brain and heart 
development 
CXCR5 CXCL13 formation of B-cell follicles; formation 
of lymph nodes and Peyer’s patches 
CXCR6 CXCL16 inflammatory liver disease; 
atherosclerosis 
CX3CR  
CX3CR1 CX3CL1 atherosclerosis 
XCR  
XCR1 XCL1 RA; IgA nephropathy; tumour response 
Table 1.2 Human chemokine receptors, their ligands, and involvement in physiological and 
pathological processes. RA: rheumatoid arthritis; MS: multiple sclerosis; DM: diabetes mellitus; 
IBD: inflammatory bowel disease; COPD: chronic obstructive pulmonary disease. Adapted from 
(Charo and Ransohoff, 2006), with updated information from (Bachelerie et al., 2014). 
 
1.6.2 Chemokine receptors 
Chemokine receptors are members of the G-protein-coupled receptors (GPCRs) 
superfamily. Their length ranges from 340 to 370 amino acids in general 
(Calderon et al., 2005). They display seven sequences of 20-25 hydrophobic 
residues that form α-helices that span the plasma membrane; an extracellular N-
terminus; three extracellular loops; three intracellular domains; and an 
intracellular C-terminal tail that contains numerous serines and threonines that 
become phosphorylated upon ligand binding to the receptor (Fig 1.4) (Calderon 
et al., 2005, Valles and Domínguez, 2006). As described earlier, binding of 
chemokines leads to dissociation of G proteins from the receptors. The target 
cells, utilising their surface receptors, gather information about the chemokines 
present and respond accordingly. The signalling cascades can result in 
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cytoskeletal reorganisation, integrin activation, and other processes that lead to 
increased cellular adhesion, migration and activation (Calderon et al., 2005). 
Mutational analyses of chemokine receptors have identified the specific regions 
that react with the ligands. It is believed that the chemokine binding and 
receptor activation sites are not the same; binding sites are spread throughout 
the polypeptide (Fernandez and Lolis, 2002). The activity of some chemokine 
receptors is also affected by post-translational modifications, for example 
sulfation of tyrosines in CCR5 is essential for the receptor to function effectively 
(Farzan et al., 1999, Fernandez and Lolis, 2002).  
Chemokine receptors are subdivided into groups depending on the subclass of 
chemokine that they typically bind to. Thus there are 10 CC chemokine 
receptors (CCR), six CXC chemokine receptors (CXCR), and one receptor each for 
CX3CL1 and XCL1, termed CX3CR1 and XCR1, respectively. Chemokines interact 
with their subgroup of receptors with considerable promiscuity.  Most receptors 
bind to multiple ligands and most ligands interact with more than one receptor 
(Zlotnik and Yoshie, 2000, Mackay, 2001, Murphy, 2002). This is particularly 
prominent amongst chemokines and their receptors that are involved in 
controlling leukocyte migration during inflammation. It is thought that this 
brings flexibility and robustness to inflammatory responses.  Pathogens, 
including viruses, bacteria and parasites have evolved ways of trying to subvert 
inflammatory chemokine networks and so receptor/ligand promiscuity may help 
ensure that leukocytes can still be recruited to infected tissues even if some of 
the components of the chemokine network have been subverted. Chemokine 
receptors have been detected on cancer and human immunodeficiency virus 
(HIV), thus they have received considerable attention in the search of 
therapeutic targets for these diseases (Frederick and Clayman, 2001).  
1.6.3 Role of chemokines in diseases 
The expression of chemokines has been studied in various disease models. The 
following sections provide a few examples of the role of chemokines in diseases. 
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1.6.3.1 Inflammatory diseases 
A number of chemokines promote infiltration and activation of specific 
leukocytes into injured or infected tissues in acute and chronic inflammatory 
conditions. This process is necessary for the removal of foreign microbial 
invaders, and also dead cells in would repair (Le et al., 2004). In sepsis, CC 
chemokines, for example CCL3 and CCL5, exert their pro-inflammatory effect by 
regulating organ specific leukocyte influx (Standiford et al., 1995, VanOtteren et 
al., 1995, Le et al., 2004). In mouse, overexpression of CXCL1 in the lung has 
been shown to provide resistance to Klebsiella pneumonia (Tsai et al., 1998). 
CCL2 and CCL22 protect mice from lethality in peritoneal sepsis (Matsukawa et 
al., 1999, Matsukawa et al., 2000). Not all chemokines are protective in 
infection. In the case of fulminant hepatic failure induced by Propionibacterium 
acnes in mice, CCL17 can markedly worsen liver damage by recruiting CCR4+ 
CD4+ T cells (Yoneyama et al., 1998, Le et al., 2004).  Interestingly, 
dysregulation of chemokine expression has also been implicated in a range of 
inflammatory disorders.  
In asthma, it is thought that the airway epithelial cells and macrophages release 
chemokines to attract mainly eosinophils, and also other asthma-related 
leukocytes such as basophils and Th2 lymphocytes (Lukacs, 2001). CCL5, CCL7 
and CCL13 have been detected in the airways of asthmatics (Wang et al., 1996, 
Lamkhioued et al., 2000). These are ligands for CCR3, which is highly expressed 
on eosinophils (Stellato et al., 1997). High levels of CCL2, CCL3 and CCL5 were 
associated with status asthmaticus, a life-threatening form of severe asthma 
(Tillie-Leblond et al., 2000, Lukacs, 2001). In patients with chronic obstructive 
pulmonary disease (COPD), CXCL8 and CXCL10 levels are increased, correlating 
with the infiltration of T cells expressing CXCR3, which is the receptor for 
CXCL10 (Saetta et al., 2002). Neutralisation of CXCL10 seems to depress allergic 
airway inflammation (Medoff et al., 2002).  
In rheumatoid arthritis, high concentration of CXCL1, CXCL5 and CXCL8 were 
detected in the sera, synovial fluids and synovial tissues, believed to be 
responsible for promoting angiogenesis and the recruitment of neutrophils to the 
joints (Szekanecz et al., 2009). Abundant CCL2, CCL3 and CCL5 have also been 
found in the tissues; these chemokines are chemoattractants to monocytes (Le 
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et al., 2004). CXCL12 is also present, and is believed to recruit CXCR4-expressing 
CD4 memory T cells (Nanki et al., 2000). The chemokine may also block T cells 
from activation-induced apoptosis, and also induce the migration of dendritic 
cells from the blood stream into the local area (Le et al., 2004).  
The role of chemokines in other inflammatory diseases has been studied. In 
animal models of acute glomerular or tubule-interstitial disease, CCL2, CCL3, 
CCL4 and CCL5 are expressed only in the diseased compartment of the kidney 
(Anders et al., 2003). Inhibition of CCL2 and CX3CR1 in rats, and also CCL5 in 
mice has been shown to reduce leukocyte infiltration, resulting in the 
improvement of renal function (Lloyd et al., 1997, Wenzel et al., 1997, Feng et 
al., 1999, Anders et al., 2003). In patients with active Crohn’s disease, mucosal 
biopsies showed a correlation of the expression of CXCL8 mRNA with clinical 
disease activity (Stallmach et al., 2004). Experiments using biopsies from 
inflammatory skin diseases including lichen planus and psoriasis demonstrated 
recruitment and maintenance of CXCR3 expressing T cells into the local area, 
regulated by the expression of CXCL9, CXCL10 and CXCL11 (Flier et al., 2001).  
1.6.3.2 Multiple sclerosis (MS) 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the 
central nervous system. It is associated with immune cells infiltration which 
consist of 10% CD4+ and CD8+ T cells, and 90% macrophages derived from 
infiltrating monocytes and resident microglia (Traugott et al., 1983, Charo and 
Ransohoff, 2006). The T cells express CCR5 and CXCR3; CCR7 expression in these 
activated effector cells is down-regulated (Balashov et al., 1999, Kivisakk et al., 
2004). Infiltrating monocytes express CCR1, CCR2 and CCR5 (Simpson et al., 
2000, Trebst et al., 2001). These monocytes down-regulate CCR1 when they 
mature into phagocytic macrophages in the later stages of MS (Trebst et al., 
2001). The ligands for these receptors (CCL2, CCL3, CCL4, CCL5, CCL8 and 
CXCL10) were detected in the lesions of multiple sclerosis (Charo and Ransohoff, 
2006). In animals, the model related to MS is autoimmune encephalomyelitis 
(EAE). This condition has similar pattern of chemokine expression as MS; 
expression of CCL2, CCL3, CCL4, CCL5 and CXCL10 is positively correlates with 
the severity of the disease (Godiska et al., 1995). Neutralising antibodies to 
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some of these chemokines can either inhibit the onset, or attenuate the severity 
of EAE (Karpus and Kennedy, 1997, Liu et al., 2001).  
1.6.3.3 Atherosclerosis 
The pathogenesis of atherosclerosis involves chronic inflammation of arterial 
blood vessels, characterised by accumulation of leukocytes, smooth muscle cells 
and lipids within the vessel wall (Ross, 1993, Reape and Groot, 1999, Calderon et 
al., 2005). The formation of fatty streaks, which consists of lipid-laden 
macrophages (foam cells), is the hallmark of early atherosclerotic lesions (Charo 
and Ransohoff, 2006). The expression of CCL2, CXCL8, CXCL12 and CX3CL1 has 
been associated with atherosclerosis. Expression of CCL2 is increased in human 
atherosclerotic plaques (Nelken et al., 1991). Production of CCL2 in endothelial 
and smooth-muscle cells is induced by the presence of minimally oxidised low-
density lipoprotein (LDL) cholesterol (Nelken et al., 1991). It is believed that 
CCL2 recruits foam cells into the vessel wall (Boring et al., 1998, Charo and 
Ransohoff, 2006). This chemokine has also been shown to enhance vascular 
smooth muscle proliferation in the presence of serotonin, a vasoconstrictor 
released by aggregated platelets (Watanabe et al., 2001). High level of serotonin 
is expressed in the coronary sinus of patients with coronary arterial disease 
(Rubanyl et al., 1987). In addition, CCL2 enhances the production of tissue 
factor by smooth muscle cells; tissue factor initiates the process of coagulation, 
and may play a role in the formation of thrombus and contribute to plaque 
instability (Schecter et al., 1997). In mice, deletion of CCL2 reduces the risk of 
diet-induced atherosclerosis (Gosling et al., 1999). In mice with apolipoprotein E 
deficiency (ApoE-/-) which were fed with a high-fat diet, the deletion of CCR2 
prevented macrophage accumulation and the formation of atherosclerosis 
(Boring et al., 1998). In contrast, the lack of CCR5, which is the receptor for 
CCL3, CCL4 and CCL5, in mice does not change their vulnerability to 
atherosclerosis (Kuziel et al., 2003). In human, the transcription of CCL2 gene is 
enhanced by a polymorphism in the promoter of CCL2, with the substitution of G 
for A at position -2518 (Rovin et al., 1999). Individuals who are homozygous for 
this polymorphism have an increased risk for conorary arterial disease (Szalai et 
al., 2001). CXCL8 is another chemokine with an increased expression in human 
atherosclerotic plaques (Wang et al., 1996).  Similar to CCL2, CXCL8 and its 
receptor CXCR2 have been linked to macrophage recruitment to atherosclerotic 
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lesions (Boisvert et al., 1998). In addition, CXCL8 also induces vascular smooth 
muscle cells proliferation and migration (Yue et al., 1994). CXCL12, on the other 
hand, induces platelet aggregation and activation, and is believed to promote 
thrombus formation during plaque rupture and vessel occlusion (Abi-Younes et 
al., 2000, Calderon et al., 2005). CXCL12 is highly expressed by smooth muscle 
cells, endothelial cells and macrophages in human atherosclerotic plaques (Abi-
Younes et al., 2000). The CX3CL1 chemokine is found in human atherosclerotic 
lesions that contain high numbers of macrophages (Greaves et al., 2001). 
Genetic variation of its receptor CX3CR1 results in a decreased number of CX3CL1 
binding sites on monocytes, fewer calcific atherosclerotic lesions formation and 
confers protection against coronary artery disease (McDermott et al., 2003, 
Calderon et al., 2005). In an animal model, the development of atherosclerosis 
was lower in the double knockout mice (CX3CL1-/- and ApoE-/-) in comparison to 
the ApoE-/- group (Combadiere et al., 2003).  
1.6.3.4 Chemokines in tumour development 
Chemokines regulate tumour growth broadly via the mechanisms of modulating 
angiogenesis and stimulating autocrine growth (Frederick and Clayman, 2001). 
Studies of G protein-coupled receptor (GPCR) encoded by Kaposi’s sarcoma 
herpesvirus (KSHV) support the idea that chemokine is also responsible for 
cellular malignant transformation. KSHV-GPCR is somewhat similar to CXCR2; it 
is constitutively in an activated state, though its reactivity is further enhanced 
by binding to CXCL1 and CXCL8. In mice, overexpression of KSHV-GPCR is 
associated with the development of lesions with features resembling Kaposi’s 
sarcoma (Yang et al., 2000). Constitutive activation can be induced in CXCR2 by 
introducing a point mutation. Cells transfected with this CXCR2 mutant undergo 
malignant changes (Burger et al., 1999).  
CXC chemokines has been shown to play a central role in the dysregulation of 
angiogenesis required for tumour development. Increased expression of ELR 
positive CXC chemokines is discovered in several tumours (Frederick and 
Clayman, 2001, Rosenkilde and Schwartz, 2004). For instance, expression of 
CXCL8 has been shown to enhance the growth of human non-small cell lung 
cancer, metastatic melanoma, ovarian carcinoma and colon carcinoma (Smith et 
al., 1994, Brew et al., 1996, Kunz et al., 1999, Ivarsson et al., 2000); in 
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bronchogenic carcinomas this chemokine enhances tumourigenesis by accounting 
for 40-80% of angiogenesis of the tumour (Rosenkilde and Schwartz, 2004). The 
rate of tumour growth can be attenuated by neutralising antibodies against 
CXCL8 (Smith et al., 1994). Other ELR positive CXC chemokines that promote 
angiogenesis in tumours include CXCL1, CXCL3, CXCL5 and CXCL6 (Luan et al., 
1997, Arenberg et al., 1998, Rosenkilde and Schwartz, 2004). For example, 
overexpression of CXCL1 and CXCL3 following transfection of non-tumourigenic 
mouse melanocytes results in the formation of highly vascular tumours in nude 
mice. Conditioned medium from these mice is shown to be angiogenic, and this 
character can be blocked by neutralising antibodies (Luan et al., 1997). Non-ELR 
CXC chemokines, via their angiostatic effect, has been shown to reduce tumour 
growth. CXCL9 and CXCL10 both have inhibitive effect on tumour growth 
(Arenberg et al., 1996, Addison et al., 2000). CXCL10 inhibits angiogenesis, 
tumour growth and spontaneous metastasis in a model of human non-small cell 
lung cancer (NSCLC) in severe combined immunodeficiency (SCID) mice; 
neutralisation antibodies against this chemokine resulted in enhanced tumour-
derived angiogenic activity (Arenberg et al., 1996).  
Some chemokines act as autocrine growth factors, in which they stimulate 
proliferation by binding to the receptors on the same tumour cells that produce 
them. An example for this includes CXCL1, which by binding to CXCR2 has 
growth stimulating activity on malignant melanoma (Richmond et al., 1988, Luan 
et al., 1997). CXCL8 is also an autocrine growth factor for certain melanomas 
and also tumour cells lines from cancers of the colon, stomach, liver, pancreas 
and skin (Miyamoto et al., 1998, Metzner et al., 1999, Brew et al., 2000, 
Fujisawa et al., 2000, Frederick and Clayman, 2001). Besides their autocrine 
effect, some chemokines are thought to play a role in the regulation of tumour 
metastasis. Chemokine receptors CXCR4 and CCR7 are highly expressed in human 
breast cancer cell lines and malignant breast tumours; their ligands CXCL12 and 
CCL21 have been detected in the metastatic organs of these tumour cells (Muller 
et al., 2001). The chemotactic effect of the CXCL12-CXCR4 reaction has been 
shown in a migratory assay of NSCLC cells (Phillips et al., 2003).  
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1.7 Chemokines and placentation 
The distribution of expression of different chemokines in the endometrium and 
decidua has been found to be distinctive, suggesting their specific roles in the 
process of placentation. The kinetic of chemokine expression changes in 
different phases of the menstrual cycle; this dynamism is believed to play an 
important role in the process of endometrial modifications. In the early luteal 
phase of the menstrual cycle, the endometrium undergoes secretory changes, 
creating an optimal environment for embryo implantation. This transformation is 
induced by the progesterone released in the luteal phase. In human the patterns 
of chemokine expression in the endometrium have been studied. The expression 
of CXCL1 and CXCL14 in the endometrium is higher in the secretory phase in 
comparison to the proliferative phase (Nasu et al., 2001, Mokhtar et al., 2010). 
Endometrial stromal cells have been isolated to study the production of CXCL1; 
the expression of this protein is enhanced by in-vitro decidualisation of the cells 
by progestin treatment (Nasu et al., 2001). The exact role of these chemokines 
in the process of secretory changes of the endometrium is yet to be discovered; 
in vitro experiment showed CXCL14 is a chemoattractant for uterine natural 
killer (uNK) cells, which are the most abundant white blood cells during 
decidualisation (Mokhtar et al., 2010). Besides CXCL1 and CXCL14, elevated 
production of other chemokines such as CCL4, CCL8, CCL14 and CX3CL1 has also 
been detected during the mid-secretory phase of menstrual cycle (Hannan et al., 
2004, Jones et al., 2004, Hannan and Salamonsen, 2007).  
During the late-secretory period, alteration of the chemokine profile has been 
discovered; this mechanism is believed to induce menstruation in the absence of 
embryo implantation. Progesterone withdrawal in mouse is associated with the 
expression of CXCL1, CXCL5 and CXCL14 (Cheng et al., 2007). In human, CCL7, 
CCL21, CCL22, CXCL8 and CX3CL1 are detected close to the spiral arteries in the 
pre-menstrual phase (Jones et al., 2004, Evans and Salamonsen, 2012). Their 
presence at this phase of the menstrual cycle provides the mechanistic insight 
into the initiation of menstruation. It seems like menstruation is an 
inflammatory process induced by white blood cells bearing the receptors to the 
chemokines expressed. These leukocytes are chemoattracted to the 
endometrium in the late-secretory phase.  
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During pregnancy, the distribution of chemokine expression can be broadly 
categorised into 4 groups: diffuse expression originating from decidual stromal 
cells; focal expression from decidual leukocytes or fibroblasts; expression from 
invading cytotrophoblasts; and localised expression in cells lining the uterine 
vessels (Red-Horse et al., 2001, Red-Horse et al., 2004). The different 
chemokines expressed by the cells in the fetal-maternal interface are shown in 
Table 1.3. In placental development, it is believed chemokines act as regulators 
of leukocyte recruitment, trophoblast differentiation and localisation, and also 
angiogenesis. Table 1.4 summarises the chemokine receptor expression by 
human cytotrophoblasts and decidual leukocytes at the fetal-maternal interface. 
Interestingly, in a recent study miscarriage of human pregnancy has been 
associated with a reduction of CXCL8 expression (Pitman et al., 2013). In the in 
vitro experiment of the study, CXCL8 was shown to disrupt vascular smooth 
muscle morphology in a model of spiral artery remodelling. Perhaps lack of 
CXCL8 results in inadequate spiral artery remodelling and subsequently non-
continuation of pregnancy. 
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Chemokine Receptor/s Ligand localisation  
Endometrial 
epithelium 
mid-
secretory  
Decidual 
cells  
Invasive 
cytotrophoblast 
CCL 
CCL2 CCR2 & CCR5 + + NT 
CCL3 CCR1 & CCR5 NT + + 
CCL4 CCR5 + + NT 
CCL5 CCR1, CCR3 & CCR5 NT ± NT 
CCL7 CCR1, CCR2, CCR3 & 
CCR5  
+ + NT 
CCL8 CCR3 & CCR5 + ~ ~ 
CCL11 CCR3 & CCR5 + + NT 
CCL14 CCR1 & CCR5 + + + 
CCL16 CCR1, CCR2 & CCR5 + + NT 
CCL21 CCR7 + + NT 
CCL22 CCR4 + + NT 
CXCL  
CXCL1 CXCR2 + + - 
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CXCL6 CXCR1 & CXCR2 NT + + 
CXCL8 CXCR1 & CXCR2 ± + + 
CXCL9 CXCR3 + NT NT 
CXCL10 CXCR3 NT + NT 
CXCL11 CXCR3 + + NT 
CXCL12 CXCR4 NT NT + 
CXCL14 Unknown + + NT 
CX3CL  
CX3CL1 CX3CR1 + + NT 
Table 1.3 Chemokine expression during human embryo implantation. + present; - not present; 
± present/ not present (conflicting findings); ~ minimal expression; NT not tested. Adapted from 
(Hannan and Salamonsen, 2007), with updated information from (De Oliveira et al., 2010, Mokhtar 
et al., 2010, Pitman et al., 2013, Bachelerie et al., 2014). 
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Chemokine receptor Expression in 
cytotrophoblasts 
Expression in decidual 
leukocytes 
CXCR 
CXCR1 + + 
CXCR2 + + 
CXCR3  +++ 
CXCR4 +++ +++ 
CXCR5  + 
CXCR6 +++ +++ 
CCR 
CCR1  +++ 
CCR2 + +++ 
CCR3 +  
CCR4  + 
CCR5 +++ +++ 
CCR7 +++ +++ 
CCR8  + 
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Table 1.4 Chemokine receptor expression at the fetal-maternal interface. +++ expression 
detected in the majority of samples tested; + expression detected in a minority of samples 
detected. Adapted from (Red-Horse et al., 2004), with updated information on the expression of 
CXCR1 in cytotrophoblasts (Pitman et al., 2013). 
 
1.7.1 Leukocyte recruitment 
As described earlier in section 1.4, the fetal-maternal interface is infiltrated 
with specific leukocytes to aid the process of implantation, and also modulate 
fetal tolerance. There is a striking concordance between the expression of 
chemokines in the human uterus and their corresponding receptors on decidual 
leukocytes, supporting the hypothesis of the recruitment of these white cells by 
the chemokines in the fetal-maternal interface (Red-Horse et al., 2001). In the 
uterine wall in human pregnancy, high RNA level of CX3CR1, CXCR3, CCR1, CCR2, 
CCR5 and CCR7 were detected; these chemokine receptors are typically 
expressed by NK cells, T cells and monocytes. Complementary ligands, CX3CL1, 
CXCL10, CCL2, CCL3, CCL14 and CCL21, were abundantly detected in the 
decidua in a reciprocal pattern (Red-Horse et al., 2001).  
As described above, CD56bright/CD16- natural killer (NK) cells are the most 
abundant leukocytes in the fetal-maternal interface. In the decidua these cells 
are termed uterine NK (uNK) cells, majority of NK cells in the decidua are 
displaying this phenotype; they also have a different gene expression in 
comparison to their counterpart in the peripheral blood (Koopman et al., 2003). 
The origin of uNK cells has long been debated. As mentioned earlier, microarray 
analysis of ~10,000 genes showed significant differences of 278 genes when uNK 
cells in the decidua were compared with peripheral NK cells (Koopman et al., 
2003). This shows that uNK cells during pregnancy are distinctive cells, 
potentially a matured subset from the peripheral NK cells. Alternatively they 
may arise from a different haematopoietic precursor either originated from the 
CX3CR  
CX3CR1 + +++  
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local tissue or homed from the peripheral blood or other organs. Reports from 
several experimental models supported the concept that uNK cells renew from 
local precursor cells in the endometrium. Xenotransplantation of normal human 
endometrial tissue into immunodeficient mice showed that local production of 
lymphocytes and uNK cells in the transplanted endometrial tissue was possible, 
in an environment where precursors for the white blood cells from the 
peripheral were lacking (Matsuura-Sawada et al., 2005). The presence of cells 
with haematopoietic stem cell phenotype in adult human endometrium has also 
been demonstrated (Lynch et al., 2007). On the other hand, it has been 
discovered that human CD56bright/CD16- NK cells express receptors for all the 
chemokines produced by endothelial and stromal cells from the decidua, 
supporting the theory that peripheral NK cells are selectively chemoattracted to 
the endometrium, and further differentiate into uNK (Carlino et al., 2008). 
Potential haematopoietic precursors for uNK cells have also been discovered in 
the thymus, peripheral lymph nodes and blood in human and mouse (Freud et 
al., 2005, van den Heuvel et al., 2005, Vosshenrich et al., 2006). In a mouse 
model, the researchers confirmed the population of uNK cells in the decidua 
were recruited from other sites, rather than expanding locally through 
proliferation (Chantakru et al., 2002). In this experiment, uterine segments from 
NK cell-competent mice were grafted into NK/uNK cell-deficient or wild-type 
mice. uNK cells were only detected in wild-type recipients, concluding that uNK 
cells or their predecessors do not self-renew in the uterus. In another mouse 
model, L-selectin dependent adhesion of peripheral blood CD56bright cells became 
exaggerated during a peri-ovulatory window, potentially improving the migratory 
characteristic of these cells into the endometrium (van den Heuvel et al., 2005). 
The mechanism of NK cells recruitment to the pregnant uterus in mouse is 
probably CXCL14 dependent. In comparison to CXCL14+/- pregnant uteri,    
CXCL14-/- pregnant uteri had significantly decreased uNK cells (Cao et al., 2013). 
In view of the results from the experiments, some authors concluded that in 
human the origin of uNK cells is a mixture of progenitors from locally and also 
the periphery (Kitaya, 2008, Zhang et al., 2011).  
The expression of chemokine receptors in uNK cells differs from the peripheral 
blood NK cells (Carlino et al., 2008). It has been discovered that human 
CD56bright/CD16- uNK cells, in comparison to the CD56bright/CD16- peripheral blood 
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NK cells, typically bear CXCR3, the receptor for CXCL9, CXCL10, and CXCL11, 
and also low levels of CXCR4, the receptor for CXCL12. In migratory assays, 
CD56bright/CD16- peripheral blood NK cells were able to migrate through decidual 
endothelial and stromal cells following chemotaxis of CXCL10, CXCL12 and 
CX3CL1. In contrast, CD56bright/CD16- uNK cells migrated only to the first two, but 
not the last chemoattractant.  
A recent study in mice showed that lack of chemokine expression in decidual 
cells is associated with impaired accumulation of T cells in the feto-maternal 
interface (Nancy et al., 2012). A mouse model was designed, in which wild-type 
females were crossed with males hemizygous for the Act-mOVA transgene to 
generate concepti expressing antigen chicken egg ovalbumin (OVA). OVA was 
expressed by the trophoblasts in direct contact with the fetal-maternal interface 
in as early as embryonic day 7.5 (E7.5). The exposure of maternal tissue to this 
surrogate antigen should in principle lead to priming of the T cells, thus resulting 
in the fetus being susceptible to the attack by antigen specific cytotoxic T 
lymphocytes (CTLs). However, in mice the antigen-specific fetal loss did not 
occur, even when systemic CTL activity was induced in late gestation 
(Erlebacher et al., 2007). In the samples, unexpectedly there was a lack of T cell 
infiltration in the decidual stromal cells. On the contrary, the accumulation of T 
cells in the adjacent myometrium, and endometrium from the interimplantation 
sites was clearly displayed. It was discovered that the expression of T helper 
(Th1) /T cytotoxic (Tc1) chemoattractants (CXCL9, CXCL10 and CCL5) in the 
decidua was low. Epigenetic silencing of these key T cell attracting 
inflammatory chemokine genes, CXCL9, CXCL10 and to an extent CCL5, was 
demonstrated in decidual stromal cells. In the experiment, the evidence of 
promoter accrual of repressive histone marks in these cells was displayed. This 
characteristic was not present in the adjacent myometrial stromal cells from the 
same experimental mouse samples. The findings led to the conclusion that 
during the process of decidualisation of endometrial stromal cells, epigenetic 
modification limits effector T cell trafficking to the feto-maternal interface, 
thus promoting feto-maternal immune tolerance.  
At placentation sites in the first trimester, decidual macrophages, along with 
uNK cells, were found to be in close proximity to invasive trophoblasts, 
indicating these cells migrate towards the trophoblast invasion front (Helige et 
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al., 2013). In an in vitro experiment, Rhesus monkey decidual macrophages and 
primary Rhesus trophoblasts were co-cultured (Rozner et al., 2011). This co-
culturing led to the decrease in the level of CCL3, CCL4 and CXCL8, when it was 
compared to the decidual macrophages being cultured alone. In the migratory 
assay, decidual macrophages migrated towards the trophoblasts. Reciprocally 
the trophoblasts also showed significantly enhanced migration towards the 
decidual macrophages; interestingly there was no migration of the trophoblasts 
towards peripheral-derived macrophages when they were co-cultured with these 
cells. In human, decidual macrophages have elevated expression of CCL2, 
supporting the theory that decidual macrophages recruit blood-borne 
monocytes, which subsequently differentiate into decidual macrophages 
(Gustafsson et al., 2008, Erlebacher, 2013). Some studies suggested that there is 
an exaggerated recruitment of macrophages in pathological pregnancies such as 
pre-eclampsia and miscarriage (Vassiliadou and Bulmer, 1996, Reister et al., 
1999, Lockwood et al., 2006). In pre-eclampsia, it is thought that the expression 
of CCL2 is dysregulated by TNF-α and IL-1β, leading to the elevated number of 
macrophages (Bulmer et al., 2010). In one study, the expression of CCL2, CCL5, 
CXCL2, CXCL3 and CXCL8 was elevated up to 975-fold when cultured first 
trimester human decidual cells were exposed to IL-1β (Huang et al., 2006).  
The recruitment of CD4+CD25+ Treg in mouse is regulated by CCR5. It was shown 
that more than 70% of CD4+CD25+ cells in the gravid uterus and placenta 
expressed CCR5, whereas CCR5 expression of Treg in the spleen, blood and other 
secondary lymphoid organs was less than 30% (Kallikourdis et al., 2007). In the in 
vitro experiment, the authors demonstrated that the majority of the CD4+ cells 
that migrated towards CCL4 expressed CCR5. In one of the mouse models, 
semilymphopenic female recipients lacking CD4+ T cells (F5xRag1-/-) were 
adoptively transferred with wild-type CD25-depleted splenocytes reconstituted 
with CD25+ cells prepared from either CCR5-deficient or wild-type mice. Then 
the females were allogeneically mated with BALB/c males. The average litter 
size (7) and the number of resorbing fetuses (2%) were similar between the 
control and the F5xRag1-/- mice that had received CD25+ cells from wild-type 
mice. In contrary, the percentage of resorbing fetuses (17%) was significantly 
higher in the F5xRag1-/- mice that had received CCR-deficient CD25+ cells. In 
order to follow Treg cells in vivo, the authors designed another experiment 
   67
where they transduced Treg cells from either wild-type mice or CCR gene 
deletion mutant mice with a retroviral vector carrying a constitutively expressed 
GFP gene, and then adoptively transferred the cells into wild-type females. The 
recipients were allogeneically mated. In the pregnant uteri they found only half 
as many tagged CCR-deficient Treg as their wild-type counterparts. From these 
experiments, the authors concluded that homing of CD4+CD25+ Treg into the 
gravid uterus in mouse is regulated by CCR5, the ligand responsible for this 
chemoattraction can be CCL4.  
Collectively, the above findings show the complex regulation of leukocyte 
recruitment in the decidua during placentation. Human leukocytes, along with 
other cell types in the decidua, not only express chemokine receptors, but also 
release chemokines themselves (Red-Horse et al., 2001). The cellular pathway of 
implantation warrants further exploration in order to gain further understanding 
of this delicate process.   
1.7.2 Trophoblast differentiation and localisation 
Precise regulation of trophoblast outgrowth, invasion, differentiation and 
localisation is required for a successful pregnancy. During the process of 
apposition, the human blastocyst is immersed in the endometrial 
microenvironment dominated with chemokine molecules (Jones et al., 2004). 
Chemokine receptors, for example CCR1, CCR2, CCR3 and CX3CR1 were detected 
in trophoblast cell lines, suggesting the importance of their ligands in influencing 
the character of these cells in vivo (Hannan et al., 2006). In vivo villous 
cytotrophoblasts (VT) undergo differentiation into syncytiotrophoblasts (ST), 
forming a thin multicellular layer in the fetal-maternal interface for efficient 
exchanges. Some other cytotrophoblasts differentiate into interstitial 
extravillous cytotrophoblasts (iEVT) and endovascular extravillous 
cytotrophoblasts (vEVT), for invasion and vascularisation during implantation (Fig 
1.5) (Damsky et al., 1992, Shih et al., 2006, Ahmed et al., 2012). CX3CR1 and 
CCR1 were detected in the human EVT, particularly the vEVT, indicating the 
specific function of the ligands of these receptors in regulating the migration of 
these specialised trophoblasts during placentation (Sato et al., 2003, Hannan et 
al., 2006). Migration assays have been used to demonstrate the migration of 
trophoblasts cell lines in response to CX3CL1, CCL14 and CCL4, and also to 
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endometrial cell conditioned media, which contain these chemokines. 
Neutralising antibodies to CX3CL1 and CCL4 attenuated the migration of these 
cells (Hannan et al., 2006). In a more recent study, invasion of EVT from human 
placental explants was shown to be stimulated by CXCL8. However, trophoblast 
invasion seems to be only partially regulated by this chemokine. Unstimulated 
CD8+ T cells did not alter EVT invasion, despite expressing CXCL8 at a level 
similar to uNK cells. Although the EVT invasion was stimulated by uNK cell 
supernatant, CXCL8 neutralising antibody only partially attenuated the degree of 
invasion (De Oliveira et al., 2010).  
 
Figure 1.5 Villous trophoblasts undergo differentiation during placentation. Schematic 
representation of trophoblast populations surrounding the villous tree. ST= syncytiotrophoblasts; 
VT= villous cytotrophoblasts; CC= cell column; iEVT= interstitial extravillous trophoblasts; vEVT= 
endovascular extravillous trophoblasts. Adapted from (Hannan et al., 2006). 
 
There are also findings showing trophoblasts control the level of chemokines, by 
expressing chemokines themselves, and also regulating the secretion of 
chemokines in the decidua. Human endometrial stromal cells treated with 
conditioned media from human trophoblasts had upregulated expression of 
CXCL1 and CCL8 (Hess et al., 2007). On the other hand, it has also been 
discovered that cytotrophoblasts express CCL3, and that cytotrophoblast 
conditioned medium has chemotactic effect on NK cells, monocytes and T cells 
(Drake et al., 2001). EVT expresses CXCL12, the ligand for CXCR4, which is 
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expressed on CD16- NK cells. CXCL12 is a chemoattractant for these cells (Hanna 
et al., 2003). This ligand-receptor interaction may be responsible for the precise 
localisation of trophoblasts and uNK cells during placentation, it may also induce 
differentiation of progenitors into uNK cells in the decidua.   
Collectively, these findings confirm that chemokines play a central role in the 
regulation of trophoblast invasion and localisation. Alongside with careful 
localisation and activation of the decidual leukocytes, it is likely that successful 
placentation is indispensably dependent on the orchestration of chemokines in 
the decidua.  Chemokines act as an essential communicative tool, aiding the 
crosstalk between trophoblasts, decidual cells and leukocytes. 
1.7.3 Angiogenesis 
Adequate vascularisation is important to ensure successful placentation, which is 
essential to support fetal growth, and prevent pathological conditions like pre-
eclampsia. EVT has the role of shaping and remodelling maternal arteries in the 
decidua during implantation. As described above, these cells preferentially 
express specific chemokine receptors CX3CR1 and CCR1, believed to be involved 
in targeting their migration into specific locations in and around the decidual 
blood vessels. They also secrete CXCL12, attracting CD16- NK cells, a phenotype 
of uNK cells, which in an in vitro study has been shown to work alongside EVT in 
the process of angiogenesis (Zhang et al., 2011).  
The CXC group of chemokines has been discovered to have either angiogenic or 
angiostatic properties, depending on whether the particular molecule contains 
the ELR motif (Strieter et al., 1995). There is considerable interest in 
determining the expression of CXC chemokines in the fetal-maternal interface. 
CXCL11, and its receptor CXCR3 have been detected in human endometrial and 
placental cells (Hirota et al., 2006). In an experiment, the authors developed a 
complex three-dimensional spheroid model for in vitro studies of placental 
vasculogenesis with regard to cell-cell interactions (Baal et al., 2009). The 
expression of CXCL12 and its receptor CXCR4 was studied, as CXCL12/CXCR4 
signalling plays a critical role in the process of embryonic vasculogenesis (Chen 
et al., 2007). In this model enhanced expression of CXCL12 and its receptor 
CXCR4 was detected in the physiological environment with low-oxygen 
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concentrations, in comparison to the pathological environment with high-oxygen 
concentrations. In another study, a trophoblast cell line was discovered to 
express CXCL2, CXCL3, CXCL6 and CXCL8 which are chemokines that bind to 
CXCR1 and CXCR2 receptors. These chemokines are known to stimulate 
angiogenesis.  They were also shown to be chemoattractive to lymphocytes; the 
recruited lymphocytes may have an effect on spiral artery modelling via the 
release of angiogenic factors (Cavanagh et al., 2009). Another CXC chemokine, 
CXCL1 was also detected in human first-trimester trophoblasts; CXCL1 incited 
chemotaxis of NK cells and monocytes (Chen et al., 2010).  
In mouse, CXCR3 deletion has been shown to reduce uNK cells recruitment to the 
decidua basalis, and mesometrial lymphoid aggregate of pregnancy; this was 
associated with abnormal formation of placental spiral arterioles with narrow 
lumen (Xie et al., 2005). CXCR3-/- mice also appeared to have hypocellular 
decidua basalis with increased intercellular space on the implantation sites. In 
another mouse study, treatment of gravid females with a CXCR4-specific 
inhibitor caused impaired homing of CXCR4+DC during early gestation, resulting 
in a disorganised decidual vasculature (Barrientos et al., 2013). Later in 
gestation, this group of mice had impaired spiral artery modelling and a 
decrease in fetal survival. The authors showed that in a different model, DC 
depleted mice had similar phenotype of extremely low fetal survival. In this 
model, adoptive transfer of CXCR4+DC into the mice rescued the pregnancy, by 
promoting vascular growth in the decidua, and enhancing the availability the 
VEGF. It is thought that VEGF is essential for adequate remodelling of the spiral 
arteries.  
Collectively, these findings confirmed the important role of angiogenic CXCL in 
the process of placental angiogenesis. Angiogenic CXCL can exert a direct effect 
on angiogenesis; by recruiting the leukocytes they also further enhance the 
process to ensure adequate vascularisation of the placenta.  
1.8 Atypical Chemokine Receptors 
Atypical Chemokine Receptors (ACKRs), also known as chemokine decoy 
receptors, share structural similarity with other chemokine receptors. Not unlike 
other receptors, they have high affinity for specific subsets of chemokines. 
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However, upon binding to their ligands there is no activation of signalling 
pathways, as occurs with other G protein coupled receptors. At present four 
ACKRs have been described: DARC, D6, CCX-CKR and CXCR7 (Graham, 2009). The 
lack of signalling through these receptors, is thought to be due to subtle 
alterations in the canonical DRYLAIV motif found in the second intracellular loop 
of the signalling chemokine receptors; interestingly modification of the DKYLEIV 
motif of D6 to DKYLAIV results in weak ligand-induced signalling activity (Nibbs 
et al., 2009).  
The ligands of the ACKRs are shown in Table 1.5. Based on in vitro study, it is 
thought that ACKRs can act as chemokine transporters to regulate chemokine 
abundance and localisation (Nibbs et al., 2003, Mantovani et al., 2006, Graham 
et al., 2012). D6, CXCR7 and CCX-CKR have also been found to have scavenging 
properties; in vitro these molecules have the ability to remove (scavenge) large 
quantities of extracellular ligands (Nibbs et al., 2009).  
D6 is abundantly expressed in the placenta and forms a key focus of the studies 
described in this thesis.  Thus, a more detailed of what is known about this 
molecule, and its potential reproductive function is described in different 
sections later in this chapter. The characteristics of DARC, CCX-CKR and CXCR7 
are summarised below. 
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ACKRs Ligands 
DARC Strong CCL2  CCL5  CCL7  CCL11  CCL13  CCL14  CCL17  CXCL1  CXCL2  
CXCL3  CXCL4  CXCL5  CXCL6  CXCL8  CXCL11 
Weak CCL1  CCL8  CCL16  CCL18  CXCL9  CXCL10  CXCL13 
D6 CCL2  CCL3  CCL3L1  CCL4  CCL5  CCL7  CCL8  CCL11  CCL13  
CCL14  CCL17  CCL22 
CCX-CKR CCL19  CCL21  CCL25 
CXCR7 CXCL11  CXCL12 
Table 1.5 Ligands of atypical chemokine receptors (ACKRs) in human. Data from (Nibbs et al., 
2009, Hansell et al., 2011a). 
 
1.8.1 DARC (Duffy antigen receptor for chemokines) 
DARC is traditionally known as the Duffy antigen. At first it was recognised as 
the entry point on erythrocyte for the malarial parasite Plasmodium Vivax (Rot, 
2005). It is a seven transmembrane spanning receptor that binds inflammatory 
CC and CXC chemokines with high affinity (Gardner et al., 2004, Graham, 2009). 
Structurally DARC has 40% similarity with other chemokine receptors, however it 
lacks the DRY motif in the second intracellular loop (Chaudhuri et al., 1993, 
Graham, 2009). Besides erythrocytes, expression of DARC is detected on vascular 
endothelial cells; the expression of this receptor is upregulated in the presence 
of inflammatory stimuli (Lee et al., 2003a, Comerford et al., 2007). More than 
95% Africans in malaria-endemic regions and 70% of African Americans lack 
expression of DARC in their erythrocytes, probably as a result of selection 
advantage provided by resistance against the infection of Plasmodium Vivax 
(Miller et al., 1976, Mantovani et al., 2006).  
DARC binds promiscuously to 11 pro-inflammatory CC and CXC chemokines; it 
does not interact with homeostatic chemokines (Gardner et al., 2004). It has 
been shown that DARC is probably responsible for the process of transcytosis of 
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chemokines, where the proteins are internalised and transported across 
endothelial cells, and are presented on the tips of lumimal microvilli (Middleton 
et al., 1997, Hub and Rot, 1998, Nibbs et al., 2003). It has also been proposed 
that the presence of DARC on erythrocytes allow the cells to act as a ‘sink’ or 
reservoir for chemokines, regulating the amount of free pro-inflammatory 
chemokines available for binding with other receptors (Darbonne et al., 1991, 
Hadley and Peiper, 1997). DARC-deficient mice phenotypically have normal 
development and haematological parameters; in a model of endotoxaemia they 
show increased granulocytic infiltration in the lungs and liver (Dawson et al., 
2000). In one experiment, mice where engineered to overexpress DARC on 
endothelial cells (Du et al., 2002). These mice showed reduced angiogenic 
responses to certain CXC chemokines, suggesting that DARC may be limiting the 
chemokines available for binding with CXCR2 on the endothelial cells. In a 
prostate cancer experiment using transgenic model, DARC-/- mice demonstrated 
greater tumour growth; they were unable to clear angiogenic chemokines 
produced by the cancer cells (Shen et al., 2006). This result is interesting, as 
African-American men, majority lacking DARC in the erythrocytes, has increased 
occurrence of mortality from prostate cancer (Lentsch, 2002). Wang et al. 
demonstrated that high DARC expression in breast cancer cell lines could limit 
tumour growth and metastasis (Wang et al., 2006a). Contradictorily, in a mouse 
model the level of injected CCL2 fell more rapidly in the plasma of DARC-/- mice 
(Fukuma et al., 2003). Similar pattern was noted in human, where erythrocyte 
DARC negative individuals have reduced CCL2 plasma levels (Jilma-Stohlawetz et 
al., 2001). Moreover, different experiments in DARC mouse model assessing the 
response of neutrophil infiltration following LPS administration produced 
conflicting results (Dawson et al., 2000, Lee et al., 2003b). Collectively these 
show the complexity of the regulation of pro-inflammatory chemokines by DARC.  
1.8.2 CCX-CKR (Chemocentryx chemokine receptor) 
CCX-CKR binds to CCL19, CCL21 and CCL25, homeostatic chemokines which 
involve in the regulation of leukocyte and thymocyte migration, and also 
formation of secondary lymphoid organs by interacting with CCR7 or CCR9 
(Gosling et al., 2000). There is no signalling event when the ligands bind to CCX-
CKR, thus CCX-CKR has been classified as an ACKR. This is due to the alteration 
of the DRY motif in the second intracellular loop of CCX-CKR to DRYVAVTKV in 
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human and DRYWACTKA in mouse (Comerford et al., 2007). CCX-CKR appears to 
be able to target their ligands for intracellular degradation. Unlike CCR7, there 
is no ligand-induced desensitisation in CCX-CKR. One study showed that CCX-CKR 
is able to continuously internalise and degrade large quantity of CCL19 over time 
(Comerford et al., 2006). 
Initial assessment of the expression of CCX-CKR showed that this receptor is 
broadly expressed, for example in the haemopoietic cells, lymphoid tissues, and 
also the heart, kidneys and lungs (Gosling et al., 2000). In a separate study using 
CCX-CKR-EGFP heterozygous knock-in mice, CCX-CKR protein was not detected 
in the tissues previously shown, instead it was expressed in thymic epithelial 
cells, and also potentially in the lymph vessels of the gut, stromal cells in the 
lymph nodes and epidermis (Heinzel et al., 2007). In the same study, the authors 
demonstrated the role of CCX-CKR in modulating adaptive immunity, by 
affecting the transport of DC to skin-draining lymph nodes, and homing of 
embryonic thymic precursors to the thymic anlage. The effect of CCX-CKR on the 
thymus has been studied; in one study CCX-CKR deficient mice were found to 
have CCL25 dysregulation, and also marked differences in the localisation and 
abundance of thymocyte subsets (Bunting et al., 2013). However, this finding 
was not consistently demonstrated in another study (Heinzel et al., 2007). It has 
also been discovered that aged CCX-CKR knock out mice spontaneously 
developed autoimmune disease resembling Sjogren’s Syndrome (Bunting et al., 
2013).  
1.8.3 CXCR7 
CXCR7 is another ACKR that has the ability to degrade chemokines (Nibbs and 
Graham, 2013). Its ligands are CXCL11 and CXCL12 (Burns et al., 2006). Similar 
to other ACKRs this molecule lacks the typical canonical DRY motif (Nibbs and 
Graham, 2013). In mouse studies, this receptor was initially only detected in the 
fetus (Graham, 2009). During fetal development, high expression of CXCR7 was 
detected in cardiac microvessels, indicating its involvement in cardiac 
development. CXCR7 deficiency led to ventricular septal defect and 
malformation of the heart valves, resulting in an increased risk of mortality in 
perinatal period and adulthood (Sierro et al., 2007). The role of CXCR7 in 
primitive vertebrate development has been studied using zebrafish; it was shown 
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that this receptor has an important role in the coordination of primordial germ 
cell migration in the lateral line primordium (Valentin et al., 2007).  
Expression of CXCR7 in adult mice has been detected recently by using 
CXCR7GFP/+ reporter mice (Cruz-Orengo et al., 2011a, Cruz-Orengo et al., 2011b). 
CXCR7 expression was detected in the brain endothelial cells. CXCR7 antagonists 
inhibited CXCL12 internalisation by the receptor, leading to an increase in 
abluminal CXCL12 level. It was opined that this mechanism prevents CXCR4+ 
leukocytes from preferentially migrating into the parenchyma. As a result, 
administration of the antagonists prophylactically and therapeutically decreased 
EAE disease activity induced by encephalogenic T cells. The benefit of CXCR7 
antagonists is also shown in a collagen-induced arthritis model in mice 
(Watanabe et al., 2010). Administration of antagonists for CXCR7 improved the 
severity of arthritis; the group of mice that received antagonists had less blood 
vessel formation in the inflamed joints. Interestingly, in human CXCR7+ vessels 
have been detected in patients with rheumatoid arthritis. These findings 
strongly suggest CXCR7 has an angiogenic effect in arthritis. 
CXCR7 immunoreactivity has been detected on tumour cells and their 
vasculature in a number of human malignancies. In vitro studies showed that 
CXCR7 can regulate angiogenesis and also tumour cell proliferation and 
migration, thus may affect the survival and metastasis of cancers (Nibbs and 
Graham, 2013). CXCR7 exerts its regulatory mechanism by interacting with its 
ligand CXCL11 and CXCL12, and also by collaborating with CXCR4.  
1.9 D6-mediated chemokine scavenging: evidence from 
in vitro and in vivo studies   
D6 is related to chemokine receptors CCR1-5 structurally and binds to many 
inflammatory CC chemokines as shown above. However unlike the other CCRs, 
upon binding to the chemokine ligands it does not trigger a cellular signalling 
pathway e.g. calcium ion fluxes (Martinez de la Torre et al., 2007), instead D6 
scavenges the ligands bound. It achieves this by constitutively travelling to and 
from the cell surface via early and recycling endosomes, internalising 
chemokines bound when it is at the cell surface (Weber et al., 2004). Unlike 
other chemokine receptors, there is no need for signalling induced by the ligands 
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for D6 to traffic into the cells. This mechanism has the advantage of avoiding 
receptor desensitisation and surface receptor depletion. The endosomes in the 
cells have very low pH; D6 is particularly sensitive to this change of acidity, and 
rapidly releases its bound ligands for retaining in the cells, which subsequently 
are degraded in the lysosomes. After releasing the ligands in the endosomes, D6 
constitutively finds its path to the cell surface for performing its role in further 
chemokine scavenging. Over time, D6 removes a large amount of ligands from 
the extracellular compartment. This effect regulates the level of CC 
chemokines, and thus controls inflammation locally and systemically.  
Different immune-regulatory in vitro and in vivo models have been used for the 
study of D6. In vivo studies have shown D6 KO mice have elevated amount of 
bioavailable chemokines, associated with over exuberant inflammatory 
responses (Jamieson et al., 2005). These findings were consistent with the 
results from in vitro experiments. Induction of skin inflammation led to a 
transient inflammatory reaction in wild type mice. On the contrary, mice lacking 
D6 have been shown to be associated with exacerbated inflammatory response, 
with close similarity to human psoriasis (Jamieson et al., 2005, Martinez de la 
Torre et al., 2005, Singh et al., 2012). This was associated with increased 
abundance of chemokines in the cutaneous sites and draining lymph nodes 
(Jamieson et al., 2005, Martinez de la Torre et al., 2005). In humans with 
psoriasis, skin biopsies showed expression of D6 was markedly elevated in 
uninvolved skin more than 8cm distant from the psoriatic plaques. In the 
psoriatic lesional and peri-lesional skin, there was a big drop in D6 expression 
(Singh et al., 2012). In an inflammation-driven skin tumourigenesis model, D6 KO 
mice were shown to have an increased susceptibility to invasive squamous cell 
carcinoma, associated with T cell and mast cell recruitment, which are known to 
contribute to skin tumours in the mouse model used (Nibbs et al., 2007). In 
humans, recently D6 has been discovered to have protective effect against 
disease progression of breast cancer. D6 expression in breast cancer is inversely 
correlated to lymph node metastasis and clinical stages, but positively 
correlated to disease-free survival rate (Wu et al., 2008). 
In a colitis mouse model, D6 deficiency has been associated with an increased 
susceptibility to colitis-associated cancer in the distal colon (Vetrano et al., 
2010). In a different study, D6 expression was discovered to be preventing 
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insulitis, and thus is protective against diabetes in mice (Lin et al., 2011). In this 
instance D6 inhibited the autoreactivity of lymphocytes, and prevented the 
migration of T and B lymphocytes into the pancreas. D6 also limited acute toxic 
liver injury in vivo, as lack of D6 was associated with increased protein levels of 
intrahepatic inflammatory chemokines CCL2, CCL3 and CCL5, leading to a higher 
amount of CD45+ T and NK cells infiltration and inflammation (Berres et al., 
2009). The role of D6 in altering the susceptibility of mouse to colitis is less well 
understood, with two different mouse studies producing contradictory results 
(Bordon et al., 2009, Vetrano et al., 2010).  
Expression of D6 was detected in infarcted myocardium from human and mouse 
(Cochain et al., 2012). In mice with myocardial infarction, D6 deficiency 
increased the likelihood of cardiac rupture, and functional analysis showed 
features of adverse cardiac remodelling with left ventricle dilation and reduce 
ejection fraction. In the ischaemic hearts of these animals, there were increased 
levels of CCL2 and CCL3, with infarcts showing increased pathogenic neutrophils 
and monocytes infiltrations (Cochain et al., 2012). In a pulmonary model, low 
dose intranasal introduction of Mycobacterium tuberculosis into D6 KO mice, at a 
dosage similar to control WT mice, rapidly killed the former animal group. This 
was associated with abnormal elevation of chemokine ligands of D6 and 
cytokines, and also increased infiltrations of macrophages, dendritic cells, CD4 
and CD8 T lymphocytes in the broncho-alveolar lavage locally and serum 
systematically. High levels of cytokines, tumour necrosis factor α, interleukin 1β 
and interferon γ, were discovered in the mice with liver and kidney damage, 
resulting in failure of those organs (Di Liberto et al., 2008). In a different study, 
allergen ovalbumin was injected into the peritoneum of the mice. Experiments 
on the airway and lung parenchyma showed increased levels of CCL17 and 
CCL22, and high abundance of dendritic cells, T cells and eosinophils in D6 KO 
mice. Interestingly, these D6 KO mice showed attenuated airway reactivity to 
methacholine (Whitehead et al., 2007).  
The role of D6 in lymphatic endothelium has been studied in in vitro and in vivo 
experiments. In human, D6 was detected in the lymphatic endothelial cells 
(LECs) (Nibbs et al., 2001). The receptor removes inflammatory CC-chemokines 
from lymphatic surfaces, minimises interaction of inflammatory leukocytes in 
this area, and therefore enhances chemokine-driven recirculation of leukocytes 
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through the lymphatics.  In mice, D6 deficiency led to elevated CC chemokine 
ligands adherence to LECs, inducing inappropriate perilymphatic accumulation of 
inflammatory leukocytes, which caused lymphatic congestion at peripheral 
inflamed sites and draining lymph nodes. This subsequently resulted in impaired 
movement of antigen-presenting cells and fluid from inflamed sites to lymph 
nodes (Lee et al., 2011).  
Besides the action of chemokine scavenging, there is evidence that D6 can 
regulate the immune system by other mechanisms. In the process of the 
resolution of acute inflammation in humans and rodents, the expression of D6 
was detected in apoptotic inflammatory polymorphonuclear (PMN) cells 
(Pashover-Schallinger et al., 2012). In a mouse ex vivo model, the receptor 
improved the interactions of the PMN cells with macrophages, controlling their 
efferocytosis and cytokine secretion. These interactions were thought to 
enhance the immune silencing phenotype of the macrophages, leading to the 
resolution of inflammation. The immune silencing effect of macrophages was 
attenuated, when D6 deficient PMN cells were used to interact with these 
phagocytes (Pashover-Schallinger et al., 2012). In contrast to the above findings 
showing the immuno-regulatory character of D6, a couple of models showed D6 
deficiency offered protection from disorders with pathologically elevated 
immune response in certain context. In one of the mouse model, D6 KO mice had 
increased number of Ly6Chigh monocytes in the circulation and secondary 
lymphoid tissues, regulated in a CCR2-dependent manner. This group of 
monocytes derived from D6 KO mice had enhanced immunosuppressive activity, 
inhibited the development of adaptive immune responses, and offered some 
protection against graft-versus-host-disease (Savino et al., 2012). In an 
experimental autoimmune encephalomyelitis (EAE) mouse model, D6 KO mice 
were unexpectedly resistant to the induction of EAE following the introduction 
of myelin oligodendroglial glycoprotein (MOG) peptide. There were reduced 
spinal cord inflammation and demyelination in the D6 KO mice. In the adoptive 
transfer experiment, MOG-primed D6+/- T cells equally triggered the disease in 
all the recipient groups regardless of their D6 expression status, whereas cells 
from D6 KO mice transferred the disease poorly even in D6+/- recipients (Liu et 
al., 2006). 
   79
In summary, the findings above confirmed the important role of D6 as a 
chemokine scavenger in the immune regulatory process. D6 also has an effect on 
other immune cells; in specific models these cells behave differently in the 
presence of D6.   
1.10 D6 in reproductive immunology 
In humans, in early studies D6 mRNA was found to be highly expressed in the 
placenta. In fact, the expression in the placenta was discovered to be by far the 
highest, compared to other solid tissues being studied (heart, brain, thymus, 
ovary, muscle, liver, kidney, spleen, lung) (Nibbs et al., 1997b). Apart from 
lymphatic endothelial cells and some leukocyte populations (Nibbs et al., 2001, 
McKimmie et al., 2008), D6 protein was highly abundant in first trimester and 
term placenta according to immunohistochemistry using a validated D6-specific 
antibody (Martinez de la Torre et al., 2007, Madigan et al., 2010). 
Immunostaining of other gestational tissues also showed exuberant expression of 
D6 in the decidua and membranes throughout pregnancy (Madigan et al., 2010).  
D6 was found to be expressed exclusively by trophoblast-derived cells in the 
placenta, this was confirmed by staining of the adjacent sections with the 
trophoblast marker anti-cytokeratin 7 antibody (Madigan et al., 2010). In the 
chorionic villi from the first trimester placenta, D6 was detected in 
cytotrophoblasts and the syncytiotrophoblast layer. In the third trimester, the 
syncytium lining the chorionic villi was strongly stained. D6 protein was apical, 
clustering towards the surface of the villi where they were in contact with 
maternal blood. There was no consistent difference in the intensity of D6 
immunoreactivity across samples from different gestational ages. In the 
gestational membranes of pregnancies between 32 and 41 weeks, the staining of 
D6 was abundant in the chorion laeve, separating the maternal decidua from the 
fetal amnion which themselves were D6 negative. On these trophoblast-derived 
cells, D6 protein was mostly localised inside the cells in a manner not unlike D6 
transfected cell lines. From here, it is thought that D6 constitutively traffics to 
and from the cell surface to mediate chemokine scavenging.  In the decidua, 
extravillous trophoblasts were expressing D6 when they were invading into the 
maternal decidua. This staining suggested that D6 plays a specific role in 
gestational tissues, delineating the fetal-maternal interface where the tissues 
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from mother and baby meet each other. By scavenging the surrounding 
chemokines, D6 probably was prepared to protect the fetal tissues from the 
attack of maternal chemokine-responsive leukocytes. It is also postulated that 
D6 may play an important role in controlling the action of trophoblasts, directing 
their movement during implantation, and affecting the formation of the 
placenta and wellbeing of the fetus. The expression of D6 was consistently 
strong in all the placental histological sections; in our laboratory placentas have 
been routinely used as a standard positive control for D6 expression studies. In 
pathological pregnancies (hydatidiform mole and choriocarcinoma), D6 
expression is also retained by trophoblasts (Madigan et al., 2010). As before, this 
was determined by immunostaining of the adjacent sections with anti-
cytokeratin 7 antibody. Similar to the normal placentas, D6 was strongly stained 
in organised trophoblast layers in a polarised manner in all the samples. In 
hydatidiform mole, D6 immunoreactivity was confined to the area of 
circumferential excess lined with trophoblasts; the staining of the swollen 
mucoid stromal core was negative. In choriocarcinomas, large patches of 
trophoblasts showed weak immunostaining, lacking the distinctive pattern seen 
in the villi and chorion in normal pregnancies.  
At term, the chorionic villi in the placenta have an estimated surface area of 
about 10m2, and blood flow through the placenta is about 600-700ml/minute 
(Wang and Zhao, 2010). With the blood flowing over a large surface with 
abundant D6, it is not surprising if D6 can affect the systemic levels of its ligands 
in the maternal blood stream. In the placenta, high expression of chemokines 
(CCL2 and CCL3) has been shown by quantitative PCR. One would expect the 
protein level of these chemokines to be elevated during pregnancy. On the 
contrary, study of D6 ligands CCL2, CCL3 and CCL11 showed that the levels in 
the plasma of pregnant women are reduced in comparison to non-pregnant 
controls. The levels were reduced in first trimester, and continued to drop 
further in term pregnancies. There was no difference in the levels of non-D6 
ligand CXCL10 between non-pregnant, first trimester and term samples. 
Interestingly in women with pre-eclampsia, which is associated with an 
exaggerated inflammatory response, the level of CXCL10 was significantly raised 
in pregnancy, whereas the levels of D6-binding chemokines were still subdued. 
Quantitative PCR of term placentas showed that the expression of D6 was 
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significantly higher in women with pre-eclampsia compared with controls. This 
shows the potential effectiveness of D6 as a scavenger, controlling the levels of 
D6-binding chemokines systematically, may prevent over exuberant 
inflammation in pregnancy (Madigan et al., 2010). In pathological condition like 
pre-eclampsia, D6 expression in the placenta may be increased to cope with a 
more pro-inflammatory environment.   
The cellular in vitro studies nearest to reflecting the function of D6 in 
trophoblasts was performed using the choriocarcinoma cell line BeWo (Martinez 
de la Torre et al., 2007, Madigan et al., 2010). BeWo cells express D6 
endogenously; prior to these studies, the detailed understanding of D6 structure 
and function has been primarily from experiments on transfected cell lines. 
Staining of D6 protein on BeWo cells showed D6 was predominantly found in 
intracellular vesicles, and was not detectable on the cell surface (Madigan et 
al., 2010). In these cells, D6 specifically internalised and degraded labelled 
CCL3, one of its ligands. The effect can be competed with other non-labelled D6 
ligands, whereas non-D6 ligands had no competitive effect. Using siRNA, D6 was 
successfully knocked down, and the scavenging of labelled CCL3 was abolished. 
In the same study, the authors incubated term placental pieces with 
radiolabelled chemokines. They found the syncytiotrophoblast layer lining the 
chorionic villi positively interacted with radiolabelled CCL2, a D6 ligand, but not 
CXCL8, a non-D6 ligand. This provided further confirmation that trophoblasts in 
situ express D6 and specifically bind to its chemokine ligands.  
In the mouse placenta, the expression of D6 mRNA is roughly the same as adult 
liver, and at a level much lower than the lungs (Madigan et al., 2010). In 
contrast to humans, where the placenta has the highest expression of D6, in the 
mouse placenta D6 is less abundantly expressed. However, the level of overall 
D6 expression in the mouse uterus still may be very high during mouse 
pregnancy, due to the multiparity nature of mouse pregnancy. Alternatively, one 
could postulate D6 expression in mouse placenta need not be as high, as the 
invasion of mouse trophoblasts into the decidua is not as drastic as the human 
placenta. The expression of D6 in the mouse placenta is fetal derived, as D6 
deficient embryos, growing in heterozygous females (D6 HET) expressing D6, 
showed negative D6 detection in the placenta (Madigan et al., 2010). This 
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supports previous human findings of D6 being expressed exclusively by 
trophoblasts, which originate from the fetus.  
In animal in vivo studies, D6 has been shown to play an important role in 
protecting the fetuses. D6 deficiency has been associated with adverse fetal 
outcomes. A defect in D6 expression was discovered in placental attachment 
sites in porcine endometrium from arresting fetuses. In healthy littermates no 
defect was detected (Wessels et al., 2007). In one key study, wild-type (WT) and 
D6-deficient mothers carrying D6-deficient pups where challenged with 
lipopolysaccharide (LPS) or antiphospholipid autoantibodies (aPL) purified from 
patients with antiphospholipid syndrome (APS) (Martinez de la Torre et al., 
2007). LPS is an endotoxin that triggers inflammatory response associated with 
adverse pregnancy outcome, for example miscarriage, or preterm labour. 
Patients with APS have higher incidence of thrombosis, fetal loss, IUGR and pre-
eclampsia. aPL-containing Ig fractions, when injected into pregnant mice, 
caused placental inflammation, necrosis and increased the rate of fetal loss; 
injection of IgG fractions from healthy women had no effect on pregnancy 
outcome (Martinez de la Torre et al., 2007).  
Comparing WT and D6 deficient mice, LPS injection resulted in a significantly 
higher rate of fetal loss in the D6 deficient group. The increase in fetal loss 
could be completely reversed by the introduction of antibodies that blocked 
inflammatory CC chemokines. D6 binding chemokines were elevated in the 
placentas and sera of pregnant D6 deficient mice compared to WT counterparts. 
There were no differences in the levels of non-D6 binding chemokines between 
the two groups. Study of leukocyte infiltration revealed the number of 
macrophages and T lymphocytes were higher in the D6 deficient placenta, 
whereas the level of neutrophil was similar between the two groups. This finding 
led to a model in which D6 deficiency resulted in higher abundance of D6-binding 
CC chemokines, which selectively attracted macrophages and T lymphocytes. D6 
deficiency also led to enhance aPL-induced fetal loss, confirming the role of D6 
in protecting the fetus from inflammatory challenge (Martinez de la Torre et al., 
2007).  
In an unchallenged environment in normal mouse breeding, D6 is currently 
thought to be dispensable for successful pregnancy for both syngeneic and 
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semiallogeneic embryos. However, embryo transfer in mice was carried out to 
study the role of placental D6 in an unchallenged, but fully allogeneic 
environment (Madigan et al., 2010). In fully allogeneic pseudo-pregnant wild 
type female recipients, the proportion of abnormal fetuses was higher in the 
transferred D6 deficient littermates, in comparison to their D6 expressing 
siblings. This difference in phenotype was not observed when the embryos were 
transferred into syngeneic recipients. In the abnormal pups, the placentas were 
often structurally defective, and infiltrated with macrophages and T 
lymphocytes. Interestingly, recent work from the Nibbs/Nelson lab suggests that 
D6 deficiency in DBA-1 mice may lead to increased syngeneic pup loss. This 
observation forms the basis for one arm of my study.  
1.11 Experimental design 
Drawing on these published data, it was hypothesised that by scavenging 
chemokines, and regulating trophoblast responses to chemokines, D6 plays a role 
in placental function to limit fetal loss, stillbirth, and neonatal death. 
Two specific areas of experimentation form the focus of the work. One arm of 
the study aims to investigate the molecular function of D6 in primary human 
trophoblasts; the second examines the basis for reproductive defects observed in 
D6 deficient DBA-1 mice. Collectively these studies aim to provide novel insights 
into the role of placental D6. 
1.11.1 Molecular characterisation of D6 function in primary 
human trophoblasts 
The function of D6 on primary cells has not been explored. The overall intention 
for this part of the research was to examine D6 expression, distribution and 
function in primary human trophoblast cultures from term placentas. Firstly, 
expression of D6 mRNA will be assessed by real time PCR. Following that the 
protein expression and localisation of D6 will be assessed by various protein 
detection techniques including flow cytometry, immunofluorescent staining and 
Western blotting. Transfected and untransfected HEK293 cell lines will be used 
as my controls. 
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To reveal the functional activities of D6, chemokine uptake assays will be 
carried out using fluorescent D6-binding chemokine CCL2. The uptake of this 
chemokine will be tracked by flow cytometry and immunofluorescence 
techniques. Known D6 ligands CCL2, CCL3L1, CCL4, CCL5, CCL7, CCL8, CCL11, 
CCL13, CCL17 and CCL22 will be used as competitive chemokines (Hansell et al., 
2011a). CCL24 and CCL26 are not known to be D6 ligands, and will be used as 
negative controls. Once again HEK293 cells will be used as controls.  
It is thought that the main task of the D6 molecule is to act as a scavenger. This 
characteristic will be studied by chemokine scavenging assays. This will be done 
by tracking the removal and destruction of biotinylated CCL2, over time, from 
media bathing cultured trophoblasts. The levels of biotinylated CCL2 at the 
various time points will be assessed by quantitative (relative) Western blot. 
Unlabelled CCL3L1 (D6 ligand) and CCL26 (non-D6 ligand) will be used as 
competitive chemokines. 
Collectively these experiments will determine, for the first time, whether D6 is 
expressed in primary human trophoblasts in culture, and if so whether this D6 
can mediate the uptake and scavenging of chemokines. This will provide novel, 
physiologically-significant insight into D6 function at the feto-maternal 
interface, and aid the interpretation of subsequent in vivo experiments.  
1.11.2 Impact of D6 deficiency on placental structure, 
chemokine expression and leukocyte abundance 
The trends of increased perinatal deaths, and decreased pup weaned/litter were 
observed in D6 deficient mice in comparison to their WT counterparts in DBA-1 
background. A complete and expanding dataset will be collected from Central 
Research Facility, University of Glasgow to confirm this finding. To ascertain the 
wellbeing of the pups postnatally, perinatal deaths and weight changes during 
neonatal period will be followed up for a cohort of mice.  
It was hypothesised that D6 deficient mice on this genetic background have 
fundamental defects in the structure of the placenta.  To test this, a detailed 
temporal comparative analysis of placentas from WT and D6 deficient DBA-1 
mice will be performed. First, in close collaboration with Professor Burton 
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(University of Cambridge), a detailed stereological analysis of the placenta 
across gestation at E10, E14 and E18 will be carried out. Wet weights of 
placentas and whole fetuses will also be recorded. These analyses will provide 
detailed comparative insight into the placentas from these animals, allowing the 
study of the differences in the three dimensional (3D) volumes of the functional 
zones in the placentas. The impact of the differences in these placental 
functional volumes to the fetal growth (weight) will be explored. If there are 
differences in the placentas between WT and D6 deficient group, heterozygous 
DBA-1 mice will be used to ascertain whether the observed phenotype is due to 
either fetal or maternal effect of D6 deficiency.  
Alongside this structural analysis, the impact of D6 deficiency on local and 
systemic chemokine expression and abundance, and also infiltration of white 
blood cells will be examined. Real time PCR will be used to compare the 
expression of the genes of D6-binding chemokines CCL2, CCL3, CCL4, CCL5, 
CCL11, CCL12, CCL17 and CCL22 in the placentas of WT and D6 deficient mice. 
Depending on the results of the expressions of these chemokines, markers of 
relevant white blood cell infiltration will be assessed using real time PCR on the 
placentas. To study the systemic effect of D6 scavenging property, Luminex 
multiplex protein assay will be performed on the serum of the pregnant mice to 
assess the differences in the levels of D6 binding chemokines between WT and 
D6 deficient group. 
These animal experiments will define indispensable roles for D6 in controlling 
placental structure, function and leukocyte content; identify the principal 
chemokines involved in leukocyte/trophoblast regulation in this tissue; and 
provide insight into how D6 regulates the local and systemic abundance of these 
chemokines. Along with the human trophoblast work above, this study will 
provide new insight into the role of D6 in the placenta.   
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2 Materials and Methods 
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2.1 In vitro study (primary human trophoblasts) 
2.1.1 Trophoblast isolation and culture 
The isolation and purification of trophoblasts from term placentas was 
performed using a modification of Kliman’s technique (Kliman et al., 1986).  
2.1.1.1 Preparation of reagents 
Cytomedium and Percoll solutions were prepared before obtaining the placentas 
for these experiments. The cytomedium was made up of medium 199 
(Invitrogen, Life Technologies, Paisley, UK) supplemented with 10% heat 
inactivated fetal bovine serum (Sigma-Aldrich, Dorset, UK) and 1% 
antibiotic/antimycotic solution (Gibco, Life Technologies, Paisley, UK). Different 
concentrations of Percoll solutions were made up in 50ml centrifuge tubes and 
stored in 4oC (Table 2.1). The different concentrations of Percoll were layered in 
three Kimber round bottom glass centrifuge 30ml tubes (Fisher Scientific UK Ltd, 
Loughborough, UK) to form a gradient of different densities, for separating 
different cell types from a placenta and allowing the identification of 
trophoblast layers (Table 2.2). To prevent disruption of the layers, the three 
tubes of Percoll gradient were kept at 4oC until the purification step when it was 
used in the procedure.  
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Concentration 
(%) 
Percoll 
volume (ml) 
Sterile water 
volume (ml) 
10x HBSS 
volume (ml) 
Total volume 
(ml) 
70 35 10 5 50 
60 30 15 5 50 
55 27.5 17.5 5 50 
50 25 20 5 50 
45 22.5 22.5 5 50 
40 20 25 5 50 
35 17.5 27.5 5 50 
30 15 30 5 50 
20 10 35 5 50 
10 5 40 5 50 
Table 2.1 Solutions for different Percoll concentrations. The stock Percoll solution was from 
Sigma-Aldrich, Dorset, UK; the 10x HBSS was from Invitrogen, Life Technologies, Paisley, UK.  
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Percoll gradient 
Top     
         2ml     10% 
         2ml     20% 
         4ml     30% 
--------------------------mark tube 
         2ml     35% 
         2ml     40% 
         2ml     45% 
         2ml     50% 
         2ml     55% 
--------------------------mark tube 
         2ml     60% 
         3ml     70% 
 
Table 2.2 Layering of the Percoll gradient for separating trophoblasts from other cells in the 
placenta. Trophoblasts typically layered out in between the two marked lines in the glass tubes 
after centrifugation. 
 
2.1.1.2 Collection and dissection of placenta 
The study was approved by the West of Scotland Research Ethics Committee 5 
(REC reference number: 10/S1001/14). Term placentas were collected from 
patients having elective Caesarean sections, with written consent obtained. In a 
primary cell culture sterile cabinet, the umbilical cord and the edge of the 
placenta were removed. Vertical dissections of the placenta were performed, 
cutting the placenta into two to three inches long cubes. The placenta was 
dissected in such a way that the cubes contained both the chorionic and basal 
surfaces for better orientation. The cubes were washed in sterile PBS twice. The 
basal plate from the cubes was removed for access to healthy tissues within the 
cubes. Following that, villous material was dissected into smaller pieces, about 
5mm3 in size. Areas that were pink were preferable, as overall these tissues 
typically gave a higher purity of trophoblasts. Tissues with visible blood vessels, 
fibrous area, and clotted blood were avoided. A small amount of PBS was needed 
to moisten the tissue. These steps were continued until about 45g of tissue was 
obtained. Then it was rinsed through gauze with PBS. Following this the tissue 
was minced with fine scissors, removing remaining visible vessels.  
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2.1.1.3 Isolation of cells 
The placental fragment underwent three steps of digestion with HBSS 
(Invitrogen, Life Technologies, Paisley, UK), 2.5% trypsin (Invitrogen, Life 
Technologies, Paisley, UK) and DNAse (Roche Diagnostics Corporation, 
Indianapolis, IN, USA). Multiple digestion steps are required for adequate yield of 
trophoblasts; this method has been performed in most experiments of 
trophoblast isolation in the past (Kliman et al., 1986, Le Bellego et al., 2009). 
The HBSS and trypsin were pre-warmed and maintained at 37oC. Firstly, placenta 
was placed in a 1L conical flask, incubated with 150ml of HBSS, 15ml of trypsin 
and 76200Kunitz units of DNAse for 30 minutes, on a shaker at 100rpm at 37oC. 
After the incubation period, 100ml of the supernatant was removed. 25ml of the 
supernatant was layered over 5ml of heat inactivated newborn bovine serum 
(Invitrogen, Life Technologies, Paisley, UK) in a centrifuge tube; the trypsin in 
the cell suspension would be neutralised when it was centrifuged through the 
newborn bovine serum. The process was repeated until four tubes were obtained 
using up all the 100ml supernatant collected. For the second digestion, 100ml of 
HBSS, 10ml of trypsin and 50800Kunitz units of DNAse were added into the 
conical flask containing the explants for similar incubation as the first step. 
100ml of the supernatant was collected for the same treatment as before. In the 
last digestion, 75ml of HBSS, 7.5ml of trypsin, and 38100 Kunitz units of DNAse 
were used. After the incubation, as much supernatant was pipetted and layered 
onto newborn bovine serum as before. While removing the supernatant, care 
was taken not to include the solid materials in the flask. Typically 100-150ml of 
supernatant was collected in the third digestion. The layered supernatant with 
newborn bovine serum was centrifuged at relative centrifugal force of 500 
gravities (RCF) for 10 minutes. After centrifugation, the supernatant, including 
the white fluffy layer at the bottom, was decanted. About 1ml of DMEM was 
added to each pellet. The pellets were disrupted, and pooled into a centrifuge 
tube. The combined cell solution was topped up with DMEM to about 50ml in 
total to fill up the centrifuge tube. It was centrifuged at 500RCF for 10 minutes. 
The supernatant was discarded after centrifugation.  
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2.1.1.4 Purifying and maintaining the trophoblasts 
Following the above steps, 6ml of DMEM was added to the pellet. 3ml of cell 
solution was layered at the top of each of the first two tubes of Percoll gradient 
prepared. The remaining cell solution left was layered at the top of the third 
tube of Percoll gradient. The Percoll/cell layers were centrifuged for 30 minutes 
at 1000RCF, with the brake off.   
After centrifugation, different cells and tissues were localised in different 
Percoll layers. Bands of trophoblasts, with densities between 1.028 and 
1.062g/ml, could be visually identified between the two lines marked at 35% and 
55% Percoll concentrations (Fig 2.1). The lower density layers above the marked 
lines consist of mostly debris, Hofbauer cells and fibroblasts. Below the marked 
lines, the higher density cells were mostly white cells (Blaschitz et al., 2000). 
Tissues and cells of the layers above the trophoblast layers were removed 
carefully, with the aim to remove as many non-trophoblastic cells as possible 
while not disrupting the trophoblast layers. Then the trophoblasts were 
collected, leaving the other layers at the bottom of the tubes. The trophoblasts 
collected were pooled together in a centrifuge tube and topped up with 
cytomedium to the rim, with the total volume of at least 45ml. The trophoblast 
solution was centrifuged at 500RCF for 10 minutes. The pellet was resuspended 
with 1ml of cytomedium. Cells were counted and plated out according to the 
needs of the subsequent experiments to be performed on the cells. The number 
of cells was counted manually under the light microscope using the Neubauer 
haemocytometer. The number of cells in the four corner and the middle 
1/25mm squares was counted. The count from these five squares was divided by 
0.02 to give the total number of cells in a cubic millimetre. The number of cells 
in a millilitre (cells/ml), the same as 1 cubic centimetre, was obtained by 
multiplying the last number of count by 1000. Generally, for maintaining the 
trophoblasts, they were plated on 90mm petri dishes. The maximum cell count 
plated out was 13 x 106 cells in each dish.13ml of cytomedium was needed to 
cover the culture surface of each dish. The cells were incubated in a humidified 
atmosphere of 5% CO2/95% air with standard level of 20% O2 at 37oC. 3ml of 
cytomedium was added into each dish daily for supplementation of the 
cytomedium. For the reporting of the in vitro experiments using the 
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trophoblasts, the day of the placenta collection and trophoblast isolation will be 
described as day 0.    
 
Figure 2.1 Percoll gradient showing the two lines marked at 35% and 55% layers, and the 
bands of trophoblasts in between these two lines.  
 
2.1.2 Assessment of purity of trophoblasts by flow cytometry 
An assessment of the purity of the trophoblasts was performed on day 1 and 2 
after the cells were isolated and plated. Cytokeratin 7 and vimentin, for their 
positive and negative staining respectively, are reliable intracellular markers to 
assess the purity of trophoblasts (Maldonado-Estrada et al., 2004). Flow 
cytometry has been to shown to be highly objective and quantitative for this 
assessment (Pötgens et al., 2001). For the preparation of this experiment, 
initially the supernatant from the cells in the petri dish was collected into a 
centrifuge tube. 10ml of Non-enzymatic Cell Dissociation Solution (Sigma-
Aldrich, Dorset, UK) was added into the dish and incubated at 37oC for 10 
minutes. Then the surface of the dish was gently scraped with a cell scraper to 
dislodge adherent cells. This suspension of adherent cells was pooled together 
with the supernatant collected earlier containing floating cells. The combined 
cell suspension was centrifuged for five minutes at 500RCF. The supernatant was 
decanted. 1ml of cytomedium was added, the number of cells was counted 
manually as described in section 2.1.1.4. Single colour flow cytometry was used 
to analyse the staining of the cells. The cells were aliquoted into three wells at 
3 x 105 cells/well on a round bottom 96-well plate, for staining with cytokeratin 
7, vimentin and isotype primary antibodies separately (Table 2.3). The cells 
were incubated with human FcR blocking reagent (Miltenyi Biotech Ltd, Bisley, 
Trophoblast layers 
between marked lines 
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UK), and permeabilised with Cytofix fixation buffer (BD, Franklin Lakes, NJ, 
USA). After the washing steps with Cytoperm permeabilisation buffer (BD, 
Franklin Lakes, NJ, USA), they were incubated in primary antibodies, at 
2.5µg/ml in 100µl/well of permeabilisation buffer. Only one primary antibody 
was used in each well, as this is a mono-colour flow cytometry analysis. The cells 
were washed again, and incubated further with secondary antibody (Table 2.3), 
with the volume of 1µl in 50µl of permeabilisation buffer. After more washing 
steps, the cells were suspended in FACS buffer before analyses in BD FACSCalibur 
flow cytometer (BD, Franklin Lakes, NJ, USA). Before the experiment samples 
were being fed through, the machine was set up for optimal data acquisition. 
The mode of the detectors was set as linear for the forward and side scatters, 
and log for the other parameters that measure the fluorescent intensities. The 
voltage and amp gain were adjusted so that the populations of interest were on 
scale in the dot plots. Then each sample was fed into the machine, left running 
until the fluid in the FACS tube was at the lowest level of the probe before it 
was manually stopped; this method allowed the maximal number of cells in each 
sample to be measured. Data were analysed using Flowjo 8.7.1 (Tree Star, 
Ashland, OR, USA). A cell was defined as being positive for a particular protein if 
it was brighter than 95% of the cells that had been treated with the isotype 
control antibody.  
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Antibody Primary/ secondary Specific/ isotype Supplier 
Monoclonal mouse 
anti-cytokeratin 7; 
Clone: OV-TL 12/30; 
Isotype: IgG1, κ  
Primary Specific Dako UK Ltd, 
Ely, UK 
Monoclonal mouse 
anti-vimentin; Clone: 
V9; Isotype: IgG1, κ 
Primary Specific Dako UK Ltd, 
Ely, UK 
IgG1, κ isotype 
control from murine 
myeloma 
Primary Isotype Sigma-
Aldrich, 
Dorset, UK 
Polyclonal rabbit anti-
mouse Ig (FITC) 
Secondary N/A Dako UK Ltd, 
Ely, UK 
Table 2.3 Antibodies used for assessment of purity of trophoblasts. FITC, fluorescein 
isothiocyanate. 
 
2.1.3 HEK293 cells maintenance and passage 
Wild type HEK293 and HEK293 stably transfected with D6 were maintained for 
use as control cells in the experiments. They were passaged every two to five 
days. The cytomedium for wild type HEK293 was made up of DMEM with sodium 
pyruvate (Gibco, Life Technologies, Paisley, UK), 1% of penicillin-streptomycin 
100x solution (Gibco, Life Technologies, Paisley, UK), 10% of non heat-
inactivated South American origin fetal bovine serum (Gibco, Life Technologies, 
Paisley, UK) and 1% of L-Glutamine solution (Sigma-Aldrich, Dorset, UK). For 
HEK293 transfected with D6, the cytomedium was the same as above but 
supplemented with G418 at 1mg/ml. The D6-expression plasmid transfected into 
HEK293 cells included a G418 resistant gene, so inclusion of G418 in the medium 
ensures that only cells containing the plasmid will grow thereby preventing loss 
of D6 expression.  
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2.1.4 Assessment of D6 mRNA expression 
On the day of isolation (day 0), trophoblasts were plated out on 24-well plate at 
1 x 106 trophoblasts per well in 0.5ml cytomedium. Cells in different wells were 
collected at day 1, 2 and 3 of culture for assessment of mRNA expression. For 
each RNA sample, four wells of cells from the same placenta were collected. 
The cytomedium in the four wells was removed. The wells were washed with 
0.5ml of cytomedium. After removing this cytomedium, 1ml of TRIzol Reagent 
(Invitrogen, Life Technologies, Paisley, UK) was added into the first well. The 
well was gently scraped to dislodge adherent cells. After pipetting up and down 
several times, the cell suspension was moved to the next well. Similar processes 
were repeated, until all the 4 wells were treated. The cell suspension was stored 
in a labelled cryogenic tube for freezing at -80oC. D6 transfected and 
untransfected HEK293 cells were used as control for comparison of D6 
expression. During HEK293 cell passaging, for each RNA sample 4 x 106 cells were 
collected, centrifuged, treated with 1ml of TRIzol Reagent (Invitrogen, Life 
Technologies, Paisley, UK) and frozen at -80oC. 
The samples were passed through 25G needle on a syringe for 10 times. RNA 
extraction was carried out using TRIzol Reagent (Invitrogen, Life Technologies, 
Paisley, UK) and chloroform (Sigma-Aldrich, Dorset, UK). The extracted RNA was 
precipitated using isopropanol (VWR, Lutterworth, UK) and stored in 75% 
ethanol. Then it was solubilised in nuclease free water. The RNA concentration 
was determined using NanoDrop ND-1000 spectrophotometer (Thermo Scientific, 
Wilmington, DE, USA). The samples were stored in -80oC.  
The RNA underwent DNAse treatment using a DNAse treatment and removal kit 
(DNA-free, Ambion, Life Technologies, Paisley, UK). Following that, cDNA 
syntheses were carried out using High Capacity cDNA Reverse Transcription Kits 
(Applied Biosystems, Life Technologies, Paisley, UK), plus superasin (Ambion, 
Life Technologies, Paisley, UK) according to the manufacturer’s instructions. 
Expression of cytokeratin 7, D6 and CCR2 was measured using the synthesised 
cDNA. Each biological sample was analysed in duplicate. cDNA, 1x Taqman 
Universal PCR Mastermix (Applied Biosystems, Life Technologies, Paisley, UK), 
appropriate probe (Table 2.4), and nuclease free water were added for the 
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samples for loading into the 7900HT Fast Real-Time PCR System machine 
(Applied Biosystems, Life Technologies, Paisley, UK). The incubation condition 
was 95oC for 10 minutes, and then 40 cycles of 95oC for 15 seconds and 60oC for 
one minute. Data were analysed using 7900HT Sequence Detection Systems v2.3 
(Applied Biosystems, Life Technologies, Paisley, UK). The final results were 
formulated using 2-ΔCT. CT of the endogenous control gene, TOP-1, for each 
sample was subtracted from CT of the target gene; this difference was depicted 
as ΔCT. ΔCT was normalised by antilog to base 2, and subsequently multiplied by 
100 for displaying the final results in percentages (Goldman and Shalev, 2006). 
Target gene (human) Product ID 
D6 Hs00174299_m1 
 
CCR2 Hs00356601_m1 
 
Cytokeratin 7 Hs00818825_m1 
GAPDH (*endogenous control) 4310884E 
TOP-1 (*endogenous control) Hs00243257_m1 
B-actin (*endogenous control) 4310881E 
18s rRNA (*endogenous control) 4310893E 
Table 2.4 Target specific and endogenous control human probes used for mRNA expression 
measurement. All products were from Applied Biosystems, Life Technologies, Paisley, UK. 
 
2.1.5 Assessment of D6 protein expression 
In-house monoclonal human D6 antibody is available in our laboratory in Glasgow 
Biomedical Research Centre at University of Glasgow. The details of the 
generation and characterisation of this antibody has been described previously 
(Nibbs et al., 2001). The antibody has been used in many subsequent 
publications (Weber et al., 2004, Madigan et al., 2010).   
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2.1.5.1 Western blotting 
To prepare the reagents for trophoblast lysis, one tablet of Complete Protease 
Inhibitor Cocktail (Roche Diagnostics Corporation, Indianapolis, IN, USA) was 
dissolved in 10ml of CelLytic MT Cell Lysis Reagent (Sigma-Aldrich, Dorset, UK). 
The lysis reagent was stored in -20oC. 
Protein lysates were collected from two placentas, each at different day of 
trophoblast culture. For the first placenta, lysates were prepared at day 3 of 
culture. From the petri dish, the culture surface was gently scraped with a cell 
scraper. The cells were collected, centrifuged and resuspended in cytomedium. 
Six samples of lysate were prepared from this placenta; they were aliquoted into 
microcentrifuge tubes at 1 x 106 cells each. The samples were centrifuged at 
450RCF for 5 minutes, at room temperature. The supernatant was discarded, 
1ml of PBS was added to each tube. After this washing step, the tubes were 
centrifuged as before and the supernatant was discarded. Following this, the cell 
pellets were resuspended in 250µl of lysis reagent. Then the cell suspensions 
were vortexed, and left on the shaker on ice for 15 minutes. After the 
incubation, the cells were passed through a 21G needle on a syringe for ~30 
times. The tubes were centrifuged for 15 minutes at 15000RCF, at 4oC. Finally 
the lysates were collected into new microcentrifuge tubes and stored in -80oC.  
The lysates were prepared on day 2 of culture for the second placenta. For this 
placenta floating and adherent cells where prepared separately for different 
sets of lysates. The culture media were pooled into a centrifuge tube for the 
collection of suspension cells. For the adherent cells, each plate was incubated 
with 10ml of Non-enzymatic Cell Dissociation Solution (Sigma-Aldrich, Dorset, 
UK) for 10 minutes at 37oC, gently scraped and the resulting cell suspension 
pooled into a tube. 2.585 x 106 of suspending cells and 8.46 x 105 of adherent 
cells were collected. The process of lysate preparation was the same as the first 
placenta. For each type of cells, 125µl of lysis reagent was used.  
In the Western Blotting, each protein sample was prepared, comprising 20µl of 
the lysate, 5µl of NuPAGE LDS Sample Buffer (Life Technologies, Paisley, UK), 
and 2.5µl of NuPAGE Sample Reducing Agent (Life Technologies, Paisley, UK). 
Then the samples were incubated at room temperature for 10 minutes; to 
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prevent D6 aggregation they were not boiled (Blackburn et al., 2004). The 
process of electrophoresis of the protein was preformed on NuPAGE 4-12% Bis-
Tris Gel 1.0mm, 10 well precast minigels, on the Novex NuPAGE Sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) Gel System (Life 
Technologies). First the wells were washed and filled up with NuPAGE MES SDS 
Running Buffer (Life Technologies, Paisley, UK). The gel was secured in the 
system, followed by loading of the samples into the wells. The chambers were 
filled with the running buffer until the wells were fully covered, electrophoresis 
was run at 200V for 52 minutes. This process was followed by transferring of the 
protein onto a Whatman nitrocellulose membrane. The gel was sandwiched with 
the nitrocellulose membrane, carefully rolling out excess air bubbles, and 
cushioned with filter papers and sponges. The sandwich was placed in the 
system and covered with the transfer buffer (NuPAGE Transfer Buffer (Life 
Technologies, Paisley, UK) + 10% methanol). The transferring process was run for 
1 hour at 30V. After this, the nitrocellulose membrane was rinsed with distilled 
water, and incubated in 20ml of non-fat milk (5% Marvel in PBS-0.05% Tween 20 
(PBST)) as a blocking agent overnight at 4oC. After the incubation, the 
nitrocellulose membrane was cut into two parts, for staining separately with in-
house D6 antibody (1:10 in 10ml PBST), and cytokeratin 7 antibody (1:1000 in 
10ml PBST) (Table 2.3). The staining of cytokeratin 7 was to confirm of the 
presence of trophoblast cells. This incubation of primary antibodies took 2 hours 
on the shaker at room temperature. After this, the nitrocellulose membrane was 
washed with PBST for three times, at room temperature for five minutes in each 
time, before incubating with the detection antibody (1:10,000 in 10ml PBST) for 
60 minutes at room temperature. The detection antibody was anti-mouse IgG 
HRP linked whole antibody from sheep (GE Healthcare, Little Chalfont Bucks, 
UK). After this incubation, the membrane was washed for another three times 
with PBST, covered with 2ml total of Supersignal West Femto Stable Peroxide 
Buffer and Supersignal West Femto Luminal/ Enhancer Solution at 1:1 ratio, and 
exposed to the X-ray film. Then the film was developed by Kodak X-Omat 
processor (Kodak, Rochester, NY, USA). 
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2.1.5.2 Flow cytometry 
2.1.5.2.1 Intracellular staining 
 
The process of mono-colour intracellular staining for D6 is similar to the staining 
for the assessment of trophoblast purity, as described above. Two different anti 
human D6 antibodies (mouse and rabbit) were used for the detection of 
intracellular D6. For the mouse anti-D6 antibody, the primary and secondary 
antibodies were 2.5µg/ml of in-house mouse anti-human D6 antibody and 
fluorescein conjugated goat F(ab’)2 anti-mouse IgG (R&D Systems Inc., 
Minneapolis, MN, USA) respectively. Mouse IgG2a (Dako UK Ltd, Ely, UK) was 
used as isotype control. For the staining using rabbit antibody, the primary and 
secondary antibodies were 2.5µg/ml of rabbit anti human D6 antibody (Sigma-
Aldrich) and fluorescein conjugated goat anti-rabbit IgG (R&D Systems Inc., 
Minneapolis, MN, USA) respectively. The isotype control was rabbit IgG (Dako UK 
Ltd, Ely, UK). Untransfected HEK293 cells were used as control cells.  
2.1.5.2.2 Surface staining 
 
The process of surface staining was largely similar to the description above, 
except that the cells were not permeabilised. Following plating on 96-well round 
bottomed plate, the cells were resuspended in 50µl/well in FACS buffer (PBS + 
3% fetal bovine serum + 2mM EDTA + 0.01% NaN3) containing 2µl human FcR 
blocking reagent (Miltenyi Biotech Ltd, Bisley, UK). After 10 minutes of 
incubation, primary in house mouse D6 or isotype antibodies at 2.5µg/ml in 
100µl/well FACS buffer were introduced. The cells were incubated for 20 
minutes on ice, and washed twice with FACS buffer before further incubation 
with 1:50 secondary antibody in 50µl/well FACS buffer. The cells had two further 
FACS buffer washes, and were then resuspended in 350µl of FACS buffer 
containing 7µl/well of 7-AAD staining solution (BD, Franklin Lakes, NJ, USA) for 
analysis in BD FACSCalibur. 7-AAD staining was used for dead cell exclusion. 
Compensation was adjusted for the dual colour staining, where live dot plot was 
set up with both channels of 7-AAD and fluorescein shown on the axes on the 
same graph. While running one of the samples prepared for compensation, with 
only 7-AAD or fluorescein staining, the compensatory controllers were calibrated 
until the overlapping or underlapping of the spectrum was corrected. The 
calibration process was repeated using the other untested (7-AAD or fluorescein) 
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sample, to compensate for the overlapping or underlapping on the opposite 
channel. Transfected and untransfected HEK293 cells were used as control cells.   
2.1.5.3 Immunofluorescence 
Trophoblasts, or transfected or untransfected HEK293 cells were seeded on 8-
well chamber slides, at 2.4 x 104 cells/well with 400µl of corresponding media. 
Cells were cultured at 37oC, 5% CO2. During the process of optimisation, 
different concentration of primary and secondary antibodies were used. The 
primary in-house mouse D6 and isotype antibodies were the same as those used 
for flow cytometry; the secondary antibody used was Alexa Fluor 488 F(ab’)2 
Fragment of Goat Anti-Mouse IgG (Invitrogen, Life Technologies, Paisley, UK) or 
FITC conjugated Polyclonal rabbit anti-mouse Ig (DAKO UK Ltd, Ely, UK). 
Immunofluorescent staining was performed on day 2 of cell culture, at room 
temperature. The media were removed, and the cells washed with PBS. This was 
followed by ten minutes of fixation with 3.5% paraformaldehyde. The cells were 
washed twice with PBS, then incubated in 50mM NH4Cl for 20 minutes to quench 
autofluorescence of unreacted aldehyde groups. After another step of washing 
with PBS, the cells were incubated with PGS (PBS, 0.2% gelatine, 0.05% saponin) 
for 30 minutes. Following that, PGS containing primary anti-D6 or isotype 
antibodies was introduced. After one hour of incubation, there were two further 
washes with PGS. Secondary antibody in PGS was introduced, and the cells were 
protected from light, incubated for 30 minutes. After three washes with PGS, 
the cells were incubated in 3.5% paraformaldehyde for a further 10 minutes. 
Finally the supernatant was removed, and the slides mounted with VECTASHIELD 
mounting medium with DAPI (Vector Laboratories Inc., Burlingame, CA, USA). 
Nail varnish was applied to secure the coverslips. The slides were viewed under 
fluorescent microscope Zeiss Imager.M2, the images were processed using 
Axiovision Rel 4.8 software. 
2.1.6 Chemokine uptake assay 
2.1.6.1 Immunofluorescence 
Trophoblasts and HEK293 cells were incubated with the chemokines before 
staining with D6 antibodies. Cells were cultured for two days on 8-well chambers 
slides as described in immunofluorescence protocol above (section 2.1.5.3). The 
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media were replaced, with fresh medium containing 10nM synthetic human 
AlexaFluor647 CCL2 (Almac Group Ltd, Craigavon, UK) (CCL2AF647) +/- 
competition of 100nM of CCL2 (Peprotech, Rocky Hill, NJ, USA) into relevant 
wells. The cells were incubated for one hour in cell culture incubator at 37oC, 5% 
CO2. After the incubation period, the cells underwent fixation and staining for D6 
protein detection as previously described. 
2.1.6.2 Flow cytometry 
Day 1 trophoblasts on petri dishes were collected and seeded on 96-well round 
bottom plate at 3 x 105 cells/well as described in previous flow cytometry 
protocols. The cells were centrifuged, and resuspended in 50µl of cytomedium 
containing 25nM CCL2AF647, with or without 10-fold excess (250nM) of unlabelled 
competitor chemokines (Peprotech, Rocky Hill, NJ, USA). They were incubated 
at 37oC, 5% CO2 for one hour. This was followed by two washes with FACS buffer, 
and subsequent resuspension of the cells in 350µl FACS buffer containing 7µl 7-
AAD staining solution (BD, Franklin Lakes, NJ, USA) for dead cell exclusion, 
before analysis in BD FACSCalibur. Compensation was adjusted for the two 
colours. Controls were performed using the HEK293 cells.  
2.1.7  Chemokine scavenging assay with quantitation by Western 
Blot 
2.1.7.1 Optimisation process 
 
100ng/µl of synthetic human biotinylated CCL2 (Almac Group Ltd, Craigavon, 
UK) (bioCCL2) was prepared, by reconstituting 10µg of the lyophilised chemokine 
with PBS. The chemokine underwent serial dilutions, to allow the determination 
of the minimum concentration detectable by Western blot. During the 
optimisation process for the Western blotting, different blocking agents, timings 
of blocking, enhanced chemiluminescent reagents and chemokine dilution 
reagents were tried to obtain the best signal to noise ratio on the films. The 
optimised protocol is outlined in the next section. 
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2.1.7.2 Chemokine scavenging assay on trophoblasts 
1.5 x 106 cells/well of primary trophoblasts were seeded on 6-well plates in  
1.5ml of cytomedium after cell isolation and purification from placentas and 
cultured at 37oC, 5% CO2 overnight. The next morning, at day 1 of culture, 0.75µl 
of 100ng/µl bioCCL2 was added into all the wells, resulting in a final 
concentration of 5nM. In relevant wells, 7.5µl of 100ng/µl CCL3L1 (Peprotech, 
Rocky Hill, NJ, USA) was added as competitor chemokine, to a final 
concentration (50nM) that was 10x greater than the bioCCL2. Immediately after 
the chemokines had been introduced into the wells, 60µl of medium was 
collected from each well; these samples were the 0-hour samples. Following this 
the trophoblasts were returned to the incubator. At set time points, a series of 
aliquots of medium were collected from all the wells, up to 72 hours after 
chemokine addition. 
Western blotting was performed on the samples from different time points to 
determine the level of bioCCL2 in the supernatants. Comparisons were made 
between samples with and without the competitor CCL3L1 chemokine. Wells 
without cells were used as negative control. The experiment was also repeated 
using non-D6 ligand CCL26 as the competitive chemokine. For the preparation of 
each sample, 20µl of harvested medium was added with 5µl Nupage LDS sample 
buffer (Invitrogen, Life Technologies, Paisley, UK) and 2.5µl 1x Nupage sample 
reducing agent (Invitrogen, Life Technologies, Paisley, UK). Samples were boiled 
at 70oC for 10 minutes, and loaded onto the wells of 10-well precast minigels, 
for the process of electrophoresis and transferring of the protein on the Novex 
NuPAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Gel System (Invitrogen, Life Technologies, Paisley, UK). The electrophoresis was 
run at 200v for 36 minutes, and the transfer was run at 30v for 1 hour. After the 
transfer, the nitrocellulose membrane was blocked with 5% skimmed milk 
(Marvel) in PBST for 1 hour at room temperature on the shaker. This was 
followed by five shake rinses, and 4x five minutes washes with PBST at room 
temperature on the shaker. Then the membrane was incubated for 60 minutes at 
room temperature with 1:2500 of streptavidin-HRP (Invitrogen, Life 
Technologies, Paisley, UK) in 15ml PBST on the shaker. After the washing steps 
as before, the membrane was dried, placed in a sheet protector and covered 
with 2ml of Novex ECL Chemiluminescent Substrate Reagent Kit (Invitrogen, Life 
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Technologies, Paisley, UK). It was placed in the film cassette for exposure to the 
X-ray film. The films were developed by Kodak X-Omat processor. The films were 
scanned into TIFF files, for the calculation of Adjusted Volume in Quantity One 
version 4.6.2 software (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK). The 
method of drawing the boundaries for calculation of Volume and Background 
Volume is as shown in Figure 2.2. 
a) 
      
b) 
 
Figure 2.2 Comparison of the intensities of the pixels of the bands (Adjusted Volume of the 
boundaries) from four different set time points. Volume is defined as the sum of the intensities 
of the pixels inside the volume boundary drawn, times the area of a single pixel (in mm2). a) U1 to 
U4 were four boundaries of the same size drawn to completely include the four bands of interest 
from different set time points. The intensities of the pixels (Volume) within the boundaries were 
calculated by the software. B1 box is the boundary drawn within the unstained area of the 
nitrocellulose membrane, to determine the average intensity of the pixels in the Background 
Volume. Adjusted Volume of U1 to U4 were analysed, whereby the average intensity of the pixels 
in the Background Volume was subtracted from each pixel in these four boundaries. Any pixels 
inside U1 to U4 that have the same intensity as the average background will be reduced to zero, 
thereby eliminating them from the quantitation. b) The result of the calculations of Volume and 
Adjusted Volume.  
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2.2 In vivo study (mouse model) 
2.2.1 Animals 
DBA-1 mice, and DBA-1 mice homozygous (D6 KO) and heterozygous (D6 HET) for 
deletion of the D6 gene, were bred and maintained in the Central Research 
Facility, University of Glasgow. D6 deficient animals were derived from C57BL/6 
D6 deficient mice but had been backcrossed for >10 generations with DBA-1 
mice. All procedures were carried out in accordance with the regulations of 
United Kingdom Home Office. The youngest age for the adult mice used in our 
experiments was eight weeks and close age-matching was done where possible. 
2.2.2 Data on stillbirth, neonatal death and pups weaned/ litter 
Data were provided by the staff in Central Research Facility. A cohort of wild 
type (WT) and D6 KO mice were placed in a breeding programme. Females in 
late pregnancy were checked for newborns daily. Once all the pups were born 
and being nursed, the number of live pups and dead carcasses were counted. 
Carcasses that were noticed when the litter was first discovered were counted 
as stillbirths; the numbers of live pups were recorded as well. Pups that did not 
survive to weaning at day 18 to 21 after birth were recorded as neonatal deaths.  
2.2.3 Record of perinatal deaths and weight changes during 
neonatal period 
This experiment was carried out over a period of two months. WT or D6 KO 
females were caged with individual males with the same genetic background. 
The females that showed sign of pregnancy were removed from their male 
partners. Females that appeared to be in late stages of pregnancy were checked 
every 11-13 hours for the appearance of pups. Females that were in labour were 
subject to minimal disturbance. Once all the pups were born and being nursed, 
the number of live pups and dead carcasses were counted. The live pups were 
weighed and returned to the cages with the mothers. This process of counting 
and weighing live pups was repeated daily until they were six days old, and then 
alternate days thereafter until either all the pups were successfully weaned at 
day 18-21 of life, or when there was no live pups left in the litter. Females that 
were no longer nursing any live pups were caged with individual males with 
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similar genetic background again until they became pregnant for repeats of the 
experiment. 
2.2.4 Timed mating of the animals  
2.2.4.1 WT and D6 KO females 
WT and D6 KO females were caged with individual males of the same genetic 
background overnight. The next morning the females were checked for evidence 
of a copulation plug demonstrating that copulation had taken place. Those 
females that exhibited a plug were caged separately, and the day the plug was 
discovered was recorded as embryonic day, E1, of gestation. At E10, 14 or 18, 
pregnant females were humanely sacrificed in accordance with Schedule 1 of the 
Animals (Scientific Procedures) Act for tissue collection.  Those females that did 
not have a plug were placed back into the cage with appropriate males, with 
repeated timed mating. They continued to be checked daily, and were 
separated once the copulation plug was observed.  
2.2.4.2 D6 HET female 
After discovering the difference in the phenotype between the WT and D6 KO 
pups at E14, a different experiment was designed to ascertain whether the 
placental defect was due to a maternal or a fetal effect. Females heterozygous 
for the deleted D6 allele (D6 HET) were bred with D6 KO males, generating D6 
HET and D6 KO pups in the same litter. This allowed the phenotype between 
these two groups of siblings, in a D6 expressing HET mother to be compared. For 
this study, D6 HET were caged together with individual D6 KO males overnight. 
They were separated the following morning regardless of the presence of 
copulation plug. At E14, those females that were pregnant were sacrificed by 
schedule 1 for tissue collection. Timed mating was repeated for the non-
pregnant females until they conceived. 
2.2.5 Tissue collection and processing 
Pups and placentas were dissected and transported in Dulbecco’s phosphate 
buffered saline (PBS) alongside their respective placentas. The wet weights of 
the pups and placentas, and also pup/placenta ratios were recorded. The 
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placentas were sectioned into two equal halves. One-half was stored in RNAlater 
RNA stabilisation reagent (Qiagen, Manchester, UK) for not more than a week, 
snap frozen with liquid nitrogen and stored at -80oC, for RNA isolation. The other 
half was processed for stereology analysis. They were stored in 4% 
paraformaldehyde/0.1 M 1,4-piperazinediethanesulfonic acid (PIPES) solution 
overnight at room temperature, and transferred to 0.1 M PIPES buffer the 
following day. After a night in the PIPES buffer they were ready for tissue 
processing and embedding in paraffin. If there was any delay in tissue 
processing, the placentas were transferred to 75% alcohol after two nights in the 
PIPES buffer. During embedding, the half placentas were orientated such that 
the hemisectioned side of the placentas was facing downwards, directed towards 
the surface of the paraffin blocks for cutting. This side of the placentas became 
the starting point for the microtome sectioning process in stereological analysis.  
Pups from D6 HET females were retained for genotyping. The PBS used for 
transporting was decanted, and the pups were kept in -20oC. Maternal blood was 
collected and centrifuged; the plasma was collected and frozen at -80oC.  
2.2.6 Stereology 
2.2.6.1 Microtome sectioning, mounting and staining 
Four pregnant mice were used for each of the WT and D6 KO groups for 
comparison of placental stereology at each time point. For each pregnant 
mouse, two placentas with the pup/placenta ratio closest to the mean were 
chosen for stereological analysis.  
In the D6 HET model, two D6 HET females were used for the experiment. For 
each of these females, four placentas with the pup/placenta ratio closest to the 
mean were chosen for each pup genotype group, resulting in the total of eight 
placentas for D6 HET and D6 KO siblings in each D6 HET female being used for 
stereological analysis.   
Unfortunately due to the small size of mouse placentas, occasionally they would 
break during microtoming. If this occurred, the next placenta within the litter 
with the pup/placenta ratio closest to the mean was chosen.  
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The technique of stereology for human and mouse placenta has been described 
in the literature (Mayhew and Burton, 1997, Coan et al., 2004, Coan et al., 2005, 
Coan et al., 2006, Coan et al., 2008, Coan et al., 2010). To begin this 
experimental method on the mouse placentas, the selected embedded half 
placentas were exhaustively sectioned at 8µm until the entire tissue was 
sectioned. Sections were then collected from the beginning until the end of the 
sample, aligned according to the sequence of the sections. The total number of 
sections obtained per placenta was recorded. 
15 sections, and backups, from a placenta were chosen systematically for 
mounting onto microscope slides. At the start of the process, a random number 
between one and 10 was generated using random integer generator on the 
internet: www.random.org. That random number generated would represent the 
first section to be chosen for mounting. The next section was also mounted as 
backup for the first mounting section. Then the subsequent number of sections 
left was divided by 15 to obtain a number (n). From the first mounted section, 
every nth sections were selected for mounting unto the slides until 15 sections 
and backups (30 in total) were mounted.  
The mounted sections underwent haematoxylin and eosin staining. For E14 
placentas, all 15 sections for each placenta were analysed by stereology. At E18, 
due to the higher volume of placenta that was needed to be analysed, eight out 
of the 15 sections per placenta were chosen for stereology analysis; these 8 
sections were randomly selected using the random integer generator, with the 
number from one to 15 randomly generated. With the introduction of systemic 
and randomised, unbiased sampling at different levels in stereology, this 
experimental method validly and efficiently extrapolated three-dimensional (3D) 
volumes from systemic plotting of areas in two-dimensional (2D) sectional 
images (Mayhew and Burton, 1997).    
2.2.6.2 Image analysis 
The sections chosen for inclusion in the stereological analysis were magnified 
100x under light microscope. The image was projected onto the computer screen 
using Image Pro 6.2 Plus (Media Cybernatics, Rockville, MD, USA). With this 
magnification, a number of fields were captured for a section to be completely 
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visible. The fields were aligned such that there was no overlapping, and the 
whole section was included for the analysis (Figure 2.3). Within each field, five 
grid points were randomly assigned using the grid of LineOrth.grd within the 
programme, where each grid point was shown as a ‘+’ (Figure 2.4). The 
functional zones (decidua basalis, junctional zone, labyrinthine zone, chorionic 
plate) where the centre of each grid point fell upon were recorded. The total 
numbers of grid points that fell on each zone were added up for each placenta. 
Then the total number of grid points in each zone were divided by the total 
number of grid points in the placenta. The result was multiplied by 100 to give 
the calculation of volume fraction (% of total placental volume for each zone).    
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Figure 2.3 An example of the fields for a section of mouse placenta. The fields are non-
overlapping, they include the whole section for stereological analysis.  
 
 
Figure 2.4 An example of five grid points being placed randomly for a field within a section 
of a mouse placenta. 
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2.2.7 Relative mRNA expression measurement by quantitative 
polymerase chain reaction (qPCR) 
8 placentas from each of the WT and D6 KO group were chosen for the 
comparison of mRNA expression. These total of 16 placentas were the same as 
the ones selected in the experiment of stereology (section 2.2.6.1).  
The processes of RNA extraction, DNAse treatment, cDNA synthesis and mRNA 
expression analysis were the same as the previous description in section 2.1.4, 
using the primers shown in Table 2.5. Expression of D6, chemokines and 
leukocyte markers was measured using the synthesised cDNA. 2-ΔCT was 
formulated; the endogenous control gene was GAPDH. 
Target gene (mouse) Product ID 
CCL2 Mm00441242_m1 
 
CCL3 Mm99999057_m1 
 
CCL4 Mm00443111_m1 
 
CCL5 Mm01302428_m1 
 
CCL11 Mm00441238_m1 
 
CCL12 Mm01617100_m1 
 
CCL17 Mm00516136_m1 
 
CCL22 Mm00436439_m1 
 
D6 Mm00445551_m1 
 
Foxp3 Mm00475162_m1 
 
F480 Mm00802529_m1 
 
CD3 Mm00438095_m1 
 
 
 
 
GAPDH (*endogenous control) 4352932E 
B-actin (*endogenous control) 4352933E 
Table 2.5 Target specific and endogenous control mouse probes used for mRNA expression 
measurement. All products were from Applied Biosystems, Life Technologies, Paisley, UK. 
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2.2.8 Genotyping of pups from HET females crossbreeding with 
D6 KO males 
5mm of tissues were removed from the head of the pups and incubated with 
100µl of lysis buffer (Table 2.6) and 100µl of 100µg/ml proteinase K (Promega, 
Madison, WI, USA) overnight at 55oC to prepare the samples for the genotyping. 
The following morning the samples were incubated at 85oC to denature the 
proteinase K. Then 500µl of sterile water was added to each sample. 
Genotyping lysis buffer 
100mM Tris-HCL pH 8.5 
5mM EDTA 
0.2% SDS 
200mM NaCl 
Table 2.6 Reagents for tail tip lysis buffer. 
 
For each PCR reaction, 2.5µl of primer mix (Table 2.7) and 2µl of each sample 
were added into a pre-aliquoted ready-mix master mix, flat cap thermo tube 
(Thermo Fisher Scientific, Waltham, MA, USA). This triplex approach to PCR 
reveals the 2 bands of 506bp and 357bp, for the wild type and the targeted 
alleles respectively. The presence of both bands would indicate a D6 HET.  
Table 2.7 Primer mix for genotyping. The primers were synthesised by Integrated DNA 
Technologies, Coralville, IA, USA. 
 
PCR was run on a Veriti 96 Well Thermal Cycler (Applied Biosystems, Life 
Technologies, Paisley, UK). The PCR conditions were 94oC for five minutes, 
Primer/ solution DNA sequence Concentration 
D6 wild type AGC ACG AAG ATC AGG CTG TAG AC 1µM 
 
 
 
D6 common TGG GGA TAC AGT CTT CAT GGT TC 2µM 
3 IRES CCC TAG ATG CAT GCT CGA CG 1µM 
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followed by 35 cycles of 94oC for 15 seconds, 55oC for 30 seconds, 68oC for 45 
seconds; and the final step of 68oC for 10 minutes. The gel was made up of 1.5g 
Seakem LE Agarose (Lonza, Basel, Switzerland) in 100ml TAE buffer (1.5%), with 
10µl of SYBR safe DNA gel stain (Invitrogen, Life Technologies, Paisley, UK). 
Electrophoresis was at 100 volts for 30 minutes. The ladder used was 1Kb Plus 
DNA Ladder (Invitrogen, Life Technologies, Paisley, UK). After electrophoresis, 
the gel was transilluminated on the Alphalmager gel imager (Alpha Innotech, 
Proteinsimple, Santa Clara, CA, USA). 
2.2.9 Quantification of chemokine levels in plasma using Luminex 
multiplex protein assay 
Chemokine levels were measured in the plasma from the pregnant females using 
Luminex protein assay. We used the inventoried singleplex bead kits for the 
chemokines, plus the buffer reagent kit from Life Technologies, Paisley, UK 
(Table 2.8).  
Mouse singleplex/ buffer 
reagent kit 
Bead region Product ID 
MCP-1(CCL2) bead kit 29 LMC1011 
MIP-1α (CCL3) bead kit 26 LMC1021 
RANTES (CCL5) bead kit 21 LMC1031 
KC (CXCL1) bead kit 41 LMC1061 
Extracellular protein buffer 
reagent kit for mouse or rat 
- LMB0001 
Table 2.8 Bead regions for the chemokine singleplex bead kits, and the product ID for the 
bead kits and buffer reagent kit for the Luminex protein assay. All products were from Life 
Technologies, Paisley, UK. 
 
The Luminex was run in collaboration with Dr Chris Hansell, postdoctoral 
researcher in Dr Nibbs’s chemokine research group. The assay was carried out 
following the procedure described in the manual, on the 96 well filter plate 
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supplied with the buffer reagent kit. All reagents were supplied with the kit. The 
wash solutions, antibody beads, biotinylated antibodies and streptavidin-RPE 
were supplied as 10x concentrates: they were diluted to 1x concentration prior 
to starting the experiment. The antibody beads and biotinylated detector 
antibodies from the four different chemokines were combined while being 
diluted into the 1x dilutions. A standard curve was made by preparing serial 
dilutions of reconstituted lyophilised standards provided with the kits. Aspiration 
of liquid from the filter plate was performed on a vacuum manifold with gentle 
vacuum lower than 5mmHg.  
For the Luminex assay, the minimum volume required for each reaction was 
50µl. The volumes of plasmas obtained were variable. Samples with more than 
100µl of volume were run in duplicates. The chemokine levels were determined 
by using the average of the two wells. Samples with less than 100µl, but more 
than 50µl available were run as singles. Some samples had less than 50µl of 
plasma and in these cases we added assay diluent to make the volumes up to 
50µl. For this group the concentrations of proteins were adjusted post-hoc 
according to the dilution factors.  
All samples were clarified by 10 minutes centrifugation before the assay. The 
assay wells were pre-wet with wash solution and incubated for 30 seconds, 
before the liquid was aspirated. Then 50µl of the vortexed and sonicated diluted 
bead solution was pipetted into each well. The plate was protected from light 
from this point as the beads were light sensitive. 200µl of wash solution was 
added into each well. It was incubated for 30 seconds before liquid aspiration. 
The wells were washed with 200µl of wash solution. After aspiration, 50µl of 
incubation buffer was added into each well. For the wells designated for the 
standard curve, 100µl of relevant standard dilutions were pipetted. For the rest 
of the wells, 50µl of assay diluent followed by 50µl of samples were added. The 
plate was incubated for two hours on a shaker. After the incubation, 2 washing 
steps were performed, before adding 100µl of biotinylated detector antibodies 
into each well. This was followed by one hour incubation on the shaker. The 
procedure was followed by two washing steps, before incubated with 100µl of 
Streptavidin-RPE for 30 minutes on the shaker. After three further washes, 100µl 
of wash solution was added to each well. The plate was left overnight at 2oC. 
The next morning, the wash solution on the wells was aspirated before 100µl 
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fresh washing solution was added. The plate was left on the shaker for 5 minutes 
to re-suspend the beads before analysed through the Bio-Plex System machine 
(Bio-Rad Laboratories Ltd, Hemel Hempstead, UK). Data were analysed by Bio-
Plex Manager Software 4.0. 
2.3 Statistical analysis 
Appropriate statistical tests were applied for the analyses of the data using 
Graphpad Prism Software and are indicated in the legends to the data figures in 
the results chapters. For the analysis of the result from the mouse serum 
chemokine levels by Luminex, linear mixed effect modelling was used to take 
into consideration the different embryonic age of E14 and E18 within the WT and 
D6 KO groups. Linear mixed effect modelling analysis was performed using SPSS 
version 19. P<0.05 was considered statistically significant for all analyses. 
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3 Studying the Function of D6 on Cultured 
Primary Human Trophoblasts 
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3.1 Selecting primary cell culture over immortalised 
trophoblast-derived cell lines  
D6 protein is abundant in the human placenta (Martinez de la Torre et al., 2007, 
Madigan et al., 2010). Given the protective effect of D6 observed on mouse 
reproduction, there is interest in understanding the distribution and function of 
D6 in human trophoblasts. Studies of the expression, distribution and action of 
D6 using human choriocarcinoma cell line BeWo have been carried out in the 
past (Martinez de la Torre et al., 2007, Madigan et al., 2010). Using this cell line 
for the experiments showed what D6 could potentially do in human trophoblasts, 
but the results may not be representative of the true property of D6 in the 
physiological environment in the human placenta. Immortalised cancer-derived 
cell lines have been modified, maintained, and passaged in a regulated, artificial 
in vitro environment over a long period of time. Therefore they may have 
undergone huge transformation, producing very different gene expression 
profiles and phenotypes in comparison to the original cells (Whitley, 2006). In 
contrast, primary cells are more closely reflective of the biological process in 
the human body, and their study brings us closer to the understanding of the 
role of D6 in the placenta in this instance. Thus for my in vitro study primary 
human trophoblasts were used.  
Using primary trophoblasts from fresh placenta did have some technical 
disadvantages. Firstly a significant amount of time and effort had to be invested 
to obtain ethical approval for the research. For each of the experiments, there 
was the inconvenience of obtaining fresh placenta and culturing trophoblasts. 
The lifespan for these primary cells is not long; trophoblasts proliferate poorly in 
culture before undergoing replicative senescence (Whitley, 2006, Orendi et al., 
2011). They form multinucleated syncytial complex within 48 to 72 hours (Newby 
et al., 2005). Due to the above reasons there was limited time to carry out the 
experiments once the cells were plated. It was appreciated that there was 
heterogeneity between placentas, and the culture from primary cells will not be 
as pure as maintained cell lines. Furthermore, at the time when the experiments 
were conducted, trophoblast isolation and culture had not been performed in 
the laboratory. The technique had to be established, and the technology for 
routine primary trophoblast isolation and culture from fresh placentas had to be 
set up. Despite these difficulties, the efforts of culturing trophoblasts are 
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worthwhile, because to gain a more realistic insight of D6 function in the human 
placenta, it is crucial to look at the function of D6 on primary cells.  
3.2 Optimising the protocol for trophoblast isolation 
The isolation, purification and analysis of trophoblasts was not routinely 
performed in our laboratory at the beginning of the project. It took much longer 
than expected to optimise the protocol, due to the fastidious steps and time 
spent on familiarisation with the batch-to-batch physical and cellular variability 
of the placentas. The aim of refining the protocol was to achieve high 
trophoblast purity, and yield optimal number of cells. Flow cytometry was used 
to assess the purity of trophoblasts, as it is more objective and quantitative than 
cytospin preparation or staining on the culture plate (Frank et al., 2001). The 
recommended antibodies for the identification of trophoblasts from other cells 
are anti-cytokeratin 7 and anti-vimentin. Trophoblasts should express 
cytokeratin 7 and not vimentin (Pötgens et al., 2001). For the staining for these 
intracellular cytoskeletal proteins, the cells were permeabilised. Cytokeratin 7 
was chosen as it is the most specific protein for all subpopulation of 
trophoblasts, in comparison to other isoforms of cytokeratin which can be 
expressed even in the mesenchymal cells of the placenta (Frank et al., 2001). 
For instance cytokeratin 18 and cytokeratin 8 had been identified in stroma of 
stem villi and cells from the lineage of a first trimester fibroblast-myofibroblast 
respectively (Blaschitz et al., 2000).  
For trophoblast isolation, it is well recognised that there can be substantial 
batch-to-batch variability of the purity of the cells. It has been recommended 
that preparations with 50% or more cytokeratin positive cells should be used in 
trophoblast research (Frank et al., 2001). In the experiments the number of cells 
and purity of trophoblasts isolated varied between placentas; however they 
improved over time as the protocol was being established. After optimisation of 
the techniques, there was no difficulty in repeatedly obtaining cultures that 
contained over 50 million cells from a single placenta; more than 70% of the 
cells were trophoblasts when analysed at day 1 of culture (Fig 3.1).  The viability 
of the cells at day 1 was between 14 to 36%. As the experiments spanned across 
two to three days, the purity and viability of the cells were also analysed at day 
2 of culture.  At this time of culture, the purity was maintained at between 67 
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to 80%, whereas the viability varied between 12 and 34%. The method of 
physical gating based on forward (FSC) and side-scatter (SSC) characteristics of 
the trophoblasts was not dissimilar to that previously described (Maldonado-
Estrada et al., 2004, Trundley et al., 2006), eliminating events with very small 
FSC and SSC, which are probably non-viable cell fragments. Figure 3.2 shows 
views of trophoblasts under light microscope at different days of culture. 
Typically on day 1, the cultured cells in suspension started to form colonies. By 
day 2, more cells had adhered to the tissue culture dish but many of the cells 
had died. On day 3 and 4, most of the cells had adhered together to form larger 
colonies; at this stage the trophoblasts should have gone through the process of 
syncytialisation (Newby et al., 2005). The appearance of the cultured cells on 
the dish was showing the characteristics resembling multinucleated syncytial 
units. However, more tests would be necessary to confirm that cell fusion has 
occurred in these cultures.  
 
 
 
 
 
 
 
 
 
 
 
119 
                
                                      
 
 
 
 
 
 
 
Figure 3.1 Purification process of placental cells using Percoll gradient yields satisfactory 
purity of trophoblasts. Assessment of trophoblast purity by flow cytometry from the cells isolated 
and purified from one placenta. Permeabilised cells were stained with either isotype control mIgG1, 
cytokeratin 7 or vimentin antibodies. First they underwent physical gating (top left); then the 
negative gating was set to including 95% of cells treated with the isotype control antibody (top 
right). For this placenta the yield of trophoblasts was 85.6% based on cytokeratin 7 positivity 
(bottom left), and confirmed by vimentin negativity (84.6%) (bottom right). 
 
 
 
 
 
 
 
Physical gating Isotype staining 
Cytokeratin 7 staining Vimentin staining 
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a)                       Day 1                                             b)                           Day 2 
 
 
 
 
 
 
 
 
c)                          Day 3                                               d)                          Day 4      
 
 
 
 
 
 
 
Figure 3.2 Views of trophoblasts under light microscope at 100x magnification. Photos of 
trophoblast culture on 90mm petri dishes on a) day 1; b) day 2; c) day 3 and d) day 4 of culture. 
Over time the cells adhered and formed colonies, this may be due to the effect of syncytialisation. 
3.3 Assessment of D6 mRNA expression in cultured 
primary trophoblasts 
The first step of the experiment in trophoblast culture was to examine if the D6 
gene was expressed in the cultured cells.  HEK293 cells transfected with D6 
expression constructs, and untransfected parental HEK293 cells, were included 
in the analysis as it was expected that they would act as positive and negative 
controls, respectively. To study the expression of D6 mRNA, first an appropriate 
endogenous control gene had to be established. The expression of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), topoisomerase 1 (TOP-1), 
B-actin and 18s rRNA was assessed in the samples, identifying the ones with low 
variability of expression between HEK293 cells and trophoblasts at different days 
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of culture. These housekeeping genes have been used in primary and cell lines 
for trophoblasts and HEK293 cells (El-Shewy et al., 2006, Goldman and Shalev, 
2006, Hannan et al., 2006, Escobar et al., 2011). For my experiment, TOP-1 was 
chosen as my endogenous control; it was found to have the smallest standard 
deviation of expressions between trophoblasts and HEK293 cells (data not 
shown). For assessment of D6 expression, the probe/primer set that spanned an 
exon junction was chosen to reduce the risk of genomic DNA amplification. CCR2 
expression in the primary trophoblasts was also analysed, as it had been 
reported to be expressed in cells from the fetomaternal interface, and shares 
some of the ligands with D6 (Hannan et al., 2006). It was planned that later in 
the experiments, CCL2, a chemokine ligand for D6 and CCR2, was to be used to 
explore the function of D6 on trophoblasts. Thus, insight into CCR2 expression 
was considered important at this stage. As a positive control, the expression of 
cytokeratin 7 was analysed. In these experiments, the genes of interest were 
analysed by relative quantification, normalising to the expression of the 
housekeeping gene TOP-1, which had low variability of expression between 
samples. Thus by qPCR the expression of D6 and other genes could be 
quantitatively compared between different cells. 
In trophoblasts, cytokeratin 7 was expressed at a very high level and D6 was also 
expressed abundantly. Although there was a drop in cytokeratin 7 expression on 
day 2 of culture, this was not accompanied by a reduction in D6 expression. The 
drop in cytokeratin 7 on day 2 may be an artefact due to technical variability, as 
the high expression of these transcripts was detected using one placenta. There 
was some expression of CCR2 transcript, albeit detected at a level much lower 
than D6 (Fig 3.3). Thus, it appears that D6 transcripts are more abundant than 
those encoding CCR2, although it is possible that differences in the efficiency of 
the primers used to detect D6 and CCR2 contributed to apparent differences in 
expression of the two receptors.  
Using the same primers, D6 mRNA was not detected in HEK293 cells that had 
been stably transfected with D6 expression constructs. This was not initially 
expected. Following this discovery the design of the construct used to make the 
transfected HEK293 cells was discussed with other team members in the 
research group, and it was confirmed that the D6 cDNA used did not contain the 
exon junction of the primers used for the detection. Thus, retrospectively the 
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result from HEK293 transfected with D6 expression constructs was exactly what 
would have been expected.  
              
 
 
 
 
 
 
 
 
 
Figure 3.3 D6 is expressed in abundance in trophoblasts at mRNA level. Expression of D6 
and CCR2 were detected in trophoblasts. Using our probe, D6 was undetectable on HEKD6 cells, 
as transfected D6 did not contain the exon junction of the primers used for the detection. Results 
from one placenta. D1, D2, D3 troph= Day 1, 2 and 3 trophoblast culture. HEKD6= HEK293 
transfected with D6 expression constructs. HEK= untransfected HEK293. ND= not detected. 
 
3.4 Assessment of D6 protein expression in cultured 
primary trophoblasts 
3.4.1 Western blotting 
The qPCR data suggested strong expression of D6 transcripts by primary cultured 
trophoblasts from days 1 to 3. Next, the expression of D6 protein in cultured 
trophoblasts was explored. Two placentas were used in this experiment, and 
controls were HEK293 +/- transfection with D6 expression constructs. For the 
first placenta, 8 x 104 adherent and floating trophoblasts at day 3 (sample T1) 
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were pooled together prior to preparing the cell lysate. For the second placenta, 
lysates were generated separately from 1.35 x 105 adherent (sample T2a) and 
4.14 x 105 floating cells (sample T2b) at day 2. All samples were electrophoresed 
on polyacrylamide gels and Western blots prepared (Fig 3.4). These blots were 
probed with antibodies against cytokeratin 7 and D6. All 3 placental samples 
stained positively for cytokeratin 7, confirming the presence of trophoblasts. 
Sample T2a clearly contained the most cytokeratin 7 protein followed by T1 and 
then T2b (Fig 3.4a). This suggested that the quantity of trophoblasts present 
between the samples was different, either due to them being more abundant in 
the T2a sample, or that a more concentrated cell lysate had been used. D6 
staining showed that the protein was most detectable in sample T2a, but it was 
also faintly present in sample T1. In sample T2a, there were two weakly stained 
bands that electrophoresed in a manner similar to those seen in the HEK293 cells 
transfected with D6 expression constructs (HEK-D6). In HEK-D6 cells there were 
two major bands on the blot at approximately 46 and 49kDa. The higher 
molecular weight band is due to N-linked glycosylation which is dispensable for 
chemokine binding by D6 (Blackburn et al., 2004). Much of the trophoblast D6 
protein was slightly larger than the bands in the HEK-D6 cells suggesting that it 
might have undergone additional post-translational modifications in 
trophoblasts. Thus, cultures of human trophoblasts prepared fresh from human 
placentas contain cells expressing D6 protein.  
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Sample     T1   T2a  T2b                         H1  H2   T1   T2a T2b                        H1   H2  T1  T2a T2b                    
a)                                             b)                                                c)                     
    
 
 
 
 
                                                             Long exposure time                          Short exposure time        
     Cytokeratin 7 staining                  D6 staining (same blot with different time of exposure)            
Sample Code Sample Number of cells 
H1 Untransfected HEK293 80 x 103 
H2 D6 transfected HEK293 80 x 103 
T1 Day 3 floating and adherent cells 80 x 103 
T2a Day 2 adherent cells 135 x 103 
T2b Day 2 floating cells 414 x 103 
Figure 3.4 D6 protein detected on trophoblasts by Western blot.  a) Cytokeratin 7 staining; b) 
and c) for better appreciation of the bands for both HEK293 and trophoblast cells, two different 
exposure times were shown for the same blot stained with D6 antibody. In this experiment three 
lysates were prepared from two placentas. Lysate T1 was prepared from adherent and floating 
cells from one placenta. Lysates T2a and T2b were adherent and floating cells respectively, from a 
different placenta. T2a had the strongest staining of D6, corresponding with the highest number of 
trophoblasts based on its cytokeratin 7 staining.  
           
49kDa 
46kDa 
49kDa 
46kDa 
55kDa 
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3.4.2 Immunofluorescence to explore subcellular distribution of 
D6 in cultured trophoblasts 
D6 protein has been successfully detected in and on HEK293 transfected with D6 
expression constructs by immunofluorescence. In HEK293, most D6 is inside the 
cells associated with early and recycling endosomes (Weber et al., 2004, 
McCulloch et al., 2008), and this also appears to be the case in trophoblasts in 
placental sections (Madigan et al., 2010). Thus the cells were examined to 
ascertain whether D6 had a similar subcellular distribution in cultured 
trophoblasts. The results using HEK-D6 cells shown in previous experiments could 
be replicated in our laboratory (Fig 3.5). No anti-D6 immunostaining was 
observed in untransfected HEK293 cells, and isotype-stained HEK-D6 cells were 
also negative. Using the same staining method, D6 was also detected in 
trophoblasts on day 2 of culture (Fig 3.6). The experiment was conducted on day 
2 because by this time there would be fewer cells being lost during wash steps, 
as trophoblasts become more adherent in comparison to day 1. The pictures of 
trophoblasts were not as impressive as the ones on HEK293. The background 
staining was higher on trophoblasts; the staining of D6 was detectable but not as 
bright as the control cells. This could be due to the presence of contaminating 
non-trophoblastic cells from the culture. By day 2, a number of trophoblasts 
would have syncytialised, causing heterogeneity in cell architecture and D6 
expression. The result can also be explained by the lower physiological 
expression of D6 protein, as opposed to the artificially transfected HEK293 cells. 
However, in those cells in the trophoblast cultures that were convincingly 
stained with the anti-D6 antibody, it appeared that the majority of the D6 was 
inside the cells in a similar manner to that seen in D6 transfected HEK293 cells. 
Previous work has shown that D6 continuously traffics to and from the cell 
surface in HEK293, with only <5% on the cell surface at any one time. This is 
important for its scavenging activity in these cells.  
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a) x20 magnification 
D6 transfected HEK293 cells stained 
with anti-D6 antibody 
D6 transfected HEK293 cells stained 
with isotype 
  
Untransfected HEK293 cells stained 
with anti-D6 antibody 
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b) x40 magnification 
 
D6 transfected HEK293 cells stained 
with anti-D6 antibody 
D6 transfected HEK293 cells stained 
with isotype 
  
Untransfected HEK293 cells stained 
with anti-D6 antibody 
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c) 
 
 
 
 
     x40 magnification 
 
d) 
 
 
 
 
     x63 magnification 
 
Figure 3.5 Immunofluorescence protocol optimised for D6 antibody staining on HEK293 
cells. Cells were permeabilised, stained with in-house anti-D6 primary antibody or isotype, and 
AF488 or FITC conjugated secondary antibodies (green). a) and b) Comparison of anti-D6 antibody 
and isotype staining. Nuclei are stained blue with DAPI. The image settings for the comparative 
anti-D6 antibody and isotype fields were synchronised for standardisation. c) and d) D6 transfected 
HEK293 cells stained with anti-D6 antibody at different magnifications; in these two figures the 
nuclear staining with DAPI is not shown. The staining of anti-D6 antibody can be seen as 
punctation in the cytoplasm associated with intracellular vesicles. 
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a) x20 magnification (3 fields) 
Anti-D6 antibody Isotype 
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b) x63 magnification (3 fields) 
Anti-D6 antibody Isotype 
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c) x63 magnification (representative photo showing punctate staining with anti-D6 antibody) 
 
Figure 3.6 D6 protein is stained in trophoblasts and is predominantly in intracellular 
vesicles. Immunofluorescence of permeabilised primary trophoblast cells. Primary antibody was 
in-house anti-D6, with AF488 conjugated secondary antibody (green). Nuclei are stained blue with 
DAPI. The image settings for the comparative D6 antibody and isotype fields were synchronised for 
standardisation. Z-stack was performed to confirm intracellular staining. The photos of the fields 
were taken from one representative placenta. 3 biological replicates were performed. In low 
magnification in a), D6 was seen as bright spots in the cytoplasm. In higher magnification in b) and 
c), the staining of D6 can be seen in the cytoplasm associated with vesicles.  
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3.4.3 Flow cytometry 
Next surface D6 expression in trophoblast was assessed by flow cytometry (Fig 
3.7). HEK-D6 cells were used as controls for this experiment initially and D6 on 
the surface of these cells was detectable by flow cytometry using anti-D6 
antibodies (Fig 3.7a). In contrast surface D6 was virtually undetectable on 
trophoblasts with only a few cells showing positive staining compared to isotype 
control stained cells (Fig 3.7b). Intracellular staining on permeabilised 
trophoblast cells was also performed using two separate anti-D6 antibodies and 
appropriate isotype controls (Fig 3.8). With mouse anti-human D6 antibodies (Fig 
3.8a), there did appear to be some specific intracellular staining and this was 
also seen in HEK-D6 cells. However, untransfected HEK293 cells gave similar 
results. This was also the case with the rabbit anti-human D6 antibody (Fig 
3.8b). This type of experiment has been performed on other cell types in our 
department, with similar problems being encountered. Without effective control 
cells to support the result, it was not possible to conclude that the positive 
staining inside trophoblasts was truly due to the presence of D6 protein. It is 
interesting to see that intracellular staining using the same mouse antibody 
worked on these cells in immunofluorescence; perhaps in flow cytometry the 
process of detaching the adherent cells into suspension had disrupted the 
cytoskeletal architecture of the cells, thus resulting in the high background 
staining from non-specific isotype binding of the antibodies. Nonetheless, it 
appears that surface D6 is barely detectable on the surface of cultured human 
trophoblasts even though it was found on HEK-D6 cells. This might be due to the 
relatively lower level of D6 expression in the physiological environment, as 
opposed to the artificially transfected HEK293 cells. In addition, perhaps in 
trophoblasts the predominantly intracellular localisation of D6 is even more 
pronounced, leaving very low level of D6 detectable on the cell surface.  
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D6 transfected cells 
 
Untransfected cells 
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b) 
            
 
          
 
 
 
 
 
 
 
Figure 3.7 D6 protein is virtually undetectable on the surface of trophoblasts. Surface staining of trophoblasts with anti-D6 antibody and isotype; cells were 
analysed by flow cytometry to detect the presence of D6 protein. HEK293 cells with or without transfected D6 were used as controls for this experiment, as shown in 
a). The cells underwent physical gating based on FSC and SSC characteristics, then viable cells were selected based on negative staining by 7-AAD viaprobe. 95% 
inclusion of isotype staining was set as the negative gating for comparison with D6 antibody staining.  The result from trophoblasts shown is representative of three 
biological replicates.                                                                     
Anti-D6 antibody 
10.4% positive 
Trophoblasts surface 
staining 
  Physical                                                    7-AAD viaprobe                                                Mouse isotype  
                                                                                                                                                4.8% positive 
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a) Mouse anti-D6 antibody staining 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 D6 transfected HEK293                               
 
Untransfected HEK293                             
 
Trophoblasts                                     
 
Isotype control  Mouse anti-D6 
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b) Rabbit anti-D6 antibody staining 
 
 
 
     
 
 
 
 
 
     
 
  
   
 
 
 
 
 
Figure 3.8 Staining permeabilised cells with anti-D6 antibodies. Cells were permeabilised, 
stained with anti-D6 antibodies or isotype control antibodies and analysed by flow cytometry to 
detect the presence of D6 protein. The cells underwent physical gating based on FSC and SSC 
characteristics. Experiments performed using mouse (a) and rabbit (b) antibodies. Trophoblast 
results were from a single placenta.   
     D6 transfected HEK293                                 
 
Untransfected HEK293                                  
 
   Trophoblasts                                          
Isotype control Rabbit anti-D6 
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3.5 Chemokine uptake assay 
3.5.1 Detection using fluorescent microscopy 
The observations using qPCR, Western Blotting, immunofluorescence and flow 
cytometry suggested that D6 is expressed by cultured trophoblasts and shows a 
subcellular distribution that is not dissimilar to that seen in D6 transfected 
HEK293 cells. It would be interesting to explore whether this D6 was functional 
for chemokine uptake and scavenging. To do this, fluorescently labelled CCL2 
which has been used successfully to assess D6 activity on mouse leukocytes and 
D6 transfected HEK293 cells was utilised (Hansell et al., 2011b). Control samples 
are used in which an excess of unlabelled CCL2 is included. Non-specific 
pinocytosis of labelled chemokine will not be inhibited by this unlabelled 
chemokine, but receptor-mediated uptake will be. As expected, CCL2AF647 was 
internalised by HEK-D6 when assessed by fluorescent microscopy although cells 
were not particularly bright when analysed in this way (Fig 3.9). However, the 
uptake was successfully competed with a 10-fold molar excess of unlabelled 
CCL2. Untransfected HEK293 cells were used as negative control and these cells 
failed to internalise any CCL2AF647. This uptake was undetectable when the assay 
was performed on trophoblasts. There was a concern about the sensitivity of 
fluorescent microscopy to detect internalised CCL2, so flow cytometry was 
studied to ascertain whether it was a better approach.  
 
 
 
 
 
 
 
138 
 
a)    
D6 transfected HEK293 cells incubated 
with CCL2AF647  
D6 transfected cells with no chemokine 
during incubation (negative control) 
  
Untransfected cells incubated with 
CCL2AF647 (negative control) 
D6 transfected cells incubated with 
CCL2AF647, with a 10-fold molar excess 
of unlabelled CCL2 
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b) 
 
 
 
 
 
 
 
 
Figure 3.9 Uptake of CCL2 in D6 transfected HEK293 cells. HEK293 cells with or without D6 
expression constructs were incubated with CCL2AF647 (red) +/- 10-fold molar excess of unlabelled 
CCL2. Nuclei were stained blue with DAPI. Z-stack was performed to confirm intracellular staining. 
a) Assessment of CCL2 uptake and competition, comparing with negative controls. Image settings 
were synchronised for standardisation b) DAPI staining of nuclei turned off, showing positive 
intracellular CCL2AF647 uptake. 
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3.5.2 Detection of quantitation of CCL2AF647 uptake using flow 
cytometry 
In comparison with fluorescent microscopy, flow cytometry proved to be a much 
more sensitive and quantitative way of detecting uptake of fluorescent 
chemokine (Fig 3.10-3.13). HEK293 cells expressing human D6 internalised large 
quantities of CCL2AF647, and this uptake could be effectively blocked by inclusion 
of a large excess of unlabelled human CCL2 (Fig 3.10-3.11). Control 
untransfected HEK293 cells internalised very little CCL2AF647. Moreover, robust 
CCL2AF647 uptake was seen with cultured trophoblasts. Next, competition assays 
were performed in which a 10-fold molar excess of a range of unlabelled 
chemokines were individually included along with the CCL2AF647 during the 
uptake incubation period (Fig 3.11-3.12). Known D6 ligands were used as 
competitors i.e. CCL2, CCL3L1, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL17 
and CCL22. CCL24 and CCL26, which are not thought to be D6 ligands, were also 
included. As expected, most of the known D6 ligands were able to prevent, to a 
greater or lesser extent, CCL2AF647 uptake by D6-expressing HEK293 cells (Fig 
3.11). CCL24 showed some ability to reduce uptake, but CCL26 was ineffective. 
Surprisingly, CCL4 was also a poor competitor, although it was possible that the 
batch of CCL4 that was used was defective. No positive control for its bioactivity 
was undertaken. When cultured trophoblasts were analysed in these assays, a 
similar profile of competition was observed (Fig 3.12). Cultured trophoblasts 
from the first placenta analysed showed that unlabelled CCL2 was the most 
effective competitor, but CCL3L1, CCL5, CCL7, CCL8, CCL11, CCL13, CCL17 and 
CCL22 all reduced CCL2AF647 uptake (Fig 3.12). CCL24 showed some weak activity 
as a competitor, but CCL26 was ineffective. As with D6-expressing HEK293 cells, 
CCL4 failed to compete CCL2AF647 uptake. Cultured trophoblasts from a further 
three placentas were then analysed to explore the reproducibility of the 
findings, and data from all four placentas were combined to produce the graphs 
show in Figure 3.13a-b. When gating for positive events, there was no 
statistically significant difference seen by the inclusion of competitor 
chemokines. When the MFI of the entire population was examined, while clear 
reductions were apparent these again failed to achieve statistical significance. 
However, if the MFI of positive events was assessed, then unlabelled CCL2, 
CCL3L1, CCL5, CCL7, CCL8, CCL13, CCL17 and CCL22 were all able to 
significantly reduce CCL2AF647 uptake by trophoblasts, while CCL4, CCL11, CCL24 
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and CCL26 were not. These data are consistent with CCL2AF647 uptake by cultured 
trophoblasts being mediated by a receptor that has ligand specificity that is very 
similar to D6 expressed in HEK293. Bearing in mind the preceding analysis of 
cultured trophoblasts, this receptor is most likely to be D6.  
The uptake assay showed a broad range of CCL2AF647 uptake by trophoblasts 
when they were gated according to the strategy shown in Figure 3.10. Since it 
was known that trophoblast cultures contained a mixture of cell types, gating 
was explored to see whether it could be refined to focus more effectively on 
cells internalising CCL2AF647. Thus, histograms of CCL2AF647 uptake (in the absence 
of any competitor chemokine) were back-gated to explore the forward scatter 
and side scatter characteristics of the CCL2AF647-high and CCL2AF647-low cells (Fig 
3.14). This clearly showed that CCL2AF647-high cells were, on average, larger than 
CCL2AF647-low cells, consistent with them being trophoblasts. Bearing this in 
mind, the CCL2AF647 uptake data was reanalysed by drawing a tighter gate with a 
FSC cut-off greater than 400 (Fig 3.15a). The histogram from this gating method 
showed a higher proportion of CCL2AF647-high cells. Combination of the data from 
four placentas using this tighter gate (Fig 3.15b) showed broadly similar pattern 
as the graphs from previous gating (Fig 3.13b), with more significant reductions 
in CCL2AF647 uptake when MFI of the entire population was examined.  
Syncytialised BeWo cells were found to have larger size when analysed by flow 
cytometry in the past (Kudo et al., 2003). Assuming trophoblasts have the same 
characteristics of syncytialisation as the BeWo cells, it may be possible that the 
population of CCL2AF647-high cells were syncytialised trophoblasts. Further 
exploration to confirm this theory is worthwhile in future experiments. If there 
is a low variability in the difference of chemokine uptake between these cell 
groups, this chemokine uptake assay can potentially be utilised effectively, to 
become a marker to differentiate subpopulations of trophoblasts in future 
experiments.  
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Figure 3.10 Trophoblast cells demonstrated CCL2AF647 uptake. Cells were incubated with CCL2AF647 and analysed by flow cytometry. The cells underwent physical 
gating, followed by exclusion of dead cells. HEK293 cells were used as controls. FACS plots and histograms from a representative placenta.                                                                     
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Figure 3.11 D6 ligands effectively compete CCL2AF647 uptake by HEK293 cells transfected with D6 expression constructs. Cells were incubated with CCL2AF647 
+/- a 10-fold excess of unlabelled chemokines and analysed by flow cytometry (page 142 and 143). Gating of the cells was shown in fig 3.10. 
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Figure 3.12 D6 mediates CCL2AF647 uptake by trophoblasts. Competition chemokine uptake assays revealed the presence of active D6 in trophoblasts. Cells were 
incubated with CCL2AF647 +/- a10-fold excess of unlabelled chemokines. Histograms from a representative placenta (page 144 and 145). Gating of the cells was shown 
in fig 3.10. 
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Figure 3.13 Analyses of D6 mediated CCL2AF647 uptake by trophoblasts. a) Examples showing 
calculation of % of positive events. Positive event was defined as any fluorescent events above the 
95% threshold from the curve where the cells were not incubated with any chemokine, as shown 
on the histogram on the left. Thus the percentage of positive events when there was no chemokine 
was 5%. This threshold was used to compare with other curves where the cells were incubated 
with CCL2AF647 +/- competition chemokines. b) Bar graphs of the positive events, and also mean 
fluorescence index (MFI) showing median + interquartile range, derived from the histograms of four 
biological replicates. The first columns show the results with CCL2AF647 incubation; the second 
columns show the results when no chemokine was introduced; from the third columns onwards 
they show the results with the presence of unlabelled competitive chemokines. * p<0.05 (Mann-
Whitney test compared with the first column).  
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Figure 3.14 Cells in trophoblast cultures positive for chemokine uptake were larger than 
cells with weak chemokine uptake. Gating method similar to figure 3.13a. Subpopulation of 
positive and negative cells from the chemokine uptake histogram were backgated to determine 
forward scatter (size) (FSC) and side scatter (granularity) (SSC). Plots are representative of data 
from four placentas. 
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Figure 3.15 Gate with FSC cut-off of greater than 400 contains more CCL2AF647-high cells. a) 
Gating of cells with FSC cut-off of greater than 400, followed by exclusion of dead cells. FACS 
plots and histograms from the same samples as Fig 3.12. b) Bar graphs of the positive events, and 
also mean fluorescence index (MFI) showing median + interquartile range, derived from the 
histograms of four biological replicates, with FSC cut-off readjusted to greater than 400. The first 
columns show the results with CCL2AF647 incubation; the second columns show the results when no 
chemokine was introduced; from the third columns onwards they show the results with the 
presence of unlabelled competitive chemokines. * p<0.05 (Mann-Whitney test compared with the 
first column).  
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3.6 Chemokine scavenging assay by Western Blot 
D6 is believed to act as a chemokine scavenging receptor. To ascertain whether 
D6 acts as a scavenger in the primary cultured human trophoblasts, chemokine 
scavenging assays were performed. Biotinylated CCL2 (bioCCL2) was used to 
study the scavenging of this D6 ligand from the supernatant over time. As this 
assay had never been performed in our laboratory with trophoblasts, firstly the 
protocol had to be optimised, and the minimal amount of bioCCL2 detectable by 
Western blot had to be determined. The result showed 100pg of bioCCL2 was 
detectable with little background (Fig 3.16). Based on this result, it was 
concluded that for performing this experiment, at least 1ng of bioCCL2 must be 
present in an aliquot of medium harvested to effectively study the scavenging 
effect of the chemokines by quantitative Western blot.   
In this experiment, bioCCL2 +/- a 10-fold excess of unlabelled CCL3L1 (D6 
ligand) and CCL26 (non-D6 ligand) were added into the wells of trophoblast 
cultures. An aliquot of medium was harvested from each well immediately after 
the addition of the chemokines (0 hour samples); this aliquot of medium 
contained 3ng of bioCCL2, based on the optimisation process described earlier. 
Subsequently at set time points, a series of aliquots of medium were collected 
from all the wells to study the scavenging effect mediated by D6. As the bands 
of bioCCL2 from the medium with trophoblasts faded over time on the Western 
blots, the result showed bioCCL2 was scavenged by trophoblasts; this effect was 
attenuated by addition of 10-fold excess of unlabelled CCL3L1 (D6 ligand) (Fig 
3.17). Non-D6 ligand CCL26 was used as a negative control for the competition of 
scavenging, and it failed to prevent bioCCL2 removal by trophoblasts (Fig 3.18).  
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          Serial dilutions of biotinylated CCL2 (ng) in duplicates 
Figure 3.16 Optimisation process to ascertain the minimal quantity of biotinylated CCL2 
(bioCCL2) detectable by Western blot. The indicated quantities of bioCCL2 were run on a 
polyacrylamide gel and a Western blot prepared. The bioCCL2 was detected with HRP-coupled 
streptavidin. 
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Curve Designation Description 
A 
 
Medium with no cells incubated with biotinylated CCL2 (negative control) 
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1.5 x103 cells incubated with biotinylated CCL2 + 10-fold excess unlabelled 
CCL3L1 
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1.5 x103 cells incubated with biotinylated CCL2  
 
Figure 3.17 Trophoblasts contain D6, which scavenges biotinylated CCL2 (bioCCL2) from 
the medium over time. The scavenging effect can be competed with CCL3L1 (D6 ligand). 
Scavenging assay of primary trophoblasts was performed; bioCCL2 was added into the wells of 
trophoblast cultures. At set time points, a series of aliquots of medium were collected from all the 
wells. Quantification of bioCCL2 was carried out by Western blotting. a) Western blot from the 
scavenging assay from one representative placenta. The bands of bioCCL2 faded over time due to 
the scavenging effect of trophoblasts. The effect was noticeably being attenuated with addition of 
10-fold excess of unlabelled CCL3L1 (D6 ligand) due to competition. b) Curves showing mean + 
standard deviation, showing changes of densitometry of the bands of bioCCL2 from four biological 
replicates of the experiment. 
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Figure 3.18 Trophoblasts contain D6, which scavenges biotinylated CCL2 (bioCCL2) from 
the medium over time. The scavenging effect is not competed with CCL26 (non-D6 ligand). 
To further support the previous finding showing the scavenging effect of D6, we used CCL26, a 
non-D6 ligand as our negative control for competition. a) Western blot from the scavenging assay 
from one representative experiment. The bands of bioCCL2 faded over time due to the scavenging 
effect of trophoblasts. The effect was not being competed with CCL26. b) Curves showing mean + 
standard deviation, showing changes of densitometry of the bands of bioCCL2 from three technical 
replicates from a placenta. 
 
Medium with no cells incubated with 
biotinylated CCL2 (negative control) 
 
1.5 x103 cells incubated with 
biotinylated CCL2 
 
1.5 x103 cells incubated with 
biotinylated CCL2 + 10-fold excess 
unlabelled CCL26 
 
155 
3.7 Summary 
For greater insight of D6 function in the human placenta, primary human 
trophoblasts that had been purified and cultured in vitro were used. It was 
hypothesised that D6 is present in these cells where it serves an important 
chemokine scavenging role and that this helps to protect the fetus.  
The protocol for routine primary trophoblast isolation, purification and culture 
from fresh placenta was optimised in the laboratory. D6 mRNA was detected in 
abundance in trophoblasts and Western blotting showed the presence of D6 
protein in these primary cells. Despite not producing excellent pictures by 
immunofluorescence, D6 protein was successfully stained in what appeared to be 
the intracellular vesicles of trophoblasts and flow cytometry showed D6 protein 
was barely detectable on the surface of primary trophoblasts. Competition 
chemokine uptake assays, analysed by flow cytometry, showed that CCL2 was 
internalised by trophoblasts using D6. Competitive chemokine scavenging assays, 
analysed by quantitative Western blot, confirmed D6 was functioning as a 
scavenger for its ligands and that it progressively removed substantial quantities 
of chemokine from medium bathing the cells.  
Collectively these results reaffirmed my initial hypothesis, that D6 is present, 
and plays a role in scavenging specific chemokines in the human placenta.  
3.8 Limitations 
Purity and viability of the cells were assessed at day 1 and 2 of culture. All 
experiments, except the chemokine scavenging assay and Western blotting to 
assess D6 protein expression, had been completed by day 2; both of these 
experiments were completed by day 3 (72 hours) of culture. By 72 hours, the 
cytotrophoblasts would be expected to syncytialise (Kliman et al., 1986, Newby 
et al., 2005). As shown by the purity assessment, other cells were present in the 
trophoblast culture due to the nature of the trophoblast isolation.  
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4 Exploring the Impact of D6 Deletion on 
Pregnancy in DBA-1 Mice  
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4.1 Stillbirth, neonatal death and pups weaned/litter in 
DBA-1 mice 
As discussed in the Introduction, D6 deficiency is associated with fetal loss in 
animal models. Wessels et al demonstrated that arresting porcine attachment 
sites have reduced expression of D6 in comparison to their viable counterparts 
(Wessels et al., 2007). Martinez de la Torre et al showed that lack of D6 in 
mother and pup results in an increased rate of fetal loss when pregnant mice 
were challenged with LPS and antiphospholipid autoantibodies (Martinez de la 
Torre et al., 2007). Madigan and colleagues showed that transferred allogeneic 
D6 deficient fetuses were preferentially lost from wild type recipients (Madigan 
et al., 2010). In our laboratory, anecdotal evidence suggested that D6 deficient 
mice on a DBA-1 background generated fewer pups per litter than WT 
counterparts. Therefore data on the stillbirth rate, neonatal death rate and pups 
weaned/litter in unchallenged WT and D6 deficient DBA-1 (D6 KO) mice were 
collected. Interestingly, D6 KO mice had higher stillbirth and neonatal death, 
resulting in a significant reduction in the number of pups successfully 
weaned/litter (Fig 4.1). This observed phenotype was not present in C57BL/6 
mice (R Nibbs, personal communication, from animal breeding data collected by 
the Central Research Facility, University of Glasgow). D6 deficient mice on a 
C57BL/6 background did not show any change in pup survival or pups 
weaned/litter (data not shown). 
WT DBA-1 mice were not particularly good breeders in our facility, and stillborn 
pups or neonatal death were not uncommon in this strain (Fig 4.1). The 
combined stillbirth and neonatal death (perinatal death) rate was 27%. The 
influence of strain on the rate of litter loss has been reported. Mortality rate of 
up to 32% of the litters in a laboratory mouse strain has been described in the 
past (Weber et al., 2013).  In our laboratory the reason for the high perinatal 
death rate for DBA-1 mice was not known. A number of antenatal or postnatal 
factors may be responsible for this phenotype. Postpartum maternal care can 
vary for different strain of mice, it has been reported that in certain strains the 
mothers have shorter latencies to nestbuild, and also to retrieve, crouch over 
and groom their pups (Champagne et al., 2007).  However, this variation in 
maternal behaviour has not been shown to be responsible for the difference in 
the fetal survival rate during perinatal period. The abnormal behaviour of 
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maternal cannibalism has also been described in DBA-1 mice (Carter et al., 
2002). On the other hand, it is also possible that the low survival rate of DBA-1 
pups is due to a suboptimal antenatal development, predisposing them to a 
compromised phenotype in the neonatal period. The observed phenotype in D6 
KO mice may be due a compound effect. The lethal effect of compound mutants 
has been described before. For example, compound mutants of Tcf1/Lef1 
transcription factors resulted in abnormal placentation and death of the pups at 
mid-gestation, but neither Tcf1 nor Lef1 standalone mutants have any placental 
phenotypes (Galceran et al., 1999, Rossant and Cross, 2001).  Perhaps in DBA-1 
there is an inherent defect in placentation and embryogenesis; the compound 
effect of this defect along with D6 deficiency could be responsible for the higher 
perinatal loss in the D6 KO group. This model provides a unique opportunity for 
the exploration of the role of D6 during placentation.  
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Figure 4.1 D6 KO mice had higher stillbirth and neonatal deaths, resulting in lower pups 
weaned/litter. Mean numbers of pups born/litter +/- SEM were 5.7 +/- 0.28 (n= 83 litters) for WT, 
and 5.4 +/- 0.25 (n= 77 litters) for KO; p=0.38 (Mann Whitney). Females in late pregnancy were 
checked for newborns daily. Once all the pups were born and being nursed, the number of live 
pups and dead carcasses were counted a) Carcasses that were noticed when the litter was first 
discovered were counted as stillbirths; n= 474 for WT, n= 418 for D6 KO; p<0.0001 (X2 test); data 
from first 3 weeks from birth. b) Pups that did not survive to weaning at day 18 to 21 after birth 
were recorded as neonatal deaths; n=400 for WT, n=322 for D6 KO; p<0.0001 (X2 test); data from 
first 3 weeks from birth. c) Pups weaned per litter; n= 80 litters for WT, n=75 litters for D6 KO; graph 
shows mean +/- SEM; p= 0.0018 (Mann Whitney). 
p<0.0001 
p<0.0001 
p=0.0018 
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4.2 Perinatal deaths and weight changes during neonatal 
period 
In view of the evidence of the increase in stillbirth and neonatal death, a more 
in depth study of the phenotype of the neonates from our DBA-1 mice was 
performed. Pregnant females were examined twice a day (at 11-13 hours 
intervals) from the time they appeared to be in late gestation, through delivery 
and nursing of the pups, for the charting of survival and weight changes of the 
pups until the neonates reached weaning age. This method allowed me to 
collect data on the timing of neonatal deaths, and also any evidence of failure 
to thrive of the pups. D6 KO mice appeared to have a higher perinatal death rate 
than the WT group, and the majority of deaths occurred either before being 
born (stillbirth) or within the first week of life. For the surviving pups however, 
there was no difference in the average weight changes between the two groups 
(Fig 4.2). The difference of the survival rate between WT and D6 KO was not 
statistically significant, however the pattern of perinatal death was rather 
similar to the data generated previously (Fig 4.1). It would be interesting to 
study the survival curve on a sample size as large as that group. Due to limited 
resources, a larger sample size could not be generated for this study. 
Nevertheless, the data reveal that in WT and D6 KO mice, most deaths occurred 
in the perinatal period within the first week, after which D6 deficiency had no 
effect on pup weight gain.  
 
 
 
161 
   a)                                                            
 
 
 
 
 
 
 
  
  b)           
 
 
 
 
 
 
 
 
 
Figure 4.2 D6 KO mice appeared to have a higher perinatal death rate than the WT group. 
Over a period of 2 months, WT and D6 KO females were mated with males with the same genetic 
background. The number of live pups and dead carcasses were counted until all the pups were 
successfully weaned, or when there was no live pups left in the litter. The weight of the live pups 
was plotted until they were successfully weaned. a) Survival curve covering the period of study. 
n=43 for WT, n=33 for D6 KO. Majority of deaths occurred either before being born (stillbirth) or 
within the first week of life. Log rank (Mantel-Cox) test, p= 0.12 b) For the surviving pups, there was 
no difference in the average weight gain between the two groups. n=10 litters for WT; n= 6 litters 
for D6 KO. 
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4.3 Relative mRNA expression of chemokines in mouse 
placentas 
It is well known that in humans and mice, the phenotypes of neonates and 
fetuses are highly affected by placental function. Placental deficiency is often 
associated with growth restriction and perinatal death. The postnatal phenotype 
of D6 deficient mice, and the fact that D6 is expressed by fetal cells in the 
placenta (Madigan et al., 2010), suggests the reason for perinatal death of D6 
deficient pups may lie within the formation and function of the placenta.  
To study if there was any evidence of inflammation in D6 deficient placenta the 
expression of D6 ligands in the placentas of D6 KO mice in comparison to WT was 
examined. qPCR was carried out to quantify the mRNA expression of CCL2, CCL3, 
CCL4, CCL5, CCL11, CCL12, CCL17 and CCL22, comparing WT and D6 KO 
placentas harvested at E18 (Fig 4.3). D6 was also analysed. As an endogenous 
control that is unlikely to be affected by D6 deficiency, GAPDH and B-actin 
expression were analysed for each sample. Between the samples, the expression 
of both of these housekeeping genes was stable; GAPDH was used for normalising 
all the results for the mouse placentas. Eight placentas from each group were 
analysed, these placentas are the same ones selected for the stereology study 
(see section 4.5). As expected, D6 mRNA was readily detected in WT placentas, 
but not in D6 deficient placentas (Fig 4.3). There was considerable variation in 
the expression of the chemokines studied, however this can be due to the 
difference in the efficiency of the primers used for their detection. All the 
chemokines analysed were not differentially expressed between WT and D6 
deficient placentas, with the exception of CCL17 transcripts which were found 
to be higher in the D6 KO group (discussed further in section 5.2.2.2). This 
finding was confirmed by qPCR to analyse the expression of CCL17 in all the 
other available E18 mouse placentas dissected from well-formed pups (Fig 4.4). 
Thus, D6 deficient E18 placentas show higher expression of the CCL17 gene. 
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Figure 4.3 mRNA encoding CCL17 was higher in the D6 KO placenta. Analyses of mRNA 
expression of D6 and its ligands by qPCR. n= 8 in each group. Placentas were harvested at E18. 
RNA was extracted, cDNA was generated and the samples were then subjected to qPCR 
analyses. Graphs show median + interquartile range and individual data points. Mann-Whitney test.  
 
      
Figure 4.4 Confirmation of higher mRNA expression of CCL17. More placentas from well 
formed pups were analysed to confirm earlier finding from eight placentas in each group. WT n= 
23, D6 KO n= 24. Graphs show median + interquartile range and individual data points. Mann-
Whitney test.  
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4.4 Relative mRNA expressions of white cell markers in 
the mouse placentas 
D6 may regulate chemokine abundance, and D6 deficient placentas contain 
higher levels of CCL17 mRNA. Thus, more leukocytes may be recruited to D6 
deficient placentas. To examine this the expression of white cell markers in the 
placentas was studied. Besides D6, CCL17 is also a ligand for CCR4, which is 
expressed in regulatory T cells (Treg) (Leber et al., 2010). Perhaps without D6, a 
higher expression of CCL17 in the D6 KO group acts as a compensatory 
mechanism to regulate inflammation by attracting more Treg to localise in the 
area. Apart from Treg, monocyte/macrophages and T cells also migrate in 
response to D6 ligands. Therefore D6 deficiency may also affect the level of the 
markers for these white cells. However, analysis of the same 8 placentas used 
earlier for chemokine expression showed there were no differences in the 
expression of Foxp3 (Treg), F480 (macrophages) or CD3 (T cells) between the 
groups (Fig 4.5). Thus, there appears to be no detectable increase in the 
recruitment of these cells to the D6 deficient placenta.  
                  
Figure 4.5 No difference in the expression of white cell markers between WT and D6 KO 
placentas. Analyses of mRNA expression of white cell markers by qPCR. n= 8 in each group, the 
same samples used in Figure 4.3. Graphs showing median + interquartile range and individual data 
points. Mann-Whitney test.   
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4.5 Stereology of mouse placentas 
To gain further insight into the D6 deficient placenta, pup weights, placental 
weights and pup/placenta ratios were examined; stereology on the placentas at 
early (E10), mid (E14) and late (E18) gestations of the mice was also performed.  
Stereology is a well established technique using systemic uniform random 
sections (Coan et al., 2004), allowing minimally-biased and economical 
quantitation of the 3D structure and function of the placenta from cellular to 
whole tissue levels (Mayhew, 2009). In the experiments the volume fractions 
(percentages of total volumes) of different functional zones of the murine 
placentas were studied. These 4 different functional zones were: decidua basalis 
(DB), junctional zone (JZ), labyrinthine zone (LZ) and chorionic plate (CP). There 
was a particularly interest in the LZ. This is the zone where the irregularly 
shaped maternal blood spaces are closely juxtaposed to fetal capillaries. This 
fetal-maternal interface represents the principal site of haemotrophic exchange 
(Coan et al., 2004). Previous studies have shown that genetic or environmental 
factors that result in low pup weights are associated with reduced LZ volume in 
mice (Coan et al., 2008, Coan et al., 2010). 
Experiments at E10 were abandoned because the placentas at that stage were 
too small, friable and technically challenging to section. Professor Burton’s 
group at the Centre of Trophoblast Research, University of Cambridge was 
consulted for advice regarding this difficulty. They confirmed that mouse 
placentas in very early gestations are unsuitable to be used for stereology study 
due to this technical issue.   
Comparison of WT and D6 KO pups at E18 showed there was no difference in pup 
weight, placental weight and pup/placenta weight ratio (Fig 4.6). Stereology of 
the placentas did not show any differences in all the functional zones at E18 (Fig 
4.7). However, at E14 the pup weight was lower for D6 KO than WT (Fig 4.8). 
The functional volumes were lower for LZ, and higher for JZ in the D6 KO group 
compared with WT counterparts (Fig 4.9).  
This phenotype in the D6 deficient placenta at E14 could potentially be due to a 
maternal or a fetal effect of D6 deficiency. To examine this, females 
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heterozygous for the deleted D6 allele (D6 HET) were bred with D6 KO males, 
generating D6 HET and D6 KO siblings in the same D6 HET mother. Pups were 
genotyped to ascertain their genetic background. Out of the total of 20 pups 
from two D6 HET females, there were 11 D6 HET and nine D6 KO pups, close to 
the expected ratio of 1:1 (Fig 4.10).  
Stereology of the placentas showed reduced LZ and increased CP volume 
fractions in the D6 KO siblings at this gestation (Fig 4.11). However, pup weight, 
placental weight and pup/placenta weight ratio were the same between the 2 
groups of D6 HET and D6 KO siblings (Fig 4.12). The result of placental stereology 
from the two HET mothers was similar to the finding in the experiment 
comparing WT and KO mice, therefore we did not have to sacrifice more HET 
females for this study. Collectively, the stereology report indicates that 
formation of placenta early to mid gestation is dependent on the D6 genotype of 
fetus. However, the weight of the D6 KO pups was not affected by fetal D6 
deficiency in the presence of D6 expression by the mother and siblings; although 
the group size is smaller this result is different from the data comparing the 
offspring from WT and D6 KO females.   
To ascertain the importance of labyrinthine zone in supporting fetal growth, the 
correlations between the volume fraction of different functional zones and 
pup/placenta weight ratio were analysed. It is more reasonable to compare the 
placental function with pup/placenta weight ratio rather than pup weight, to 
normalise the size of the placenta in the analysis. For this analysis, all the 
placentas with data from stereology as described above were included. At E18, 
the placentas from WT and D6 KO females bred with males of the same genetic 
background were included. At E14, the placentas included were from WT and D6 
KO females bred with males of the same genetic background, and also from D6 
HET females bred with D6 KO males. There were significant positive correlations 
between pup/placenta weight ratio and labyrinthine zone volume fraction at 
both E18 and E14 (Fig 4.13 and 4.14). The volume fractions of junctional zone 
(E14 and E18), and to a certain extent chorionic plate (E14), were negatively 
correlated to pup/placenta weight ratio, presumably as a result of replacement 
of the loss in the volume of labyrinthine zone. 
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Collectively, stereology of mouse placentas showed D6 deficiency of the fetus 
leads to a decrease in the functional volume of labyrinthine zone in the placenta 
in early to mid gestation. The functional volume of labyrinthine zone is essential 
in supporting fetal growth, as there are significant positive correlations between 
pup/placenta ratio and labyrinthine zone volume fraction. 
 
              
Figure 4.6 No differences in pup weight, placental weight and pup/placenta weight ratio 
between WT and D6 KO at E18. Comparisons of wet weight of pups and placentas, and also 
pup/placenta ratio at E18 between the two groups.  WT n=36; D6 KO n=25. Graphs showing 
median + interquartile range and individual data points. Mann-Whitney test. 
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Figure 4.7 No difference in the volume of the functional zones in the placentas between WT 
and D6 KO at E18. One half of each placenta was serially sectioned at 8µm, and aligned in the 
correct order from the beginning until the end. At fixed interval, representative sections from each 
placenta were mounted on slides, and stained with haematoxylin and eosin. Stereology was carried 
out where the sections were gridded and randomly plotted to compare the volume of different 
functional zones. n=2 placentas from each litter, four litters for each group. Graphs showing the 
mean of each litter and median + interquartile range for each group. Mann-Whitney test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Pup weight was significantly less in D6 KO in comparison to WT at E14. 
Comparisons of wet weight of pups and placentas, and also pup/placenta ratio at E14 between the 
two groups. Placental weight and pup/placenta ratio were similar between the two groups. WT 
n=47; D6 KO n=24. Graphs showing median + interquartile range and individual data points. Mann-
Whitney test. 
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Figure 4.9 Decreased labyrinthine zone and increased junctional zone in D6 KO at E14. 
Stereology analyses of the placentas comparing WT and D6 KO groups at E14. a) n=2 placentas 
from each litter, four litters for each group. Graphs showing the mean of each litter and median + 
interquartile range for each group. Mann-Whitney test. b) Histological sections showing thickened 
junctional zone and smaller labyrinthine zone in D6 KO at E14. DB= decidua basalis; JZ= junctional 
zone;  LZ= labyrinthine zone; CP= chorionic plate. 
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Figure 4.10 1:1 ratio of D6 HET and D6 KO pups. Genotype of pups from two D6 HET females 
bred with D6 KO males. Columns with two bands depicted genotype of D6 HET pups; one band 
depicted genotype of D6 KO pups. One HET female had 12 pups (columns 1 to 12); the other had 
8 pups (columns 13 to 20). Samples taken from pups, and genomic DNA isolated. PCR was 
performed using three primers, one common to both WT and D6 KO alleles, and one specific to 
each allele.  
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Figure 4.11 Decreased labyrinthine zone and increased chorionic plate in D6 KO comparing 
with their D6 HET siblings at E14. Stereology analyses of the placentas comparing D6 KO and 
their D6 HET siblings at E14. The pups were genotyped. a) n= 4 placentas for each litter for each 
group, two litters in total. Graphs showing the result for each placenta and median + interquartile 
range for each group. Mann-Whitney test. b) Histological sections showing thickened chorionic 
plate in D6 KO at E14. DB=decidua basalis; JZ=junctional zone; LZ=labyrinthine zone; 
CP=chorionic plate. 
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Figure 4.12 No differences in pup weight, placental weight and pup/placenta ratio between 
D6 HET and their D6 KO siblings at E14. Comparisons of wet weight of pups and placentas, and 
also pup/placenta ratio at E14 between the two groups. The pups were genotyped. D6 HET n=10; 
D6 KO n=9. Graphs showing median + interquartile range and individual data points. Mann-
Whitney test. 
 
 
 
 
173 
 
Figure 4.13 Pup/placenta ratio significantly correlates to labyrinthine zone volume fraction 
at E18. Significant positive correlations to labyrinthine zone and negative correlations to junctional 
zone. Spearman rank correlation coefficient. n=16; placentas from WT and D6 KO females bred 
with males of the same genetic background.. DB= decidua basalis; JZ= junctional zone; LZ= 
labyrinthine zone; CP= chorionic plate. 
 
 
Figure 4.14 Pup/placenta ratio significantly correlates to labyrinthine zone volume fraction 
at E14. Significant positive correlations to labyrinthine zone and negative correlations to junctional 
zone. There is also a trend showing negative correlations to chorionic plate. Spearman rank 
correlation coefficient. n=32; placentas from WT and D6 KO females bred with males of the same 
genetic background, and also from D6 HET females bred with D6 KO males. DB=decidua basalis; 
JZ=junctional zone; LZ=labyrinthine zone; CP=chorionic plate.                                         
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4.6 Quantification of chemokine levels in plasma using 
Luminex multiplex protein assay 
In humans, D6 is much more highly expressed in the placenta in comparison to 
other solid tissues (Nibbs et al., 1997b) . Furthermore, in term human placenta, 
the chorionic villi are thought to have a surface area of about 10m2 (Biswas et 
al., 2008). One would expect the level of D6 ligands to be reduced in pregnancy, 
as the maternal blood flows through the large surface area of D6 abundance in 
the placenta. The results from Madigan et al suggest that this postulation is true 
in humans (Madigan et al., 2010).   
In mouse, D6 is also expressed in the placenta, albeit at a lower level than in 
humans (Nibbs et al., 1997a). Stereological analysis shows the surface area of 
maternal blood space in a mouse placenta at E18.5 to be 23.87cm2 (Coan et al., 
2004). Given that a litter can consist of more than 10 pups, the combined 
surface area of maternal blood space in the placentas of a pregnant mouse is 
substantial. Thus the placentas in a pregnant mouse may have a major 
contribution in regulating the level of D6 ligands in the blood. Perhaps if there 
are differences in the systemic levels of D6 binding pro-inflammatory 
chemokines between WT and D6 KO, they also play a major role in determining 
the phenotype of the offspring.   
Luminex multiplex protein assay showed that in mouse plasma, the level of CCL2 
(D6 ligand) is higher in pregnant D6 KO mice than pregnant WT animals. The 
difference is more marked at E14 in comparison to E18. However, due to 
insufficient power, the difference of CCL2 between WT and D6 KO did not reach 
statistical significance when E14 and E18 were analysed separately. There is no 
difference in the level of D6 ligands CCL3 and CCL5, or the non-D6 ligand CXCL1 
between the two groups of mice (Fig 4.15).  
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Figure 4.15 D6 KO pregnant mice had significantly higher CCL2 in the plasma. Quantification 
of chemokine levels in the plasma for pregnant mice at E14 and E18 by Luminex multiplex protein 
assay. CCL2, CCL3 and CCL5 are known D6 ligands. CXCL1 is a non-D6 ligand, used as a 
negative control. **Linear mixed effect statistical modelling; difference between WT and D6 KO p= 
0.001; difference between E14 and E18 p= 0.03. n=11 for WT and n=7 for D6 KO; one sample was 
excluded each for WT and D6 KO due to the level of chemokines clearly not representative of the 
rest of the group, shown as significant outliers from the rest by Grubbs’ test (http://graphpad.com/ 
quickcalcs/Grubbs1.cfm). Individual analysis of CCL2 level at E14 and E18 showed the difference 
between WT and D6 KO was more marked at E14, however this did not reach statistical 
significance due to inadequate sample size, resulting in an underpowered study. 
 
4.7 Summary 
Animal models showed that D6 deficiency is associated with fetal loss. In this 
chapter, the phenotypes of D6 deficiency in the placentas and pups of DBA-1 
mouse was studied in order to understand the pathophysiology underlying these 
compromised features. The initial hypothesis was that, the suboptimal 
reproductive outcome in D6 KO pups was due to a fundamental defect in the 
formation of functional anatomy of the placenta.  
D6 KO DBA-1 mice cohort had higher stillbirth and neonatal deaths, resulting in 
lower pups weaned/litter in comparison to their WT counterpart. A more 
detailed analysis showed the majority of deaths in both groups occurred either 
E14 D6 KO mother 
 
E14 WT mother 
E18 WT mother 
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before birth (stillbirth) or within the first week of life. For the surviving pups, 
there was no difference in the average weight gain between the two groups.  
At E18, there was no difference in mRNA expression of D6 ligands in the 
placentas apart from CCL17. mRNA expression of CCL17 was higher in D6 KO 
placentas. Despite the higher level of expression of this chemokine in the D6 KO 
group, there were no differences in the expression of the markers for Treg, 
macrophages or T cells. 
At E18, no differences were detected in the pup weight, placental weight and 
pup/placenta weight ratio between WT and D6 KO. At this gestation, stereology 
showed no difference in the volume fractions of the functional zones in the 
placentas between WT and D6 KO. However at the earlier gestational age of E14, 
the pup weight was significantly smaller in the D6 KO mice. Stereology analysis 
at this gestation showed a decrease in labyrinthine zone volume fraction. The 
experiment at E14 was extended, breeding D6 HET DBA-1 females with D6 KO 
males, to compare the phenotypes of D6 KO pups and placentas with their D6 
HET siblings that developed in a mother expressing some D6 (i.e. D6 HET). 
Although there were no differences in pup weight, placental weight and 
pup/placenta ratio between these two groups, stereology revealed a decrease in 
labyrinthine zone volume fraction in the D6 KO placentas in comparison to their 
D6 HET siblings.  
Analysis of the correlation between pup/placenta ratio and different functional 
zones of the placentas showed that at all gestations there were significant 
positive correlations of the pup/placenta ratio to the labyrinthine zone volume 
fraction, and significant negative correlations to the junctional zone volume 
fraction.  
Quantification of chemokine levels in plasma using Luminex multiplex protein 
assay showed D6 KO pregnant mice had significantly higher CCL2 in the serum in 
comparison to the WT counterpart. No differences were detected in the level of 
CCL3 and CCL5 (both D6 ligands), and also CXCL1 (non D6 ligand). 
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Thus, D6 deficiency in DBA-1 mice is associated with increased neonatal death, 
reduced labyrinthine zone size, and dysregulation of circulating chemokine 
levels.  These findings are discussed in greater depth in the Discussion section. 
4.8 Limitations  
WT and KO mice have been bred as separate colonies for many generations, thus 
genetic drift could have occurred as a result and affected the phenotypes of the 
mice. For the WT and KO comparison, we relied on the detection of copulation 
plug for the determination of the gestational age. This technique is known to be 
an efficient way for conducting mouse experiments within a set time limit, 
albeit not the most accurate method of dating mouse pregnancies. The results 
from HET mice from subsequent experiments were helpful in confirming the 
findings on WT and KO mice; in this experiment the method of timing of 
gestational period was improved.  
The frequent intervention of weighing the pups in the neonatal period could 
have caused distress to the mothers and pups, this may have also affected the 
behaviour of the mothers. However, despite the intervention in the neonatal 
period, the rate of neonatal death is similar to the data provided by the staff in 
the Central Research Facility.  
The study of mRNA expression of the chemokines in the mouse placentas 
indicated the pattern of protein synthesis, however the level of protein in the 
tissues may not be truly reflected by this experiment. On a related note, the 
study of mRNA expression of white blood cell markers would not have shown any 
difference in the pattern of distribution of the cells. These experiments can be 
complemented by studies of protein levels.  
The sample size of the animals needed was difficult to be determined before 
starting the stereology experiment. Prior to the experiment, it was not known 
whether the expression of D6 would have caused any difference in stereological 
analysis. Taking the welfare of the animals into consideration, the aim was to 
sacrifice as few mice as possible. We started the stereology experiment with 
four litters in each arm. As shown in the results, no difference was detected in 
our first experiment at E18. In this instance it is difficult to gauge whether any 
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difference will be detected if a larger sample size is used. However by studying 
the patterns of pup/placenta ratio at E18 and also the correlations between 
labyrinthine zone volume fraction and pup/placenta ratio, it is postulated that 
no difference will be detected even if a larger sample size is used.
179 
5 Discussion 
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During implantation, the decidua has to be receptive to the implantation of the 
semi-allogeneic embryo. This delicate process, along with the formation of the 
placenta, requires intimate cross-talk between fetal trophoblasts cells, maternal 
stromal cells in the uterine wall, and specialised maternal decidual leukocytes, 
which are recruited to the decidua during pregnancy.   
The placenta serves to support the nutrition, survival and wellbeing of 
mammalian fetuses until they are mature and ready to be delivered from the 
uterus. A good pregnancy outcome is greatly dependent on successful 
placentation, with adequate depth of invasion into the myometrium. Abnormal 
placentation is one of the common findings in pregnancies that lead to 
intrauterine growth restriction and stillbirth (Khong et al., 1986, Bukowski et al., 
2011); it has also been shown to be related to late sporadic miscarriage and 
preterm labour (Kim et al., 2003, Ball et al., 2006, Brosens et al., 2011, Kovo et 
al., 2013). There is also a report that a risk of stillbirth can be predicted by 
placental function in the first ten weeks after conception (Smith et al., 2004). 
Placentas that invade too deeply into the myometrium result in placenta 
accreta, which poses a great risk of haemorrhage to pregnant women during 
delivery. On the contrary, inadequate placentation in human is associated with 
the above complications in pregnancy and also pre-eclampsia and eclampsia, 
with significant risk of fetal and maternal morbidity and mortality in pregnancy.  
Chemokines play a major role in regulating the process of placentation. By 
binding to G-protein coupled receptors, chemokines become important 
communication tools between leukocytes and trophoblasts. They are believed to 
be one of the central mechanisms that control the infiltration and localisation of 
specific cells in the placenta and decidua. In the decidua, the distribution of 
expression of different chemokines and their receptors are distinctive, defining 
the specific role they play in the process of placentation (Red-Horse et al., 2004, 
Hannan and Salamonsen, 2007) 
D6, an atypical chemokine receptor, is highly expressed in the placenta, and is 
postulated to exert its role as a scavenger of CC chemokines in the organ. It is 
expressed by fetal trophoblasts at the feto-maternal interface that separates 
fetal cells from the maternal tissues, and it has been proposed to play a role in 
protecting the embryo from immunological detection and attack from maternal 
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leukocytes (Madigan et al., 2010). Previous in vivo experiments showed that D6 
has an indispensible protective role in pregnancy in challenged and fully 
allogeneic models (Martinez de la Torre et al., 2007, Madigan et al., 2010, 
Kliman et al., 1986). In vivo experiments using BeWo cells reported D6 is present 
in this trophoblast-derived choriocarcinoma cell line, and acts as a chemokine 
scavenger (Madigan et al., 2010).  
At present, the pathophysiology of abnormal placentation, a process that starts 
at early gestation, is poorly understood. Based on previous findings, it is 
plausible that dysfunction in chemokine regulation could greatly affect this 
delicate process, resulting in the pregnancy disorders described. The abundance 
and precise localisation of D6 in the placenta indicate that it plays an important 
role in regulating the bioavailability of chemokines at specific microanatomical 
locations. The findings in this thesis lend further support to the idea that D6 on 
trophoblasts scavenges chemokines.  Moreover, they demonstrate that loss of D6 
can lead to fundamental defects in placental structure that appear to 
compromise the health of neonates. 
5.1 Molecular function of D6 
5.1.1 Approaches to exploring D6 function in vitro  
Much of what we know about the function of D6 has come from the analysis of 
its behaviour when it is over-expressed in an immortalised cell line.  In this 
context, D6 binds with high affinity to many pro-inflammatory CC chemokines 
but appears unable to couple to signal transduction pathways that are typically 
activated by chemokine receptors.  However, because of its trafficking 
properties in these cells lines, D6 can continuously remove chemokines from the 
extracellular environment and it is this behaviour that has led to the concept 
that the function of D6 in vivo is to act as a non-signalling chemokine scavenger 
in vivo.  This idea has been supported by the analysis of D6 function in 
immortalised choriocarcinoma cells (BeWo) and is consistent with many of the 
phenotypes observed in D6 deficient mice.  However, the function of D6 had not 
been explored on primary human cells, yet this is important to get a more 
reliable insight into D6 function in vivo. 
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Primary cultured human trophoblasts are arguably the most representative cells 
in which to explore the function of D6 in the human placenta. This approach is 
far more technically challenging than using immortalised cell lines, which are 
easy to culture, store and analyse, and there is no limitation on the number of 
cells that can be generated.  In contrast, when working with primary 
trophoblasts careful planning was required to obtain a regular supply of fresh 
placentas and isolate the cells, and these cells only have a limited lifespan and 
undergo syncytialisation within 48 to 72 hours of isolation (Whitley, 2006, Orendi 
et al., 2011). Moreover, only a limited number of cells could be purified from 
each placenta, and the time period available for performing experiments was 
restricted by the time that these cells survive in culture. A considerable amount 
of time was spent establishing and developing this technique to effectively and 
reproducibly isolate and culture trophoblasts from fresh samples.  Nonetheless, 
despite the difficulties and inconveniences, using primary human trophoblasts is 
the optimal method of studying D6, because it is in these cells that it will show 
its characteristics closest to its biological form in the body. Importantly, this 
work is the first experimental report of D6 on primary human cells.  
In my experiments, human placentas underwent enzymatic digestion and cells 
were purified in layered Percoll gradients. This technique was first described by 
Kliman et al., and is known as a high-yielding protocol of isolating primary 
trophoblasts with sufficient purity (Kliman et al., 1986). This approach of 
trophoblast isolation and purification was adopted even in experiments in recent 
years (Aye et al., 2010, Desforges and Westwood, 2011). Immunoselection 
methods may produce a higher purity of trophoblasts (Pötgens et al., 2003), but 
this was not practical in our laboratory, due to the scale and time required for 
the experiments. For each placenta collected, limited time was available for 
performing different experiments before the cells lost viability or syncytialised.  
Concentration of oxygen may affect the behaviour of the cells in trophoblast 
culture. In vivo, the level of oxygen in the placenta fluctuates from the start of 
placentation until the end of the first trimester. As described earlier, after 
implantation endovascular extravillous trophoblast cells migrate to the lumens 
of the spiral arteries and occlude them. This limits the maternal blood flow into 
the placenta. At this stage the partial pressure of oxygen in the placenta is less 
than 20mmHg; thus the embryo is protected from free radicals (Rodesch et al., 
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1992, Burton and Jauniaux, 2004). Incomplete plugging of the arteries leads to 
premature intervillous circulation, which can result in abnormal placental 
development and pathological conditions in pregnancy (Jauniaux et al., 2003, 
Burton and Jauniaux, 2004). Normally the low oxygen environment is maintained 
until about 10-12 weeks of gestation, and begins to rise when maternal blood 
starts entering the intervillous space. After the twelfth week of gestation, the 
oxygen partial pressure rises to 40-60mmHg (5-8% oxygen); the oxygen 
concentration continues at this level until the third trimester (Rodesch et al., 
1992, Burton and Jauniaux, 2004). In vitro studies showed that when 
trophoblasts were exposed to hypoxic conditions with oxygen concentration of 
2% or below, the epigenetic profile, and also gene and protein expression of the 
cells altered (Newby et al., 2005, Oh et al., 2011, Yuen et al., 2013). In this 
environment the cells also differentiated poorly, and did not cease to 
proliferate; this regulatory mechanism that influence the behaviour of 
trophoblasts is thought to be crucial in determining the success of placental 
development (Genbacev et al., 1997). Interesting, in the same experiments the 
authors did not detect any change in the phenotype of the trophoblasts when 
they were cultured in 8% oxygen concentration in comparison to the standard 
incubating oxygen concentration of 20% (Oh et al., 2011, Yuen et al., 2013). In 
my experiment, the trophoblasts from term pregnancies were cultured in the 
standard oxygen concentration of 20% to avoid the conditioning effect of 
hypoxia.  
The purity of trophoblasts was assessed using flow cytometry, the most 
objective and quantitative technique described (Frank et al., 2001). 
Recommended reliable markers cytokeratin 7 and vimentin were used for 
staining (Frank et al., 2001, Pötgens et al., 2001). Despite initial poor yields and 
low viability, routine cultures of placental cells that contained 50-100 x 106 
cells, with 70-85% of which were trophoblasts based on expression of cytokeratin 
7 and lack of vimentin were established.  With these cultures, experiments were 
carried out to explore D6 expression and function. 
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5.1.2 Expression and function of D6 in primary human 
trophoblasts 
By examining RNA and protein, the results clearly demonstrated high expression 
of D6 in primary cultured trophoblasts. Moreover, immunofluorescence stained 
D6 protein predominantly intracellular, with no detectable receptor on the 
surface. This is interesting because this subcellular distribution of D6 is similar 
to that observed for endogenous D6 in BeWo cells, D6 in trophoblasts in situ in 
gestational membranes (Madigan et al., 2010), and exogenous D6 overexpressed 
in HEK293 cells (Weber et al., 2004, Madigan et al., 2010). In HEK293 cells, this 
distribution is caused by the ability of D6 to rapidly internalise into endosomes 
after reaching the cell surface, a process that is critical for the ability of D6 to 
scavenge chemokines in these cells.  Thus, this observation implied that D6 
might show similar trafficking properties in primary cultured trophoblasts.  More 
importantly, the chemokine uptake and scavenging assays directly demonstrated 
that D6 in primary trophoblasts can act as a chemokine scavenger and lead to 
the progressive removal of extracellular pro-inflammatory CC chemokines.  
Therefore, in many respects, D6 in trophoblasts is behaving as reported in 
previous studies using immortalised cell lines.  
In the experiments assessing the chemokine uptake activity of D6, a slight 
variation in its specificity in primary trophoblasts in comparison to the D6 
transfected HEK293 cells was discovered. D6 in trophoblasts was shown to have a 
broadly similar ligand binding profile as D6 in HEK293 cells, but CCL11 appeared 
not to be a ligand for D6 in trophoblasts, despite binding D6 in HEK293. In 
addition, D6 in HEK293 appeared to have a much stronger affinity for CCL22 than 
CCL2, but this was not apparent in primary trophoblasts. The molecular basis for 
these discrepancies is not clear.  However, it is worth noting that Western 
blotting revealed differences in the molecular weights of D6 protein between 
HEK293 cells and primary trophoblasts. Much of the D6 protein in trophoblasts 
was of a higher molecular weight than that seen in HEK293 overexpressing 
exogenous D6.  Higher molecular weight of D6 has been reported in the past, 
and found to be due to N-linked glycosylation of the molecule. It was shown to 
be dispensable for CCL3 binding by the molecule, but a full analysis of ligand 
specificity of glycosylation-free D6 was not performed (Blackburn et al., 2004). 
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Thus, it is possible that differences in the post-translational modification of D6 
in HEK293 cells and trophoblasts are responsible for subtle alterations in ligand 
binding specificity.  This would not be surprising as negative charge on 
chemokine receptors (in the form of negatively-charged amino acids, sulphated 
tyrosine residues, and/or glycosylation) is important for forming initial 
interactions with chemokines during the binding process.  An alternative 
explanation is that D6 in trophoblasts contains additional protein-coding exons 
and that this alters ligand specificity and affinity.  It is possible that the splice 
sites within the intron of D6 gene are different, resulting in the variations in the 
mRNA generated. This phenomenon has been observed with other human 
chemokine receptors, most notably CXCR3.  It exists in two forms, CXCR3A and 
CXCR3B, which differ at their extreme C-terminus.  This alters ligand specificity 
and signalling activity (Lasagni et al., 2003).  Further work will be required to 
more fully analyse the specificity and affinity of chemokines for D6 in 
trophoblasts, and define the molecular basis for any differences between its 
properties in trophoblasts and HEK293 cells. 
Due to time constraints, the analysis of D6 expression and chemokine uptake by 
subgroups of trophoblasts in the cultures was not carried out. However, gating of 
the histograms from the flow cytometry for CCL2AF647 uptake showed that the 
CCL2AF647-high group consisted of larger cells than the CCL2AF647-low group. 
Perhaps this difference in CCL2AF647 uptake was due to the presence of different 
groups of trophoblasts (villous cytotrophoblasts, extravillous cytotrophoblasts 
and syncytiotrophoblasts) (Pötgens et al., 2003). Syncytiotrophoblasts are known 
to be larger than cytotrophoblasts in flow cytometry analysis (Kudo et al., 2003). 
Further experiments may be able to differentiate the subgroups with CCL2AF647-
high and CCL2AF647-low cells. D6 may have a different scavenging activity 
depending on the type of trophoblast that expresses it. Alternatively, the 
difference in CCL2AF647 uptake can also be due to distinctive pattern of D6 
expression in different group of trophoblasts. With further studies, it may be 
possible to use CCL2AF647 uptake to purify certain types of trophoblasts directly 
from the culture.  
Following the findings from the above studies, the experiments of D6 in 
trophoblasts could be expanded to further understand the regulation of 
expression, function and distribution of this protein in these cells. For instance, 
186 
trophoblasts could be exposed to different pH’s to assess the ability of D6 to 
bind its ligands. One would expect the affinity of the receptor to its ligand to be 
reduced in low pH environment. This character of D6 is believed to ensure 
chemokines bound to D6 are retained inside cells, as when D6 encounter low pH 
in the endosomes, it releases them for endosomal passage instead of bringing 
them back to the surface of the cells (Weber et al., 2004).  
Trophoblasts could also be pretreated with unlabelled D6 ligands before 
chemokine uptake and scavenging assays are performed. This would assess 
whether the receptor is desensitised over time, after repeated exposure to the 
ligands. In HEK293 cell line, there was no apparent desensitisation of this 
receptor to subsequent chemokine uptake (Weber et al., 2004).  
The scavenging property of D6 can be complemented by experiments using 
radioligand degradation assays. After introducing radiolabelled chemokine e.g. 
125I-mCCL3 to trophoblasts, the degree of degradation of the ligand over time 
can be measured, correlating to the emergence of non-trichloroacetic acid (TCA) 
precipitable radioactivity of the supernatant. SDS-PAGE analysis of the 
supernatants may be able to detect these degraded radioiodinated amino acids 
or short peptides, represented by diffuse bands with slower electrophoretic 
mobility than intact 125I-mCCL3 (Weber et al., 2004). Over time, the bands of 
intact and degraded 125I-mCCL3 from cell lysate and supernatant can be 
compared quantitatively to picture the pattern of chemokine scavenging activity 
of D6. The degradation of D6 ligands by lysosomes has been shown to be 
inhibited by neutralisation of vesicle acidification by NH4Cl in HEK293 cell line, 
this study can be carried out in trophoblasts to explore whether similar results 
are shown (Weber et al., 2004).  
By regulating the availability of chemokines, D6 probably has a role to play in 
orchestrating the chemotactic migration of white cells, and perhaps trophoblasts 
in the decidua. To investigate this further, migration assays could be performed 
to explore whether trophoblasts have the ability to migrate towards D6 ligands. 
In addition, white cells e.g. THP1, a human monocytic cell line, and also Treg or 
NK cells can be used to study their migratory potential towards trophoblast 
medium supplemented with chemokine ligands. 
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The expression of D6 in BeWo cell line has been successfully subdued by the 
siRNA approach (Madigan et al., 2010). If by using this method the protein 
expression is significantly reduced, my experiments on chemokine uptake and 
scavenging, and also migration assays could be repeated to assess the impact of 
D6 downregulation. D6 activity could also be potentially interfered by using 
transient transfection methodology to introduce mutant versions of proteins 
known to interfere with endocytotic pathways, as shown in HEK293 cells in the 
study by Weber et al (Weber et al., 2004).  
In summary, this work demonstrates that cultured primary trophoblasts express 
D6 protein, and that, in this context, D6 is capable of efficiently scavenging 
extracellular chemokines.  These data lend important support to the idea, 
developed using immortalised cell lines, that D6 protein regulates chemokine 
abundance in vivo particularly at the fetomaternal interface, which is by far the 
richest source of D6 in the human body. 
5.2 Role of D6 during reproduction in DBA-1 mice 
Two previous studies have investigated the impact of D6 deficiency on 
pregnancy.  In one study, it was shown that D6 deficient mothers carrying D6 
deficient pups were more susceptible to LPS- or aPL-induced fetal loss (Martinez 
de la Torre et al., 2007).  In the second study, D6 was demonstrated to enhance 
the survival of embryos transferred into allogeneic pseudopregnant recipients 
(Madigan et al., 2010). The data in this thesis clearly show that the survival of 
fully syngeneic pups is compromised in D6 deficient DBA-1 mice in comparison to 
WT DBA-1 counterparts. This is the first time that exaggerated perinatal death 
has been observed in D6 KO mice, and it is not seen when D6 is deleted from 
C57BL/6 mice. The majority of deaths observed in DBA-1 were stillbirths, or 
neonatal deaths that occurred within the first week of life.  The surviving pups 
for both WT and D6 KO continued to thrive postnatally. It appears that WT DBA-1 
pups, even in an unchallenged environment, are prone to neonatal death and 
many WT DBA-1 pups were stillborn or died shortly after birth.  This was 
enhanced by loss of D6.  Perhaps in this strain of mouse the trophoblasts and 
leukocytes are highly sensitive to the precise localisation of chemokines required 
for successful placentation and that lack of D6, by causing deregulation of this 
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process, results in dire consequences for some of the pups. Clinically this is an 
exciting finding because it shows that D6, influenced by other genetic factors, 
can play an indispensible role in protecting fetuses, even in an unchallenged 
environment.  Due to the known expression of D6 by fetal cells in the placenta 
(Madigan et al., 2010), it seemed likely that the enhanced neonatal death of D6 
deficient pups could be due to a defect in the placenta.  Indeed, stereology 
revealed a marked difference in the structure of the placenta feeding D6 
deficient pups at E14 in mothers homozygous or heterozygous for the deleted D6 
allele.   
5.2.1 Stereology reveals labyrinthine zone defects in the E14 D6 
deficient placenta 
Stereology is an effective, albeit time consuming, way to study the structure and 
function of an organ. In contrary to two dimensional (2D) histological sections, 
this systematic, and randomised method allows nonbiased, accurate assessment 
of the sample, making it possible to obtain a three dimensional (3D) picture of 
the functional architecture.  
On discovering the enhanced neonatal death of D6 deficient pups, one of the key 
subsequent aims of the project was to examine whether there were fundamental 
defects in the structure of the D6 deficient placenta. By stereology, it was 
possible to compare the volumes of different functional zones in the placentas 
of the mice. The labyrinthine zone (LZ) is the main area where the placenta 
performs its function in supporting the fetus. This is the zone where maternal 
blood spaces are interfacing with the fetal blood vessels, supplying nutrients and 
gases, and removing waste. The fact that the size of the LZ significantly 
correlated with pup/placenta ratio at all gestations studied shows its importance 
for feto-maternal exchanges, and for supporting the wellbeing of the fetus. 
Thus, the smaller the LZ volume, the smaller the fetus.  
Comparison between WT and D6 KO mice at E14 showed significant reduction in 
the LZ functional volume in the D6 KO group, supporting the initial hypothesis 
that D6 deficiency is responsible for a defect in the structural formation of the 
placenta. This defect in the functional volume of feto-maternal interface 
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resulted in a significant reduction in the pup weight, and a trend towards 
reduced pup/placenta ratio. In the model where we crossbred D6 HET females 
with D6 KO males, there was also a difference between the placentas supporting 
D6 HET and their D6 KO siblings. D6 deficiency caused a significant reduction in 
LZ functional volume, and a trend towards reduced pup/placenta ratio. This 
confirmed that the placental phenotype associated with D6 deficiency was 
caused by a fetal effect rather than lack of D6 in the mother.  
It was notable that the placental phenotype and reduced pup weight observed at 
E14 were not apparent at E18. Perhaps at the later stages of pregnancy, D6 is 
dispensable for the subsequent development of the placenta, and the LZ 
continues to grow up to E18 of mouse gestation (Coan et al., 2004).  Thus, it 
appears that the functional volume of the LZ in the placenta of D6 KO pups 
catches up with their WT counterparts and normalises as pregnancy advances. 
The placental defect and fetal compromise at the early ages of pregnancy may 
have a long lasting effect on the wellbeing of the offspring, leading to the 
increase in perinatal deaths in the D6 deficient group in DBA-1 mice. In human, 
illnesses in adulthood are linked to relatively brief periods of fetal compromise 
during a sensitive stage of in utero development (Lapillonne and Griffin, 2013). 
The detrimental effect may not be reversed even if the child’s growth is 
normalised during early infancy. For this study while the link between the 
phenotypes in early pregnancy and perinatal period is biologically plausible, 
more experiments are needed to confirm the hypothesis.  
The reduction of LZ volume fraction in the mouse placenta reflects a reduction 
of the area available for fetal-maternal exchanges. The evidence of poor pup 
growth associated with the reduction in LZ volume in mouse pregnancies has 
already been shown by stereology in the past. Environmental and genetic factors 
can cause the reduction in LZ volume, and subsequently affecting the growth of 
the pups (Coan et al., 2008, Coan et al., 2010). This finding of placental 
insufficiency can be translated to human pregnancies. Reduced efficiency of 
maternal-fetal exchanges in the human placenta is known clinically to be a 
cause of fetal growth restriction, resulting in fetal compromise. Recently there 
is interest in confirming this placental pathology by stereology, first described 
by Mayhew et al in 1997 (Mayhew, 1997). Reductions in the volume of 
syncytiotrophoblast and placental villi have been associated with exposure to 
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polychlorinated biphenyls (PCBs), and also in pregnancies associated with pre-
eclampsia and fetal growth restriction (Odibo et al., 2011, Tsuji et al., 2013). 
Syncytiotrophoblast and placental villi are important areas for maternal-fetal 
exchanges in human placenta, playing similar role to LZ in mouse placenta. PCBs 
are an environmental pollutant, whereas pre-eclampsia is an illness in human 
pregnancy, but both are known to be associated with fetal growth restriction. In 
clinical practice there have been many instances where placental insufficiencies 
are detected by histology in pregnancies with fetal growth restriction and fetal 
death; often no aetiology has been found to be the cause of this defect. Perhaps 
in a number of these patients there is a lack of, or reduced expression of D6. D6 
expression in the human placenta may be regulated by more complex 
mechanisms, for example single nucleotide polymorphisms (SNPs). Further 
exploration of D6 expression in the human placentas associated with growth 
restriction, pre-eclampsia or other conditions that affect fetal growth could 
prove informative and interesting.  
5.2.2 Role of D6 in the regulation of chemokine abundance   
Based on the studies of D6 in immortalised cell lines, and this work here using 
primary human trophoblasts, it seems likely that D6 in the placenta functions 
primarily to control chemokine abundance and distribution.  As outlined in the 
introduction, chemokines likely serve several roles during placentation; 
therefore elevated level of chemokines arising from loss of D6 could deregulate 
leukocyte recruitment into the placenta and/or alter the behaviour of 
trophoblasts.  
5.2.2.1 D6 regulates the plasma level of chemokines in pregnancy 
There is evidence of chemokine dysregulation in pregnant D6 deficient mice.  
The protein levels of D6 binding chemokines in the blood have been studied on 
pregnant mice injected with LPS. D6 binding CCL2, CCL11 and CCL22 were found 
to be higher in the D6 KO mice than WT controls, whereas there was no 
difference in the level of non-D6 ligand CXCL2 (Martinez de la Torre et al., 
2007). The surface area of placenta where the maternal blood flows through is 
significant in size. Together with other mouse organs, the placenta probably 
makes a major contribution in scavenging the ligands, affecting their levels 
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systematically. In human, plasma level of chemokine ligands CCL2, CCL3, CCL4 
and CCL11 is reduced from the first to the third trimester of pregnancy, as the 
placenta grew when pregnancy advanced. In contrast, the level of CXCL10, a 
non-D6 ligand, did not change between those different periods of pregnancy. 
Interestingly, in women with pre-eclampsia CXCL10 was significantly elevated, 
while no significant difference was detected in the earlier D6 ligands between 
these women and the control group (Madigan et al., 2010). This suggests that 
the levels of D6-binding ligands are well regulated in pregnancy, even in an 
environment when there is robust expression of these pro-inflammatory 
chemokines.  
In the Luminex multiplex protein assay of DBA-1 mouse plasma in my work, 
among all the D6 binding chemokines studied (CCL2, CCL3 and CCL5), only CCL2 
showed a significant difference in DBA-1 mice. The reason for this selective 
difference is yet to be explored. In the study of Martinez de la Torre, the level 
of plasma CCL3 in challenged pregnant mice was similar between WT and D6 KO 
mice, while the levels of other D6 binding chemokines (CCL2, CCL11, CCL22) 
were elevated in the D6 KO group (Martinez de la Torre et al., 2007). In 
comparison to the other D6 ligands, CCL3 disappeared very quickly from the 
circulation after LPS administration, even in the WT mice. The explanation of 
the quick disappearance of CCL3 is yet to be discovered. However from the 
result D6 seems to be dispensable in removing CCL3 from the circulation. In this 
experiment, no difference was detected in the plasma protein level of CCL3 and 
CCL5 between WT and D6 KO mice in an unchallenged environment. Perhaps the 
level of CCL5, like CCL3, fluctuates quickly in the mouse circulation. D6 may be 
more important in the regulation of the systemic level of ligands with higher 
protein stability in the circulation. The significantly higher plasma level of CCL2 
in the D6 KO mice was not due to the differences in placental expression of this 
chemokine. Like almost all the other chemokines examined this experiment, the 
expression of CCL2 transcript was not different between WT and D6 KO 
placentas at E18.  
Following the interesting findings above, further investigations of chemokine 
abundance in the plasma of D6 deficient mice are worthwhile in future 
experiments.  First, as the difference in chemokine abundance discovered was 
more marked at E14, the experiments should be repeated with an increased 
192 
sample size for E14 to enable the study of more D6 binding ligands with 
sufficient power. In addition, it will also be interesting to see if non-pregnant D6 
deficient DBA-1 mice have elevated levels of CCL2 (and other D6-binding 
chemokines) in their plasma.   
The relationship between fetal survival and the plasma level of D6 binding 
chemokines is still unclear. It is possible that the elevated systemic level of D6 
ligands in the D6 KO mice affects the structure and function of the placenta, or 
alternatively it may directly influence the survival of the pups in this group. The 
answer may be found by examining circulating chemokine levels in pregnant D6 
heterozygous mothers carrying a mixture of D6 heterozygous and D6 deficient 
pups.  In this experiment D6 deficient placentas in the pregnancies of D6 
heterozygous mothers were abnormal. The presence of D6 expression by the 
mother and by the D6 heterozygous placentas might be expected to prevent 
elevated CCL2 in the plasma, if this is true perhaps the local regulation of 
chemokines in the placenta itself might be more important than systemic 
chemokine control. 
5.2.2.2 Role of D6 in the local regulation of chemokines in the 
placenta 
In the study the abundance of transcripts encoding chemokines in WT and D6 
deficient placentas was compared.  Apart from CCL17, there were no significant 
differences between the placentas of WT and D6 KO mice. These results show 
that D6 does not affect the production of most chemokines locally, and it will 
now be interesting to examine protein levels of D6 binding chemokines.  It would 
not be surprising to find that the levels for these chemokines are lower in the 
WT group, due to the scavenging effect from D6. These subdued protein levels of 
D6 binding chemokines have been demonstrated in a study. In comparison to the 
D6 KO mice, the pregnant WT animals injected with LPS were found to have 
lower protein levels of CCL2, CCL3, CCL11 and CCL22; the non-D6 binding CXCL2 
level was similar between the 2 groups (Martinez de la Torre et al., 2007). The 
higher level of CCL17 transcript in D6 KO than WT DBA-1 placentas in this 
experiment was unexpected. The placentas might elevate CCL17 production to 
counteract the effect of D6 deficiency. If this is a compensatory mechanism, the 
exact pathway is still unknown. By expressing CCR4, regulatory T cells are known 
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to respond to CCL17 and could be recruited more effectively to the D6 KO 
placenta.  However, there was no difference in expression of FoxP3, a marker of 
regulatory T cells, between WT and D6 deficient placentas. In addition, there 
were no differences in the expression of markers for macrophages (F480) or T 
cells (CD3). Thus, my study provided no evidence of altered leukocyte 
recruitment to the placenta in response to D6 loss.  However, in future, the 
experiment could be expanded to include other populations of white cells, such 
as mast cells, NK cells and neutrophils.  Moreover, these various cell types 
should be enumerated and localised in WT and D6 deficient placentas by 
immunocytochemistry.  
5.3 Conclusions and future directions 
This project brings our understanding of the importance of D6 in reproductive 
tissues to a higher level. Together the results from animal in vivo and human in 
vitro cellular studies provide valuable information on function of D6 in the 
placenta.  
By studying D6, for the first time, in primary human cells it showed that it is 
capable of performing the scavenging function ascribed to it in transfected 
HEK293 and BeWo cells (Weber et al., 2004, Madigan et al., 2010). In DBA-1 
mice, D6 deficiency affects the growth of fetus in the early gestational age 
(E14), and has a detrimental effect of fetal survival in the neonatal period. A 
fundamental defect in the formation of labyrinthine zone at E14 was detected in 
D6 KO placenta, which, by using D6 HET females, was shown to be due to D6 
deficiency in fetal cells, most likely the trophoblasts of the placenta. 
Further experiments are required to determine the exact mechanism by which 
D6 protects offspring. Chemokines may exert chemotactic effect to trophoblasts, 
controlling its migration into desired location. By scavenging chemokines, D6 
may directly influence the character of trophoblasts and their responsiveness to 
chemokines when invading the decidua, modifying existing and forming new 
blood vessels, and shaping the formation of functional units of the placenta. In 
addition, D6 may also alter the signalling behaviour of trophoblasts with other 
cells. The ability of D6 in affecting the migratory potential of the cells 
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expressing the receptor has been demonstrated before (Hansell et al., 2011b). 
Innate-like B cells in mouse uniquely and universally express D6. D6 was shown 
to suppress the chemotactic responsiveness of these cells to CXCL13, a non-D6 
ligand. It was thought that D6 regulates this response by controlling β-arrestin 
redistribution, therefore alters signalling and subsequent migratory responses of 
the B cells to CXCL13 mediated by CXCR5.  
The abundance of CC chemokine is also likely to influence leukocyte 
recruitment. Perhaps the efficiency of embryo implantation, and the process of 
placentation, is indirectly influenced by the interaction between trophoblasts 
and leukocytes locally and systemically. Locally in the gestation tissues, precise 
control of the level of chemokines could steer and localise leukocytes to assist, 
or play a direct role, in ensuring a successful implantation and placentation. 
Delicate orchestration of the level of chemokines may also prevent inappropriate 
leukocyte adhesion on the vessels of gestational tissue, which could possibly 
reduce the efficiency of gaseous and nutrient exchange in the feto-maternal 
interface. Systematically, uncontrolled, overabundance of chemokines could 
lead to the desensitisation, and subsequently inadequate response of the 
leukocytes to chemokine stimulation. The phenomenon of desensitisation of 
chemotactic response of leukocytes towards ligand chemokines has been 
demonstrated. Leukocytes overexposed to chemokines have been shown to have 
reduced migratory responsiveness (Noso et al., 1994, Uguccioni et al., 1995). 
Many G-protein coupled chemokine receptors on these cells, unlike D6, are 
internalised and desensitised to further ligand uptake following prolonged 
exposure to agonist activation (Uguccioni et al., 1995, Vila-Coro et al., 1999, 
Weber et al., 2004, Escola et al., 2010). Thus by regulating the level of 
chemokine systematically, D6 might ensure the robust response of leukocytes to 
chemokines is maintained, and thus increasing leukocyte migratory potential.  
To complement the findings from the in vitro study, further cellular and 
molecular experiments of D6 can be performed on first trimester placentas, and 
also placentas from abnormal pregnancies, for examples miscarriages, and 
pregnancies with pre-eclampsia, or being diagnosed with placental insufficiency. 
Early pre-eclampsia occurring before 34 weeks is often more severe and 
associated with a worse perinatal outcome in comparison to the later onset 
disease (Gong et al., 2012). It would be interesting to compare the status of D6 
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expression from the placentas between these two groups. Besides the techniques 
that have been described in this project, other techniques like stereology could 
be utilised in human placentas to further understand the three-dimensional 
pattern of distribution of D6 and leukocytes. Considering that variation in D6 
expression might be due to the presence of single nucleotide polymorphisms 
(SNPs), studies could be carried out to detect any such variants and whether 
they are associated with any particular placental defects. 
In conclusion, the phenotype and cellular discoveries from this project provide 
novel physiologically significant insight into D6 function in the placenta. It also 
opens the door to aid the design of future experiments to reveal the code of 
chemokine regulations of D6, and its precise role in determining the outcome of 
pregnancies.
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